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Abstract 
 
Title: Investigating PLK4- regulated signalling pathways using SILAC-based quantitative 
phosphoproteomics 
 
Author: Samantha Ferries 
 
Protein phosphorylation plays a critical role in regulating cellular responses, including the co-
ordination of cell division. Polo-like kinase 4 (PLK4), a cell cycle regulated Ser/Thr protein kinase, is 
the master regulator of centriole biogenesis, a process required for formation of the biopolar mitotic 
spindle. PLK4 expression and activity are both very tightly controlled, and dysregulation leads to 
aberrant centrosome duplication resulting in chromosome missegregation and aneuploidy. Despite 
its rising importance as a potential anti-cancer target, few PLK4 substrates have been identified, and 
much remains to be understood about basic PLK4 biology at the centrosome, and wider potential 
roles within the cell. The experiments described in this thesis focused on an evaluation of PLK4 
signalling, exploiting SILAC-based quantitative phosphoproteomics and the protein kinase inhibitor 
centrinone to probe cellular function.  
 
Initially, I describe the development of biochemical tools to study PLK4-dependent signalling, and its 
inhibition by centrinone. This included the generation of stable isogenic U2OS cell lines, transfected 
with either WT PLK4 or a centrinone-resistant G95R PLK4 mutant. The G95R PLK4 cell line was 
designed to explore potential off-target effects of centrinone inhibition, and biochemical and cellular 
assays confirmed the ‘drug-resistant’ status of this protein. An optimal concentration of centrinone 
was established to ensure inhibition of WT PLK4, whilst minimising off-target effects.  
 
Next, mass spectrometric (MS) acquisition parameters for phosphopeptide analysis were optimised 
on an Orbitrap Fusion, using a synthetic phosphopeptide library and phosphopeptide-enriched cell 
lysate. Eight acquisition methods were assessed, considering mode of fragmentation (HCD, EThcD, 
and neutral loss triggered ET(ca/hc)D), and analysers for MS2 (orbitrap and ion trap) in addition to 
assessment of optimal downstream processing. HCD, with orbitrap MS2 analysis provided high 
numbers of identifications with high phosphosite localisation and was used to study the PLK4 
regulated phosphoproteome. 
 
Building upon this, phosphoproteomics subsequently revealed 412 significantly (p ≤0.075) regulated 
proteins in WT PLK4 expressing cells following centrinone treatment, and 471 regulated 
phosphosites, with 313 downregulated (inhibited) and 158 upregulated (activated) after compound 
exposure. A target of centrinone was implicated in MAPK signalling and G1/S phases of the cell cycle. 
In addition, regulation of biological processes including rRNA processing, cell-adhesion and 
transcription was observed. A novel PLK4 proline directed consensus phosphorylation motif was also 
identified from phosphoproteomic data and validated biochemically with recombinant PLK4 in vitro.  
 
Finally, PLK4 was demonstrated to be a biochemical upstream activator of Aurora A kinase, 
phosphorylating it at Thr288 within the activation loop, which led to hyperactivation. In addition, 
both proteins co-localised in human cultured interphase cells, suggesting potential novel functions 
for PLK4-regulated Aurora A in the early stages of the cell cycle. Taken together, this work provides a 
series of novel insights into PLK4-regulated signalling, which will be useful for future studies 
evaluating the biological and disease-related functions of this important fundamental protein kinase.  
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 Introduction 
 
1.1. Protein Kinases 
 
Eukaryotic cells are continuously exposed to extracellular signals, all of which must be 
transduced and interpreted downstream, leading to specific cellular responses. Intracellular 
signalling is directed by post-translational modifications, of which phosphorylation is one of 
the most prevalent (Hunter, 1995). Protein phosphorylation is driven by the activity of 
protein kinases, which reversibly add phosphate groups via the hydrolysis of ATP to a 
number of amino acids, of which serine, threonine and tyrosine are the most widely studied 
(Figure 1.1). There is also some evidence that phosphorylation can  occur on residues 
including histidine, arginine, lysine, aspartate, glutamate and cysteine (Hardman et al., 
2017). Phosphate groups on Ser, Thr and Tyr are removed by the subsequent regulated 
activity of protein phosphatases. Phosphorylation at specific sites within a protein leads to 
a diverse range of ‘downstream’ effects, including protein activation, deactivation, 
regulating of protein stability and subcellular localisation. All of these effects are integrated 
to drive cellular processes including cell division, differentiation and apoptosis, amongst 
many others (Manning et al., 2002; Bononi et al., 2011). 
 
Figure 1.1 Structure of phosphoserine, phosphothreonine and phosphotyrosine 
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Over 500 protein kinases are encoded in the human genome and have been classified in to 
a hierarchy of groups depending on sequence similarity, overall domain structure, substrate 
specificity and mode of regulation (Hanks & Hunter, 1995). Conventional protein kinases 
(ePKs) are classified in to eight groups (Figure 1.2), whereas atypical protein kinases (aPKs), 
defined as those without sufficient sequence similarity to be classified as an ePK, are 
divided in to four separate groups.  
 
 
 
Figure 1.2 Classification of conventional protein kinases. Conventional protein kinases are divided in 
to 8 groups depending on sequence similarity, domain structure, substrate specificity and mode of 
regulation. Figure adapted from Manning et al., 2002.  
 
Protein kinases incorporate a number of unique structural features including a conserved 
core of two lobes (Knighton et al., 1991). The N-lobe consists of a five stranded β-sheet and 
an αC helix, whereas the C-lobe is mostly helical (Figure 1.3. A). A cleft between the two 
lobes forms the active site, which binds ATP co-ordinated to two divalent cations 
(magnesium or manganese) (Kornev et al., 2006).  
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Figure 1.3 Domain structure of protein kinases.  A) Tertiary structure of the Ser/Thr protein kinase, 
Aurora A, highlighting the N- and C- lobes, the activation loop and the bound ADP and Mg2+. B) The 
DFG and HRD regulatory motifs positioned in Aurora A. Images were produced in PyMOL. 
 
Protein kinases contain a number of conserved regulatory features, including the activation 
segment. The activation segment is phosphorylated as the kinase becomes active and forms 
an extended conformation to allow substrate binding. The activation loop is stabilised by an 
invariant aspartate located within a DxWxxG motif in the C-lobe and the APE motif, which 
lies at the C-terminal end of the activation segment. An invariant glutamate residue in the 
N-lobe forms a salt bridge with a key lysine residue that is essential for protein kinase 
activity (Figure 1.4) (Schenk & Snaar-Jagalska, 1999; Spitaler et al., 2000). The activation 
segment is positioned adjacent to the Asp-Phe-Gly (DFG) motif, a key regulatory motif that 
adopts different conformations depending on whether the kinase is in its active or inactive 
state. In active kinases, the DFG motif plays a key role in catalysis and adopts an ‘in’ 
conformation that orientates the motif toward the bound ATP (Huse & Kuriyan, 2002). The 
Asp residue is then correctly positioned to coordinate to the divalent cations bound to the 
β- and - phosphate groups of ATP in the active site (Figure 1.3. B; Figure 1.4). Another 
important regulatory feature of protein kinases is the His-Arg-Asp (HRD) motif, which is 
positioned correctly upon phosphorylation of the activation loop (Figure 1.3. B; Figure 1.4). 
In the active kinase, the Asp residue of this motif acts as a catalytic base for nucleophilic 
attack of the hydroxyl group of the substrate required for transfer of the -phosphate 
(Hanks et al., 1988; Johnson et al., 1996). A glycine rich loop at the N-terminus is a key part 
of the ATP binding site, which anchors and shields the bound ATP (Hemmer et al., 1997). 
Also within the ATP binding site is the important ‘gatekeeper residue’ which confers 
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selectivity for nucleotide binding, and is frequently mutated upon targeting of a kinase with 
an inhibitor to confer drug resistance (Figure 1.4) (Bishop et al., 2000; Treiber & Shah, 
2013). Highly controlled phosphorylation of protein substrates by protein kinases is a direct 
result of the dynamic regulation of these key structural features within the kinase active 
site. 
 
 
 
Figure 1.4 Conserved protein kinase structural features. The sequence alignments of PLK1, PKA, 
Aurora A and PLK4 demonstrate conserved structural elements including the Gly-rich ATP binding 
loop (orange); invariant lysine residue, essential for kinase activity (green); invariant glutamate 
which forms a salt bridge with the invariant lysine (purple); the gatekeeper residue responsible for 
nucleotide and inhibitor binding selectivity (red); the HRD motif, required for catalysis (yellow); the 
activation segment, incorporating the DFG motif required for co-ordination of the bound divalent 
cations and APE motif which stabilises the activation segment (light blue), along with the invariant 
aspartate (dark blue).  
 
  Chapter 1 
5 
 
1.2. The cell cycle  
 
Protein kinases play a major role in regulating the cell cycle. For a somatic cell to undergo 
mitosis, it must first replicate its organelles and DNA before partitioning the chromosomes 
into the daughter cell.  The cell cycle is divided in to distinct stages: interphase, prophase, 
prometaphase, metaphase, anaphase and telophase. Each stage of the cell cycle is carefully 
controlled by the co-ordinated activities of protein kinases to ensure the fidelity of the 
process (Schafer, 1998).  
 
Interphase describes the processes required to prepare the cell for mitosis and can be 
divided in to G1, S and G2 (Figure 1.5). Cyclin-dependent kinases (CDKs) bound to specific 
cyclins are the major regulators of cell division and act to phosphorylate a number of 
substrates to drive proliferation, while other families of protein kinases (including Polo-like 
and Aurora kinases) regulate specific mitotic events (Nigg, 2001; Malumbres & Barbacid, 
2005).   
 
In G1, the cells grow larger and duplicate their organelles and must pass a ‘restriction 
point’, defined as the stage at which the cell has committed to dividing and no longer 
responds to growth factors. CDK4-cyclin D is responsible for co-ordinating the activities in 
G1 and in comparison to other CDK-cyclin complexes, requires additional cofactors to 
become active (Baldin et al., 1993; Kato et al., 1994); the cofactor Cip/Kip proteins (p21, 
p27 and p57) play both an activating and inhibitory role depending on their 
phosphorylation state (Cheng et al., 1999). Unphosphorylated Cip/Kip proteins inhibit 
CDK4-cyclin D activity, whereas phosphorylation of specific tyrosine residues results in a 
conformational change, preventing inhibition and releasing CDK4-cyclin D to phosphorylate 
downstream substrates (James et al., 2008).  
 
Once active, CDK4-cyclin D regulates the restriction point via its interaction with 
retinoblastoma protein (RB1). Hypophosphorylated RB1 interacts with E2F transcription 
factors, sequestering them to prevent transcription of downstream targets (Ikeda et al., 
1996). CDK4-cyclin D phosphorylation of RB1 on specific residues releases E2F, which 
transcribes genes involved in DNA synthesis, marking the transition from G1 to S phase 
(Zarkowska & Mittnacht, 1997; Rubin et al., 2005).  
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At the G1/S phase transition, levels of another CDK-cyclin complex, CDK2-cyclin E increase 
(Lauper et al., 1998). This complex, in conjunction with Cdc6, stimulates the assembly of the 
pre-replication complex, preparing the chromatin for replication (Lunn et al., 2010). Once 
this has been achieved, cyclin A levels increase and form complexes with CDK2 to initiate 
DNA synthesis (Coverley et al., 2002). Cells then progress into G2 and continue to grow in 
preparation for entry to mitosis.  Cyclin A is degraded, whilst cyclin B is synthesised and 
forms a complex with CDK1. CDK1 becomes active following dephosphorylation at Thr14 
and Tyr15 by Cdc25 phosphatases (Sebastian et al., 1993). CDK1-Cyclin B then 
phosphorylate a wide range of substrates including lamins, microtubule binding proteins 
and condensins that regulate important M phase processes such as breakdown of the 
nuclear envelope and spindle assembly (Blethrow et al., 2008).   
 
 
 
Figure 1.5 Stages of interphase in the eukaryotic cell cycle. Interphase is divided in to G1, S and G2 
phase, preparing the cell for entry in to mitosis.  
 
In prophase, the chromatin begins to condense via the action of condensin complexes, 
whilst cohesin complexes keep sister chromatids together. In addition, the nuclear 
envelope begins to break down to release the DNA so that the chromosomes can associate 
with spindle fibres as mitosis progresses (Salina et al., 2002). The centrosomes begin to 
migrate to opposite poles of the cell and start to assemble spindle fibres. In prometaphase, 
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the spindle fibres continue to assemble and chromosomes develop kinetochores which are 
required to attach sister chromatids to the spindle (Figure 1.6) (Kirschner & Mitchison, 
1986).  
 
In metaphase, the centrosomes have migrated to opposite poles of the cell and 
chromosomes are accurately aligned along the metaphase plate (Rieder et al., 1986). In 
anaphase, cohesin complexes are cleaved by the protease separin and the separated 
chromatids are pulled towards opposite poles of the cell (Waizenegger et al., 2000).  The 
chromosomes start to decondense in telophase, and the nuclear envelope reforms to 
surround the DNA. A contractile ring then forms under the plasma membrane and 
constricts, forming a cleavage furrow that splits the daughter cells in two (Glotzer, 2005). 
The cells then re-enter interphase and prepare for another round of cell division.  
 
 
 
Figure 1.6 Stages of mitosis in the eukaryotic cell cycle.  Mitosis is divided in to six stages: prophase, 
prometaphase, metaphase, anaphase, telophase and cytokinesis.  
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1.3. The centrosome cycle 
 
Centrosomes are the microtubule organising centres of the cell. They are composed of two 
microtubule-based structures called centrioles, which are formed with nine-fold symmetry 
and are surrounded pericentriolar material (PCM) containing a matrix of proteins. 
(Kochanski & Borisy, 1990; Dammermann et al., 2004). The centrosome is responsible for 
nucleating microtubules to form the spindle fibres required for chromosome segregation 
during the cell cycle. In addition, the centrosome also regulates cilia formation by 
functioning as basal bodies and thus plays an important role in cell signalling (Goetz & 
Anderson, 2010).  
  
Each cell contains one centrosome and is duplicated only once per cell cycle in a highly 
controlled process at the G1/S transition. Exactly one procentriole forms perpendicular to 
each of the two parent centrioles, which continue to elongate, mature and are finally 
released from the parent centriole in late mitosis (Figure 1.7). This process is regulated by a 
number of key proteins, including members of the Polo-like kinase family and Aurora 
kinases. The role of these kinases in co-ordinating activities at the centrosome is described 
in detail below.  
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Figure 1.7 The centrosome cycle. The centrosome cycle begins with centriole disengagement (1) prior to the recruitment of PLK4, STIL and SAS6 to initiate centriole 
biogenesis at the G1/S. transition. In S phase, the procentriole elongates and PLK4 is degraded by the 26S proteasome (3). In G2, the centrosome undergoes maturation via 
Aurora A phosphorylation of substrates including TACC3 and the centrosome separates by the activity of PLK1 phosphorylated Nek2A (4). In mitosis, the centrioles migrate 
and assemble the spindle fibres. The cohesin ring holding the mother and daughter centrioles together is degraded to complete the cycle (5).  Adapted from Wang et al., 
2014.
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1.4. Polo-like kinases 
 
The family of Polo-like protein kinases were first discovered in Drosophila, when mutant 
alleles of the polo locus were identified, which resulted in the development of abnormal 
spindle poles (Sunkel & Glover, 1988). Five members of the Polo-like kinase (PLK) family 
have been identified (Figure 1.8). PLK1-3 share a similar architecture, with an N-terminal 
Ser/Thr kinase domain and two C-terminal regulatory domains termed polo box domains 
(PBD) responsible for subcellular localisation and substrate specificity (Lowery et al., 2005). 
PLK4 is structurally divergent, as it contains three PBDs rather than two (Leung et al., 2002). 
A fifth member, PLK5 is identified by the absence of a functional kinase domain (de Carcer 
et al., 2011).  
 
 
 
Figure 1.8 Schematic of the domain structures in Polo-like kinases.  The domain structure of polo-
like kinases is illustrated, depicting the N-terminal kinase domain (KD), and C-terminal polo-box 
domains (PB) involved in regulation. The destruction box (D-box) of PLK1 is shown in yellow. The 
number of amino acids of each kinase is shown on the right. The labelled Thr residues represent the 
activating residue within the kinase activation segment.  
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 PLK1 
 
PLK1 is the most widely studied polo-kinase and has important roles across the cell cycle, 
including at the centrosome. At the G2/M phase transition, PLK1 is involved in centrosome 
maturation via phosphorylation of pericentrin. This recruits key proteins to the centrosome 
including -tubulin, GCP-WD and the scaffold protein Cep192, involved in centrosome 
maturation (Lee & Rhee, 2011). PLK1 also functions to separate the centrosomes so that 
spindle assembly can occur prior to segregation of the chromosomes. In interphase, 
centrosomes are joined together by proteins including C-Nap1 and rootletin (Yang et al., 
2006). These proteins are displaced upon entry to mitosis by PLK1 phosphorylation of 
Nek2A kinase, which acts at the centrosome linker allowing the centrosomes to separate 
(Mardin et al., 2011) (Figure 1.7). 
 
As the cell exits mitosis, PLK1 aids in separation of the mother and daughter centrioles by 
phosphorylating a cehesin ring subunit, Scc1, which can then be cleaved by separase, 
releasing the centrioles (Losada et al., 2002; Hauf et al., 2005) (Figure 1.7). In addition to 
these roles in centrosome biology, PLK1 has extensive functions across the cell cycle, 
including mitotic entry in conjunction with CDK1-cyclin B, spindle assembly, chromosome 
segregation and cytokinesis (Jackman et al., 2003; Burkard et al., 2007).  
 
PLK1 is overexpressed in many cancers and widely considered as an oncogene. NIH 323 
cells constitutively expressing PLK1 formed tumours when injected into nude mice, 
suggesting that PLK1 contributes to the progression of human cancers (Smith et al., 1997). 
In prostate cancer cells, PLK1 overexpression is linked to inactivation of PTEN, and loss of 
PTEN is believed to drive the majority of prostate cancers (Liu et al., 2011). However, recent 
work has revealed that dysregulation of PLK1 can reduce aberrant cell proliferation in 
cancer cells. Overexpression in mammary tumour cells led to abnormal chromosome 
segregation and a failure of the cell to undergo cytokinesis, suppressing tumour 
development (de Carcer et al., 2018). PLK1 may therefore possess both oncogenic and 
tumour suppressive functions, depending on the cancer under study.  
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 PLK2 
 
PLK2 localises to the centrosome and is activated at the G1/S transition. PLK2 is involved in 
centriole duplication via a destabilising phosphorylation of three conserved residues in 
FBXW7 (a substrate recognition component of an SCF E3 ubiquitin ligase). FBXW7 regulates 
the degradation of target proteins, including cyclin E and therefore, a decrease in FBXW7 
leads to an accumulation of cyclin E in the cell. In addition to the roles described above, 
cyclin E, bound to CDK2, localizes to the centrosomes where the complex can 
phosphorylate centrosomal substrates including nucleophosmin (NPM) thereby promoting 
centriole duplication (Okuda et al., 2000; Cizmecioglu et al., 2012).  
 
PLK2 has typically been considered as a tumour suppressor, as it is transcriptionally 
regulated by p53 (Burns et al., 2003). In addition, silencing of PLK2 expression occurs in 
malignant B cells, highlighting its tumour suppressive effects (Syed et al., 2006). However, 
overexpression of PLK2 has been identified in colorectal cancer cells where hyperactivity 
and uncontrolled degradation of FBXW7 leads to accumulation of FBXW7 target proteins 
including cyclin E, driving uncontrolled cell growth in this cancer type (Ou et al., 2016). It is 
therefore possible that PLK2, like PLK1, is both a tumour suppressor and oncogene 
depending on cell type.  
 
 PLK3 
 
PLK3 is expressed throughout the cell cycle and is activated during G2. It is found in the 
cytoplasm, at the cell membrane and in the nucleus. Similar to the other PLKs, PLK3 has 
roles in the cell cycle, including the indirect control of cyclin E levels. PLK3 phosphorylates 
the protein phosphatase Cdc25a, which acts to remove inhibitory phosphate groups from 
cyclin E dependent kinases, promoting entry into S phase (Blomberg & Hoffmann, 1999; 
Zimmerman & Erikson, 2007).  
 
PLK3 also has roles outside of the cell cycle including cellular responses to stress. Oxidative 
stress activates p53, which regulates transcription of genes involved in the stress response. 
This activation is, in part, mediated by PLK3 via phosphorylation at Ser20 of p53, leading to 
cell cycle arrest and apoptosis. PLK3 activity therefore provides a link between the DNA 
damage response and apoptosis (Xie et al., 2001).  
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The cellular responses to oxidative stress suggest that PLK3 functions as a tumour 
suppressor. PLK3 has been shown to negatively regulate HIF-1α, a master transcriptional 
regulator of genes in response to hypoxia.  HIF-1α activity enables survival of cancer cells in 
hypoxic conditions and therefore, its negative regulation by PLK3 highlights the tumour 
suppressive functions of this kinase (Yang et al., 2008; Xu et al., 2010). 
 
 PLK4 
 
PLK4 is a serine/threonine protein kinase, first discovered in mouse, with shared homology 
with the Drosophila polo kinase (Fode et al., 1994). PLK4 localises at the centrosome and is 
the master regulator of centriole duplication, ensuring centrosomes are replicated only 
once per cell cycle (Habedanck et al., 2005; Kleylein-Sohn et al., 2007). 
 
PLK4 is a low abundance protein and levels in the cell are tightly regulated to control 
centriole duplication and maintain genomic integrity. PLK4 is degraded via ubiquitin-
mediated degradation by the 26S proteasome. The E3 ubiquitin ligase SKP1-CUL1-F Box 
(SCF) complex contains a β-TrCP F box protein that recognises its substrates upon 
phosphorylation in specific regions, promoting protein degradation. PLK4 forms 
homodimers and undergoes trans-autophosphorylation within a specific destruction (DSG) 
motif (residues 282-305), known as the phosphodegron. This is recognised by the E3 
ubiquitin ligase which ubiquitylates PLK4 within its kinase domain to signal it for 
proteasomal degradation (Holland et al., 2010; Sillibourne et al., 2010; Cunha-Ferreira et 
al., 2013). PLK4 is stabilised by the activities of protein phosphatase 2A, which 
dephosphorylates PLK4, preventing its autodestruction and allowing licenced centriole 
duplication to occur (Brownlee et al., 2011). 
 
An additional E3 ubiquitin ligase, Mib1, has been identified as a regulator of PLK4 levels in 
the cell. Mib1 has traditionally been associated with Notch and NF-B signalling. However, 
Mib1 has also been shown to localise to centrosomes upon initiation of centriole 
biogenesis. At the centrosome, Mib1 ubiquitylates PLK4 at fifteen Lys residues across the 
kinase and polo-box domains and the Lys29- and Lys48 ubiquitin linkages formed resulted 
in proteasomal degradation.  Mib1 ubiquitylation of PLK4 is not mediated by the SCF β-
TrCP, and it is hypothesised that SCF β-TrCP controls PLK4 abundance in the cell cycle 
whereas Mib1 ubiquitylation acts on overexpressed PLK4 (Cajanek et al., 2015).  
  Chapter 1 
14 
 
 
Studies in Drosophila revealed that PLK4 also trans-autophosphorylates at Thr172 (Thr170 
in humans) within its activation loop following accumulation at the centrioles (Lopes et al., 
2015). This results in autoactivation of PLK4 and permits the phosphorylation of its 
substrates to initiate centriole duplication. PLK4 is recruited to the centrosome by the 
scaffold proteins Cep152 and Cep192 and is capable of phosphorylating Cep152 in the 
process of preparing the molecular machinery required for centriole biogenesis (Figure 1.7) 
(Bahtz et al., 2012; Kim et al., 2013).  Another key PLK4 substrate is GCP6, a member of the 
tubulin ring complex (TuRC). This complex localises to the PCM and distal ends of the 
centrosomes and has a role in nucleating microtubules. GCP6 has been shown to be 
required for centriole duplication and it is regulated by phosphorylation within a tandem 
repeat segment by PLK4 (Bahtz et al., 2012).  
 
To initiate centriole duplication, PLK4 phosphorylates another of its substrates: the 
centrosomal localised protein STIL. STIL is recruited to the centrosome by the centrosomal 
scaffold protein Cep85, which binds STIL in its N-terminal domain (Liu et al., 2018).  STIL 
protein undergoes self-oligomerization via its conserved CC domain, which is also required 
to bind PLK4 (Arquint et al., 2015). Once bound, PLK4 activity is stimulated and 
phosphorylates STIL at a number of residues within its STAN domain, including Ser1108 and 
Ser1116 (Moyer et al., 2015). Phosphorylated STIL then recruits SAS6, a structural protein 
involved in forming the nine-fold symmetry typical of microtubules, forming a new 
centriole (Dzhindzhev et al., 2017) (Figure 1.7; Figure 1.9). PLK4 also phosphorylates the 
coiled-coil protein CP110, which acts antagonistically with the centrosomal protein CPAP 
(also recruited by Cep152) to determine centriole length. Phosphorylated CP110 acts to 
stabilise SAS6 during cartwheel formation to establish the nine-fold symmetry of the 
growing centriole (Lee et al., 2017). SAS-6 levels in the cell are regulated by the SCF-FBXW5 
E3 ubiquitin ligase, which adds ubiquitin groups to SAS6 to signal the protein for 
degradation following the formation of the nascent centriole. FBXW5 activity must be 
controlled to prevent premature ubiquitylation of SAS6 and it has been shown that FBXW5 
is negatively regulated by PLK4 phosphorylation at Ser151. Following centriole duplication, 
PLK4 autophosphorylation and subsequent degradation relieves the SCF-FBXW5 complex to 
ubiquitylate SAS6 and prevent additional centrosome duplication events from occurring 
(Puklowski et al., 2011). 
 
  Chapter 1 
15 
 
An additional mechanism to prevent multiple duplication events involves CDK1-cyclin B 
activity in the later phases of the cell cycle. A portion of PLK4, STIL and SAS6 can be 
identified at the mother and daughter centrioles following centrosome duplication (Leidel 
et al., 2005; Arquint et al., 2012; Kratz et al., 2015) however, CDK1-cyclin B binding to the 
CC domain of STIL prevents complex formation. CDK-cyclin B binds at the CC domain and 
phosphorylates STIL at the N-terminus. This prevents PLK4 binding to STIL and reduces PLK4 
autoactivation, preventing overduplication of the centrosomes (Zitouni et al., 2016). 
Furthermore, PLK4 activity is negatively regulated by acetylation of two Lys residues within 
the catalytic domain. The Lys acetyltransferase (KAT2A and KAT2B) acetylates PLK4 on 
Lys45 and Lys46, causing a conformational shift to the inactive state, inhibiting PLK4 activity 
and preventing further amplification of the centrosomes (Fournier et al., 2016). Taken 
together, a number of important regulatory components act to control the levels of active 
PLK4 to ensure the fidelity of centriole duplication to once per cell cycle.  
 
  
 
 
Figure 1.9 The PLK4-STIL-SAS-6 interaction.  PLK4 binds to the CC domain of STIL via the L1 linker 
and polo-box 3. PLK4 then phosphorylates STIL within its STAN domain. Phosphorylated STIL then 
recruits SAS-6 to the centrosome to initiate centriole biogenesis. Adapted from Arquint & Nigg, 2016. 
 
Overexpression of PLK4 leads to the production of supernumerary centrioles and over 
amplification of centrosomes. This leads to missegregation of chromosomes, which is a 
hallmark of many cancers (Habedanck et al., 2005). A direct role in cancer progression was 
identified in Drosophila, where PLK4 overexpression in neuroblasts promoted 
tumorigenesis (Basto et al., 2008). Mouse models (p53 null mice) have shown that PLK4 
overexpression and centrosome amplification results in hyperproliferation and early onset 
tumour formation. In addition, overexpression resulted in a failure to produce basal bodies 
and primary cilia, which greatly disrupted cell signalling and caused uncontrolled 
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differentiation of the epidermis (Coelho et al., 2015). In humans, PLK4 overexpression has 
been observed in many cancers, including breast, colorectal and gastric cancers (Macmillan 
et al., 2001; Shinmura et al., 2014; Li et al., 2016). A role in metastasis was demonstrated 
via the interaction of PLK4 with the Arp2/3 complex responsible for regulating the actin 
cytoskeleton. PLK4 binding to Arp2/3 results in phosphorylation of the complex that is 
required for cytoskeletal rearrangement and subsequent cell motility. This suggested a 
mechanism of PLK4 driven cell metastases in human cancers (Kazazian et al., 2017).  
 
Loss of PLK4 results in a failure to duplicate the centrioles (Coelho et al., 2015; Wong et al., 
2015). Without centriole duplication, the dividing cells will contain a single centrosome, 
resulting in the formation of aberrant mitotic spindles, causing errors in chromosome 
segregation. Loss of PLK4 has also been identified as a causal factor of microcephaly and 
retinopathy (Martin et al., 2014; Tsutsumi et al., 2016). Mutations in PLK4 transcripts were 
identified in patients with microcephaly, including a deletion mutation and premature 
truncation of PLK4 within PB3. This greatly reduced the amount of functional PLK4 in the 
cell and consequently impaired centriole duplication. Studies in zebrafish confirmed that 
mutated PLK4 led to a reduction in overall size and impaired vision, which are the known 
phenotypes of microcephaly and retinopathy (Martin et al., 2014).  
 
Taken together, dysregulation of PLK4, leading to either over- or under-expression, and 
consequently altered levels of activity, is implicated in a range of diseases and disorders. A 
comprehensive understanding of the global roles of PLK4 is therefore required to fully 
elucidate the importance of the involvement of this kinase in the cell cycle, at the 
centrosome and in other cellular processes. This is the main focus of the work presented in 
this PhD thesis.  
 
 PLK5 
 
PLK5 lacks a functional kinase domain due to the presence of a stop codon disrupting the 
open reading frame. PLK5 does not appear to have roles in cell division and instead 
functions in neuron development. It is believed to serve a tumour suppressive function as it 
induces apoptosis in astrocytoma and glioblastoma tumour cells (de Carcer et al., 2011).  
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1.5. Aurora kinases 
 
The Aurora kinases were first discovered in Drosophila with homologs subsequently 
identified in all other eukaryotes (Glover et al., 1995). There are three members of this 
kinase family: Aurora A, B and C, each of which share conserved structural features (Figure 
1.10). Aurora kinases have a regulatory domain at the N-terminus and a C-terminal catalytic 
domain. Aurora A and B have an A box at the N-terminus, implicated in kinase degradation, 
which is missing in the shorter Aurora C. However, all three contain a D-box at the C-
terminus, which is also responsible for regulating degradation. Despite the catalytic 
domains sharing near identical sequence identity, Aurora A has 50 times greater activity 
than Aurora B, thought to be due to a single key residue, G205 in Aurora A, which results in 
a conformational change bringing the αC-helix closer to the activation loop (Eyers et al., 
2005). 
 
 
 
Figure 1.10. Schematic of the domain structures in Aurora kinases. The domain structure of Aurora 
kinases is illustrated, depicting the C-terminal kinase domain (KD) and the destruction box (D-box). A 
secondary destruction box, the A-box is found on Aurora A and Aurora B.  The number of amino 
acids of each kinase is shown on the right. The labeled Thr residues represent the activating residue 
within the kinase activation segment. 
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 Aurora A 
 
Aurora A has a diverse range of functions including roles at the centrosome, entry in to 
mitosis, and assembly of the spindle fibres (Hannak et al., 2001; Marumoto et al., 2002). 
Aurora A activity is regulated by phosphorylation at Thr288 within its activation segment 
(Walter et al., 2000) and its activity toward protein substrates is facilitated by the binding of 
cofactors including TPX2, Ajuba and Bora (Eyers et al., 2003; Hirota et al., 2003; Hutterer et 
al., 2006).  
 
In G2 phase cells, Aurora A is recruited to the centrosome by upstream regulators CDK11 
and PAK1 (Zhao et al., 2005; Petretti et al., 2006). At the centrosomes, Aurora A is activated 
by the LIM protein Ajuba. Active Aurora A then recruits proteins involved in centrosome 
maturation, including -tubulin and the TACC3-Msps complex. Aurora A activates this 
complex which then stabilizes the microtubules, a key aspect of centrosome maturation 
(Figure 1.7) (Barros et al., 2005). In addition, Aurora A phosphorylates Cdc25b which 
becomes active and dephosphorylates CDK1-cyclin B at Thr14 and Tyr15 residues (Cazales 
et al., 2005). Activated CDK1-cyclin B then drives the cell to enter mitosis. 
 
TPX2 was identified as an activator of Aurora A required for it to function in spindle 
assembly (Eyers et al., 2003). The N-terminus of TPX2 binds to the C-terminus of Aurora A, 
inducing conformational changes which both enhance autophosphorylation at Thr288 
within the activation loop, and shield the phosphorylated residue from the activity of 
downstream phosphatases (Bayliss et al., 2003). TPX2 bound Aurora A has been identified 
in a complex with microtubule proteins including XMAP215 and HURP, which act together 
to drive spindle assembly (Wong et al., 2008). 
 
Aurora A degradation is mediated by the anaphase-promoting complex/cyclosome (APC/C). 
This ubiquitin ligase targets a wide range of substrates, resulting in proteolytic degradation 
of mitotic proteins as the cell prepares to exit mitosis. The APC/C, bound to a co-activator 
Cdh1, recognises the degradation motifs (D-box and A-box) within Aurora A (Taguchi et al., 
2002).  Then, two APC/C associated enzymes; Ube2C and Ube2S add ubiquitin groups 
leading to rapid degradation of the kinase.  
 
Overexpressed Aurora A has been identified in a range of cancers, including breast, 
colorectal, ovarian and pancreatic (Bischoff et al., 1998). Aberrant Aurora A results in a 
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failure of the cell to undergo cytokinesis and centrosome amplification via multinucleation 
of microtubules (Meraldi et al., 2002). In addition, cells overexpressing Aurora A exhibit 
reduced p53 activity. This is due to phosphorylation at specific residues by Aurora A, 
preventing DNA binding and transcription of downstream target genes. This 
phosphorylation also enhances interaction between p53 and Mdm2 protein, promoting p53 
degradation (Liu et al., 2004b). Taken together, Aurora A expression must be carefully 
controlled to ensure the fidelity of cell cycle processes.   
 
 Aurora B 
 
Aurora B functions in the later stages of the cell cycle and its roles include chromatin 
modification, attachment of the spindle microtubules to kinetochores and cytokinesis. 
Localisation and activation of Aurora B is dependent on the regulatory subunits of the 
chromosome passenger complex (CPC): INCENP, Survivin and Borealin (Bolton et al., 2002). 
Binding of INCENP to Aurora B results in allosteric activation via a conformational change of 
the activation loop. In a feedback mechanism, Aurora B phosphorylates INCENP to become 
fully active (Honda et al., 2003). At centromeres, Borealin concentrates Aurora B leading to 
increased autoactivation.  
 
Aurora B bound to the CPC regulatory subunits plays a key role in regulating kinetochore 
attachments to the spindle, to ensure accurate segregation of sister chromatids. 
Phosphorylation of kinetochore proteins, such as NDC80 and KNL1, result in a destabilising 
effect between kinetochore-microtubule interactions. This is required to ensure that the 
chromosomes can re-align and eventually bi-orient correctly for segregation (Cheeseman et 
al., 2006; Welburn et al., 2010). 
 
CPC bound Aurora B also plays a key role in cytokinesis (Giet & Glover, 2001). In anaphase, 
Aurora B localises to the central spindle midzone and phosphorylates proteins involved in 
cytokinesis including vimentin present at the cleavage furrow, myosin II and desmin. Aurora 
B ensures the correct localisation and activity of the centralspindlin complex. This complex 
is required by the cytokinesis regulator RhoA, which signals the formation of the contractile 
ring to separate the cytoplasm in to the daughter cells (Basant et al., 2015).  
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Dysregulation of Aurora B has been identified in gliomas, thyroid carcinomas and colon 
cancers. Overexpression disrupts Aurora B activities at the kinetochore, preventing the 
accurate segregation of chromosomes, resulting in aneuploid cells (Gonzalez-Loyola et al., 
2015).  
 
 Aurora C  
 
Aurora C is the least studied of the Aurora family. It has been shown to localise to the 
centrosomes in a similar pattern to Aurora B. It can also interact with the CPC subunits 
INCENP and Survivin (Sasai et al., 2016). Aurora C is mostly expressed in the testis and is 
required for spermatogenesis (Tseng et al., 1998). Its role at the centrosome in somatic 
cells has not yet been studied. However, an increase in Aurora C mRNA levels have been 
observed in breast and prostate cancer cell lines, suggesting Aurora C may have a functional 
role in cancer progression (Zekri et al., 2012). 
 
 
1.6. Protein kinases as drug targets 
  
Aberrant phosphorylation is implicated in all stages of neoplasia, including uncontrolled cell 
division and therefore, protein kinases have been identified as key chemotherapeutic 
targets.  The first kinase inhibitor to reach the market was Imatinib, designed to treat 
chronic myelogenous leukaemia (CML) by inhibiting the proto-oncogene BCR-ABL 
(Deininger et al., 1997). The success of this compound has led to the development of many 
small molecule inhibitors targeting the ATP binding site of protein kinases for the treatment 
of disease, including cancer. Protein kinase inhibitors are divided in to type I, type II and 
type III (Dar & Shokat, 2011). Type I inhibitors bind to the active, DFG ‘in’ conformation in 
an ATP competitive manner, and use the gatekeeper residues within kinases to gain 
selectivity. Type II inhibitors bind to the inactive, DFG ‘out’ conformation and type III 
inhibitors are non-ATP competitive and confer allosteric inhibition.  
 
The highly conserved catalytic domain of protein kinases poses a vast challenge for the 
development of small-molecule compounds, particularly ATP competitive type I inhibitors. 
These inhibitors have multiple targets leading to the possibility of unknown off-target 
effects. Type II and type III inhibitors exhibit greater specificity toward their targets and 
overcome this issue to some degree. However, an additional issue arises from the ability of 
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protein kinases to mutate key residues to confer drug resistance. This was identified in 
patients treated with Imatinib, where a significant proportion developed mutations in the 
protein, including the gatekeeper residue (T315I) (Gorre et al., 2001). This led to the 
development of next generation ABL inhibitors including Dasatinib, Nilotinib and Ponatinib 
(Figure 1.11) (Shah et al., 2004; O'Hare et al., 2009; Blay & von Mehren, 2011). The 
development of kinase inhibitors is continuously advancing in pursuit of developing new, 
highly specific inhibitors and overcoming the issues of drug resistance.  
 
 
 
Figure 1.11. Structures of first and second generation protein kinase inhibitors.  Imatinib was the 
first approved small-molecule inhibitor used to treat CML (Deininger et al., 1997). Extensive drug 
resistance in patients in response to imatinib treatment led to the generation of next generation 
inhibitors to treat CML, including dasatinib, neratinib and ponatinib (Shah et al., 2004; O'Hare et al., 
2009; Blay & von Mehren, 2011). All four inhibitors are designed to target the BCR-ABL fusion 
protein found in CML patients.   
 
 Aurora & Polo-like kinases as drug targets  
 
Both Polo-like and Aurora kinases have been identified as drug targets, due to their key 
roles in regulating mitosis and frequent misregulation in cancer cells. A number of inhibitors 
designed against these kinases are currently undergoing clinical trials. PLK inhibitors in 
clinical development include Volasertib, Rigosertib (a dual PLK and PI3K inhibitor) and 
GSK461364A (Gilmartin et al., 2009; Rudolph et al., 2009; Casolaro et al., 2013). Volasertib 
is an ATP-competitive inhibitor, which potently inhibits PLK1-3 and has reached phase III 
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clinical trials to treat leukaemias. Volasertib was shown to treat bladder cancers by inducing 
cell cycle arrest and apoptosis.  
 
PLK4 was identified as a drug target following the results of an siRNA screen against protein 
kinases in breast cancers, which revealed reduced proliferation upon gene silencing of 
PLK4. A subsequent drug screen identified the ATP-competitive inhibitor, CFI-400945 as a 
potent inhibitor of PLK4 activity (Mason et al., 2014). Inhibition with CFI-400945 prevented 
centriole over duplication and led to an accumulation of PLK4, resulting from an inability to 
trans-autophosphorylate within its degradation motif. PLK4 is the most structurally diverse 
of the polo-like kinase family and CFI-400945 does not inhibit PLK1-3. However, it does 
potently inhibit several other protein kinases, including Aurora B.  
 
The critical role of Aurora kinases has resulted in the development of a number of inhibitors 
targeting the activity of these enzymes. These include the Aurora A inhibitors Alisertib and 
Danusertib currently in clinical trials, and Barasertib which inhibits Aurora B (Manfredi et 
al., 2011; Qin et al., 2015). In addition, VX-680 is a potent inhibitor of Aurora A, B and C and 
induces cell cycle arrest and apoptosis when used as a treatment for leukaemia, lymphoma 
and colorectal cancer (Harrington et al., 2004) (Figure 1.12).  
 
 
 
 
Figure 1.12. Protein kinases bound to small-molecule inhibitors. A) Aurora A inhibited by the ATP-
competitive inhibitor VX-680. B) PLK4 inhibited by the ATP-competitive inhibitor, centrinone. Images 
produced in PyMOL. 
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VX-680 is also a potent inhibitor of PLK4 and was used as a template for the design of the 
novel PLK4 inhibitor, centrinone (Tyler et al., 2007; Sloane et al., 2010). Chemical 
alterations to VX-680 included the addition of a methoxy substituent at the C5 position, 
targeting Met91 in the PLK4 hinge loop region (Harrington et al., 2004; Wong et al., 2015) 
(Figure 1.12). Centrinone treatment of cancer cells resulted in the depletion of centrosomes 
and cell-cycle arrest in G1 via a p53-dependent mechanism, potentially by loss of the 
interaction between p53 and MDM2. Inhibition of cells containing a drug-resistant PLK4 (in 
which Gly95 important for selectivity was mutated to Leu) provided confirmation that the 
loss of centrosome phenotype was a direct result of PLK4 inhibition, as centrosome 
duplication proceeded in this cell line (Wong et al., 2015). Centrinone is suggested to 
exhibit three orders of magnitude greater affinity for PLK4 over Aurora A, and is now 
frequently used in research laboratories to study the activities of PLK4 in cells.  
 
 
1.7. Mass Spectrometry-based proteomics  
 
Proteomics is defined as the study of the complete set of proteins expressed by a genome 
within a particular cell, at any given time (Wilkins et al., 1996).  Proteomics has become an 
invaluable tool for the assessment of the global role of protein kinases in co-ordinating 
distinct cellular processes. As protein kinases primarily function by signal transduction via 
the transfer of phosphate to substrates, the phosphorylation status (and other PTMs) of 
proteins within the cell must also be comprehensively investigated to gain a true insight 
into the activities of kinases within the cell. Mass spectrometry (MS)-based proteomics 
using liquid chromatography-tandem mass spectrometry (LC-MS/MS) has developed rapidly 
over the past 20 years and allows theoretically for an unbiased assessment of the global 
proteome/modified proteome under study.  
 
 Tandem mass spectrometry  
 
MS for proteomics studies typically couples liquid chromatography (LC) separation with 
tandem MS. For the analysis of peptides, reversed phase high-pressure liquid 
chromatography (RP-HPLC) is most commonly used due to the high level of separation that 
can be achieved and the use of solvents compatible with downstream electrospray 
ionisation (ESI). In RP-HPLC, peptides are bound to a column packed with silica particles 
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containing alkyl chains, of which C18 is the most common. Bound peptides are eluted from 
the column based on their relative hydrophobicity with increasing concentrations of organic 
solvent.  
 
 
Figure 1.13. Schematic of a typical mass spectrometer. Ions are introduced in to the mass 
spectrometer following formation of gaseous ions at the source. Ions are resolved in the mass 
analyser based on their m/z, and detected. The information (m/z, relative abundance) is recorded by 
a data system. The grey box indicates the parts of the mass spectrometer that are operated under 
high vacuum.  
 
As peptides elute from the reversed-phase column, they are first introduced to an 
ionisation source, which generates gaseous ions. The ions are then resolved based on their 
mass-to-charge ratio (m/z) and detected to produce a mass spectrum (Figure 1.13). In a 
typical tandem MS experiment required for proteomics studies, a survey scan (MS1), is first 
performed, to detect all ions of a defined m/z range at a given time and record their 
intensity. The mass of a peptide ion alone is insufficient for robust identification from a 
complex mixture, and therefore, peptide ions must be fragmented so that the constituent 
amino acids can be determined. In data-dependent acquisition (DDA) approaches, ions are 
selected for fragmentation based on their relative intensity, with the TopN most abundant 
ions being selected from the MS1 full scan (Mann et al., 2001). These ions then undergo 
fragmentation and the product ions produced are detected to produce an MS2 spectrum. 
The quality of each spectrum determines the confidence in downstream identification by 
data processing software. One limitation of DDA experiments is the preclusion of low 
intensity precursors being selected for fragmentation and therefore a certain loss of 
information (Han et al., 2008). An alternative, data-independent acquisition (DIA) approach, 
whereby all precursors over the defined m/z range are subjected to fragmentation, was 
developed to overcome this limitation (Chapman et al., 2014). With both approaches, 
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peptide sequences are identified from the product ion spectra, and these peptide IDs are 
used to infer protein identity.   
 
 Electrospray Ionisation 
 
Once ions have been introduced to the source, they must rapidly desolvate and enter the 
gas phase as charged ions in a process known as electrospray ionisation (ESI). ESI was first 
demonstrated by Fenn et al., in 1989 and later adapted into nanoelectrospray by Wilm & 
Mann in 1994 to use lower flow rates (Fenn et al., 1989; S. Wilm & Mann, 1994).  
 
In ESI, the sample is sprayed from a capillary subjected to a strong electric field and high 
temperature at atmospheric pressure. In positive-mode ESI, the sample is typically in an 
acidic solution and as it is sprayed from the capillary, the analytes move under the influence 
of the electric field (Kebarle & Verkerk, 2009; Wilm, 2011). The positively charged ions will 
move to the surface of the droplet and polarization causes the droplet to distort in to a 
cone shape, known as the Taylor cone (Taylor & McEwan, 1965). Instability at the cone 
results in droplets being emitted that undergo rapid desolvation until charged gas-phase 
ions are produced.  Two models describe how charged gaseous ions are produced from a 
liquid sample: the ion evaporation model and charge residue model (Figure 1.14).  
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Figure 1.14. Electrospray ionisation.  Two models describe the process of gaseous ion formation. 1) 
The ion evaporation model explains how smaller ions enter the gas phase (V. Iribarne & Thomson, 
1976; Thomson & Iribarne, 1979) and 2) the charge residue model describes the process for larger 
molecules, including proteins (red circles) (Dole et al., 1968). The grey circles depict peptides in the 
droplet. Figure adapted from (Wilm, 2011) 
 
In the ion evaporation model, the emitted droplets undergo solvent evaporation, aided by 
heat. As the solvent evaporates and the water content of the droplet increases, the surface 
tension increases and charge density of the droplet builds up. Eventually, at what is defined 
as the Rayleigh limit, the repulsion between the charges exceeds the surface tension (V. 
Iribarne & Thomson, 1976; Thomson & Iribarne, 1979).  At this point, Coulomb fission of the 
droplet occurs, leading to the ejection of solvated ions from the droplet surface.  It is now 
widely accepted that this model explains ESI of small molecular weight molecules 
(Konermann et al., 2013) (Figure 1.14).  
 
The charge residue model is suggested to explain ESI of larger molecules, such as intact 
proteins (Dole et al., 1968). This model assumes that ESI produces droplets containing one 
ion. As the droplet evaporates, a new Taylor cone is formed and emits smaller, highly 
charged droplets. Multiple iterations of this process continue until droplets containing a 
single ion are produced. These ions are released into the gas phase by desolvation and 
declustering (Figure 1.14).  
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 Thermo Orbitrap Fusion  
 
The Thermo Orbitrap Fusion is one of the most advanced mass spectrometers currently 
available, capable of achieving a resolution of 500,000 at 200 m/z (Figure 1.15). This ‘tribrid’ 
instrument consists of three different mass analysers: a quadrupole mass filter, ion trap and 
an orbitrap; a number of fragmentation modes including collision-induced dissociation 
(CID), higher-energy collisional dissociation (HCD) and electron transfer dissociation (ETD) 
are also permissible (Senko et al., 2013). Ions produced by ETD can be further activated by 
supplemental collision energy. This fragmentation strategy is described as ETcaD with low 
supplemental energy or EThcD if higher collision energies are applied. The mass analysers 
and fragmentation modes available on the Orbitrap Fusion will be discussed in detail below.  
 
 
 
Figure 1.15. Schematic of the Orbitrap Fusion mass spectrometer.  The Orbitrap Fusion Tribrid mass 
spectrometer includes a quadrupole mass filter, ion trap and Orbitrap mass analysers. CID and ETD 
can be performed in the linear ion trap, and HCD in the ion-routing multipole.  
 
Following ESI in the Orbitrap Fusion, ions are passed through an S-lens, which increases 
sensitivity by focusing the ion beam and prevents unwanted mass separation. An active 
beam guide also helps to reduce noise by preventing neutrals from entering the quadrupole 
(Senko et al., 2013). For ion selection, an RF potential is applied to the quadrupole, enabling 
it to act as a mass filter, and transmit precursor ions of a defined m/z for analysis, with the 
m/z value transmitted being dependent on the voltages applied. Ions are then routed by 
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the ion-routing multiple which permits stable ion transfer between the multipole and both 
the linear ion trap and orbitrap mass analysers.  
 
 Ion Trap 
 
Ion traps store ions using an oscillating electric field and can be used for mass analysis by 
measuring ion m/z. There are two types of ion trap: the 3D (or Paul) trap and the later 
developed 2D (or linear) ion trap which is implemented in the Orbitrap Fusion instrument 
(Schwartz et al., 2002). The key advantages of linear ion traps over the Paul trap is reduced 
space-charge effects from an increased volume for ion storage, alongside higher trapping 
efficiencies which leads to greater sensitivity.  
 
 
Figure 1.16. Linear ion trap mass analyser.  The ions enter the trap and two sets of RF voltages cause 
the ions to oscillate in the radial direction, whilst a DC potential applied to the electrodes confines 
the ions axially. Ions exit the trap and are detected by one of two detectors. Adapted from Schwartz 
et al., 2002.  
 
A linear ion trap is composed of four rods arranged around a central axis (Figure 1.16). 
When ions enter the ion trap, two sets of RF voltages are applied to the rods, with one set 
out of phase with the other. This confines the ions in the radial dimension, whilst ions are 
confined axially by a DC potential applied to the end electrodes. Ions are cooled by the 
injection of helium and mass analysis can be performed by the mass selective instability 
technique. This involves linearly ramping up the RF potential at one end of the electrode, 
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resulting in ion instability and ejection from the trap via two slots in opposite rods leading 
to two detectors for mass analysis (Stafford et al., 1984; Douglas et al., 2005). 
 
Alternatively, mass analysis can be performed by resonant ejection, which enhances 
sensitivity and resolution. Resonant ejection exploits the relationship between resonance 
frequency and m/z. Specific resonance frequencies can be employed to select ions of 
specific m/z for ejection from the trap due to the increased amplitude of their oscillations 
(Goeringer et al., 1992; March, 2012; Snyder et al., 2017).  This principle led to the ability to 
utilise ion traps for fragmentation and MS/MS analysis.  By implementing frequencies that 
are resonant to all ions except the ion of interest, these ions will be ejected from the trap, 
leaving an ion of specific m/z that can be fragmented by collisional dissociation and mass 
analysed (Snyder et al., 2017).  
 
Although linear ion traps contain a larger volume for ion storage than 3D ion traps, the 
number of ions that enter the trap must still be controlled to prevent space-charging 
effects. As the number of ions increases, repulsion between ions increases (Vedel & André, 
1984). This affects ion motion in the trap resulting in decreased resolving power and poor 
mass accuracy (Cox et al., 1995). 
 
 Orbitrap 
 
The Orbitrap mass analyser was developed by Alexander Makarov as a new approach for 
dynamic trapping of ions in an electrostatic field (Makarov, 2000). It consists of an outer 
‘barrel-like’ electrode and an inner ‘spindle-like’ electrode (Figure 1.17). For ions to enter 
the orbitrap, they must first accumulate in the ‘C-trap’, an RF-only quadrupole, which is 
composed of four curved electrodes and located perpendicular to the orbitrap. The C-trap 
is filled with nitrogen bath gas to cool the ions prior to injection in to the orbitrap. The RF is 
ramped down and a high voltage is applied across the C-trap, which ejects ions of a specific 
m/z in to the Orbitrap (Makarov, 2000).  
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Figure 1.17. Orbitrap mass analyser.  The ions are ejected from the C-trap and enter the orbitrap. 
Strong axial and radial electric fields result in the ions oscillating and orbiting around the central 
electrode. The frequency of oscillations is directly proportional to m/z. The ions are detected by the 
outer electrodes and the time-domain signal is Fourier Transformed (FT) to produce a mass 
spectrum.  Figure adapted from Eliuk & Makarov, 2015.  
 
Voltages applied between the two electrodes of the orbitrap result in strong axial and radial 
electric fields, which force the ions to oscillate in the z- direction, whilst simultaneously 
orbiting around the central electrode. To prevent ions from collisions with the outer 
electrodes, the voltages are increased, resulting in ‘electrodynamic squeezing’.   The 
electric field is strictly linear across the axis resulting in harmonic oscillations in this 
direction. The frequency of these oscillations is directly proportional to m/z and 
independent of the initial properties of the ion and is therefore the parameter used to 
determine mass. The outer electrodes serve as receiver plates to detect the current 
induced by the oscillating ions, as a ‘time-domain’ signal. This signal is then Fourier 
Transformed to produce a mass spectrum (Zubarev & Makarov, 2013; Eliuk & Makarov, 
2015).  
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The implementation of the Orbitrap in commercial mass spectrometers has become a 
powerful tool in the proteomics field, as ions can be measured at high resolution (up to 
1,000,000 at 200 m/z) and with high mass accuracy, significantly enhancing peptide 
identification confidence.  
 
 Collision-induced dissociation (CID) 
 
In the Orbitrap Fusion, CID is performed in the high-pressure cell of the dual pressure linear 
ion trap (Figure 1.15). Precursor ions collide with the inert helium gas in the trap and the 
kinetic energy is transferred to vibrational energy. This vibrational energy re-distributes 
throughout the peptide ion, resulting in bond cleavage (Summerfield & Gaskell, 1997) 
(Figure 1.18). The ‘mobile proton’ theory suggests that peptide ion cleavage is charge-
directed and that protons acquired during (n)ESI in positive ion mode localise at basic 
residues (Arg, Lys, His), but can be transferred upon activation to amide nitrogen atoms 
across the peptide. Consequently, the C-N amide bond is then cleaved, producing a series 
of b- and y- ions from the N- and C-termini respectively, depending on which terminus the 
charge is located (Roepstorff & Fohlman, 1984; Dongré et al., 1996). 
 
Figure 1.18. Collision induced dissociation (CID) mechanism of fragmentation.  Peptide collisions 
with inert gas result in cleavage at the C-N bond, producing b- and y- ion series. Figure adapted from 
Wysocki et al., 2000.  
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The efficiency of CID is strongly influenced by the residues present within the peptide. Basic 
residues (Arg, Lys, His) and their location within the peptide affect ionisation efficiency, 
charge state and consequently the fragmentation pathways and thus the CID product ion 
generated. Once a peptide has been cleaved, the fragment ions produced can form a 
temporary dimer to try to retain the proton therefore, basic residues with high proton 
affinity will influence fragmentation (Tabb et al., 2004). In addition, proline exhibits high 
gas-phase basicity as it is a secondary amine with high proton affinity. Therefore, cleavage 
N-terminal to Pro is favourable and intense y-ions are typically observed in the resulting 
mass spectrum (Hunt et al., 1986).  
 
Once the peptide ion has been fragmented, no further collisions occur during resonant CID, 
as the product ions will no longer be resonant with the frequency being applied in the trap, 
limiting the number of product ions detected. In addition, CID in an ion trap is limited by 
the ‘one-third rule’ whereby fragment ions with an m/z less than one-third of the precursor 
will suffer from instability in the ion trap and be lost. Despite this, the speed and sensitivity 
of CID fragmentation in an ion trap has led to it being widely used for peptide analysis.  
 
 Higher-energy collisional dissociation (HCD) 
 
HCD describes the fragmentation mode implemented within Orbitrap instruments and is 
broadly speaking, equivalent to the higher energy CID that occurs in a hybrid 
quadrupole/time-of-flight mass analyser. In HCD, ions are also fragmented upon collision 
with an inert gas. However, fragmentation occurs within a collision cell with high RF 
voltage, rather than in an ion trap. This has a number of advantages including no low mass 
cut-off, high resolution mass analysis and the potential for increased sequence coverage 
due to the application of higher energies than are used in CID. In addition, HCD in a collision 
cell allows the peptides to undergo multiple fragmentation events. HCD fragmentation can 
also produce additional fragments, such as immonium ions, which can aid peptide 
identification (Olsen et al., 2007).  
 
One limitation of HCD fragmentation is that acquisition times are much longer than that for 
CID in an ion trap due to a much greater number of ions being required for Orbitrap mass 
analysis (Jedrychowski et al., 2011). This can impede the number of identifications. 
However, recent developments in Orbitrap platforms, such as the Orbitrap Q-Exactive HF-X 
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have much faster ion-transfer times enabling rapid MS/MS analysis and higher numbers of 
identifications in a shotgun proteomics experiment (Kelstrup et al., 2018).  
 
 Electron transfer dissociation (ETD) 
 
ETD fragmentation was developed in 2004 to overcome the limitations of electron capture 
dissociation (ECD) fragmentation, which requires FT-ICR instrumentation not commonly 
used in the proteomics field. Instead of using near thermal electrons as in ECD, ETD uses 
reagent anions for ion-ion reactions to transfer an electron to the peptide cation, resulting 
in peptide cleavage at the N-Cα bond and a series of ‘even electron’ c- and ‘odd electron’ z- 
type fragment ions (Syka et al., 2004) (Figure 1.19).  
 
The first step of ETD is the generation of reagent anions and can be achieved in a number of 
ways. Chemical ionisation (CI) sources produce near-thermal electrons from the collisions 
between electrons and an inert gas. Reagent anions (most commonly fluoranthene) can 
then capture the electrons, producing radical anions.  Alternatively, a Townsend glow 
discharge can be used to produce thermal electrons used to generate radical anions and is 
utilised in both the Orbitrap Fusion and Lumos instruments. The reagent source is located 
at the front end of the instrument, between the S-Lens and Active Beam Guide. Switching 
polarity of the instrument allows the radical anions to be m/z selected and transferred to 
the high pressure cell of the ion trap for the ETD reaction.  
 
Transfer of an electron to the peptide is a non-ergodic process and thus, the energy does 
not distribute throughout the ion in the same way as during collisional dissociation. 
Therefore, labile modifications (such as phosphorylation) can be maintained on the 
modified amino acid which greatly aids phosphosite localisation. Electron transfer results in 
charge neutralisation and therefore, ETD requires multiply protonated peptides for 
cleavage. Peptides with low charge form compact structures in the gas-phase whereas ions 
with greater charge density exhibit linear gas-phase structures (Riley & Coon, 2018). The 
application of ETD to peptides with compact structures often leads to non-covalent 
interactions between the resulting c- and z- ions, greatly reducing sequence information in 
the mass spectrum (Good et al., 2007; Liu & McLuckey, 2012).  
 
  Chapter 1 
34 
 
 
 
Figure 1.19. Electron transfer dissociation (ETD) mechanism of fragmentation. Electrons are 
donated by radical fluoranthene anions. This results in cleavage at the N-Cα bond, producing c- and 
z- ion series. Adapted from Syka et al., 2004. 
 
Strategies to overcome non-covalent interactions between fragment ions include the use of 
supplemental energy to dissociate these interactions and generate richer product ion 
spectra to aid peptide identification. Following ETD, the unreacted and charge reduced 
precursor and non-dissociative product ions can be transferred to the collision cell for 
additional ion activation. If low supplemental energy is applied (NCE <15), then the 
resulting mass spectrum will contain a richer c- and z- ion series than that of ETD alone 
(Swaney et al., 2007). However, if higher collision energies are applied, then in addition to 
dissociating ETD product ions, additional fragmentation via collisions with the inert gas will 
occur, leading to spectra containing c-, z-, b- and y- ion series. This generates much greater 
sequence coverage, aiding peptide identifications (Frese et al., 2012; Frese et al., 2013) 
 
ETD efficiency is also influenced by peptide sequence. In contrast to CID, ETD is unable to 
cleave peptides N-terminal to proline residues. This is because the cyclic secondary amine 
structure of the proline side chain would require two N-Cα bonds to be broken to produce 
the fragment ion (Kim & Pandey, 2012). In this way, CID and ETD can be used as 
complementary techniques to improve sequence coverage.  
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 Thermo Orbitrap Fusion flexibility 
 
The advanced capabilities of the Orbitrap Fusion allow for deep coverage of the proteome 
and phosphoproteome, which will be required to study the global activities of protein 
kinases discussed in this thesis. The ion trap and orbitrap mass analysers can operate in 
parallel such that a full-scan can be performed in the orbitrap, whilst ions from the previous 
full scan are fragmented and detected in the ion trap. Previous Orbitrap instruments have 
employed a TopN approach to select ions for fragmentation. However, the Orbitrap Fusion 
utilises a ‘Top Speed’ approach where ions are fragmented over a pre-determined cycle 
time. This approach allows for potentially larger numbers of identifications without 
extending the overall duty cycle.  
 
Flexibility at all stages, including the selection of mass analyser to be used for ion detection 
and fragmentation mode to be utilised, ensures that the setup of system can be customised 
for specific applications.  
 
 Proteomics workflows 
 
The most widely utilised strategy for proteomics analysis is a ‘bottom up’ approach, in 
which proteins are first digested in to peptides for MS analysis. This strategy is summarised 
in Figure 1.20. First, samples are lysed using an appropriate lysis buffer to release the 
proteins within the cells. The disulphide bonds maintaining protein tertiary structure are 
reduced using dithiothreitol (DTT) or tris(2-carboxyethyl)phosphine (TCEP). To prevent 
disulphide bonds from re-forming, samples are incubated with iodoacetamide or iodoacetic 
acid to alkylate free cysteine sulfhydryl groups. Samples must then be digested to form 
peptides of a suitable size for analysis, with trypsin the most common choice. Trypsin 
cleaves C-terminal to Lys and Arg residues (except when the residue is followed by a Pro 
residue) and produces peptides of suitable length for C18 reversed-phase separation and 
MS analysis (7-20 amino acids). In addition, the basicity of Lys and Arg means that all tryptic 
peptide ions will carry an extra proton, in addition to the proton localised to the NH2- group 
of the N-terminus following ESI.  
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Figure 1.20. Bottom-up proteomics workflow. Proteins from a biological sample are digested to 
form peptides and analysed by LC-MS/MS 
 
 
1.8. Quantification strategies 
 
Typically, large-scale proteomics analyses aim to not only identify which proteins are 
expressed within a cell, but also to quantify the relative or absolute abundances of the 
identified proteins. Often, differences in protein expression arising from specific cell stimuli, 
or in response to drug treatments, are required to understand biological processes.  
 
 Absolute quantification 
 
Absolute quantification reports exactly how much of a given protein is expressed, and this 
is typically reported as number of copies per cell, or moles per cell. Intensity-based 
absolute quantification (iBAQ) is commonly employed for measuring how much protein is in 
the sample. In iBAQ, the total intensities of the observed peptides are summed and divided 
by the number of theoretically observable peptides of a protein (Schwanhausser et al., 
2011). The iBAQ scores can then be converted in to number of copies of a particular protein 
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per cell. Alternatively, absolute quantification can be performed by adding known amounts 
of an isotopically labelled identical analyte standard, such as chemically synthesised AQUA 
peptides or peptide concatamer QconCAT standards. Known amounts of standard are 
spiked in to samples prior to MS analysis, allowing the amount of peptide (and therefore 
protein) within a sample to be determined (Beynon et al., 2005; Rivers et al., 2007; 
Kettenbach et al., 2011a).  
 
 Relative quantification 
 
Relative quantification of peptides can be performed using label-based or label-free 
approaches. In label free quantification, each sample to be measured (e.g. control vs 
treated) is analysed in a separate experiment (Figure 1.21). If carefully controlled, the 
retention times for ions will be the same across runs and can be aligned. The signal 
intensity (or peak area) is then measured for each peptide and the areas for peptides of a 
particular protein are averaged. The areas are then compared to proteins in different 
samples to assess relative changes (Bondarenko et al., 2002). Spectral counting can also be 
used to quantify proteins in a label-free experiment.  In this approach, the number of MS2 
spectra acquired for a given peptide is summed to determine relative protein abundance. 
This is based on the observation that the number of MS2 spectra acquired and the peptides 
identified for a protein increases as protein abundance increases (Liu et al., 2004a) This can 
then be compared to different samples to assess relative changes in protein abundance. 
This is because in DDA experiments, an abundant peptide will be sampled more frequently. 
This approach has a number of inherent limitations including the stochastic nature of DDA 
reducing reproducibility and the inherent bias toward abundant proteins (Lundgren et al., 
2010).  
 
Labelling strategies for relative quantification include metabolic approaches to label 
proteins as they are synthesised within the cell (i.e. SILAC), or chemical approaches to label 
digested peptides.  
 
Stable-isotope labelling by amino acids in cell culture (SILAC) is the most popular labelling 
method and widely utilised in quantitative proteomic workflows. SILAC involves 
supplementing culture medium with stable isotopes of amino acids, which are incorporated 
in to the proteome through normal metabolic processes (Ong et al., 2002; Ong & Mann, 
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2007). Heavy lysine (13C6, 15N2) and arginine (13C6, 15N4) are most commonly used, as 
peptides for LC-MS/MS analysis are produced following tryptic digestion at these residues. 
When proteins from heavy and light samples are mixed 1:1 and analysed by LC-MS, the 
peptides appear as a pair in the mass spectrum, separated by the difference in mass 
corresponding to the incorporated stable isotope (Figure 1.21). The ratio of signal 
intensities can then be compared to provide quantitative information on the relative 
protein abundance in the cell. SILAC-based quantification ideally requires cells to be fully 
labelled prior to sample mixing, as partially labelled cells will contribute to the ‘light’ 
peptide signal upon analysis of the resulting peptides by MS, resulting in inaccurate 
quantification. SILAC labelling was the strategy used in this thesis for peptide and protein 
quantification.  
 
As an extension of SILAC, a super-SILAC approach was developed in which a SILAC sample is 
prepared separately and spiked in to each of the samples to be analysed. The ratio between 
the ‘light’ peptides and the SILAC standard can be determined and as the amount of spiked 
in standard is equal across samples, a ‘ratio of ratios’ can be performed (Geiger et al., 
2011). 
 
 
 
Figure 1.21. Comparison of label-based and label-free quantitative proteomics workflows.  The 
upper panel shows a typical SILAC workflow. Cells are cultured in medium containing heavy or light 
stable amino acid isotopes. Samples are mixed 1:1, digested and analysed by LC-MS/MS. SILAC pairs 
are identified by a predefined difference in mass and quantified based on MS1 intensity. The lower 
panel shows a label-free workflow where samples are prepared separately and analysed in parallel. 
The peaks are quantified by comparing extracted ion chromatograms.  
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Chemical labelling approaches include stable-isotope dimethyl labelling, or isobaric labelling 
with iTRAQ or TMT reagents. Dimethyl labelling uses formaldehyde to convert all primary 
amines (N-terminus and Lys side chains) to dimethyl amines. The resulting tryptic peptides 
will therefore have one dimethyl group for Arg terminating peptides and two for Lys 
terminating peptides, generating mass shifts of 4 Da and 8 Da respectively (Hsu et al., 2003; 
Boersema et al., 2009b). These mass shifts are then used to determine the ratio between 
‘heavy’ and ‘light’ samples. Labelling with iTRAQ or TMT reagents use isobaric amine 
reactive tags to label peptides. Up to 8 iTRAQ labels and 11 TMT labels can be used in 
multiplex experiments with no difference in mass therefore; quantification is performed at 
the MS2 level. Upon peptide fragmentation, a reporter ion is released from the tags, each 
with a different mass. The relative intensities of each can be used to determine relative 
abundance of the peptide in each sample analysed (Thompson et al., 2003; Ross et al., 
2004) 
 
 
1.9. Phosphoproteomics 
 
Phosphoproteomics is the study of the phosphorylation status of all of the proteins 
expressed within a cell. The increase in mass (80 Da) of a phosphorylated peptide allows 
modified peptides to be distinguished from their non-phosphorylated counterparts. 
Fragmentation of phosphopeptides can isolate the exact site of modification if sufficient 
coverage of the peptide sequence is obtained. However, analysing the phosphoproteome is 
a considerable challenge, with many ‘bottlenecks’ that need to be overcome.  
 
One key issue is that phosphopeptide ions subjected to collisional dissociation can lose the 
attached phosphate group during fragmentation, a process termed ‘neutral loss’. Losses of 
80 Da, corresponding to HPO3 or 98 Da, corresponding to H3PO4 can occur, with loss of 98 
Da most commonly observed for pSer and pThr containing peptides. Neutral loss is most 
frequently observed when phosphopeptides are fragmented with CID and can be explained 
by the mobile proton model. In a mobile proton environment (fewer basic residues than 
the number of acquired protons), the protons can transfer to the negatively charged 
phosphate group, making the β-carbon of the side chain more electrophilic, which can then 
undergo intramolecular nucleophilic substitution leading to neutral loss of H3PO4 (Figure 
1.22 A).  In a limited mobile proton environment, neutral loss can also occur, due to the 
lower energy of the phosphoester bond compared with the amide bond. In this 
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environment, protons are localised to basic residues in the peptide, which can interact with 
the phosphate group and drive preferential cleavage of the phosphoester bond (Figure 1.22 
B) (Palumbo et al., 2008; Boersema et al., 2009a; Lanucara et al., 2014). The aromatic ring 
of pTyr prevents neutral loss of H3PO4 and loss of HPO3 is primarily observed (Tholey et al., 
1999). CID in an ion trap often results in a mass spectrum dominated by the precursor 
exhibiting neutral loss, as no further fragmentation of the peptide will occur as the CID 
product ions are no longer resonant.  
 
 
 
 
Figure 1. 22. Proposed pathways for neutral loss of H3PO4 from a phosphorylated peptide.  A) 
Neutral loss in a mobile proton environment via an intramolecular nucleophilic substitution reaction. 
B) Neutral loss in a limited mobile proton environment via a charge directed nucleophilic substitution 
reaction. Adapted from Lanucara et al., 2014. 
 
Methods to improve fragment ion spectra acquired through CID fragmentation have 
included the development of multistage activation (MSA) methods. In MSA, the 
phosphorylated precursor is first activated, which will produce a predominant neutral loss 
fragment. This fragment then undergoes further dissociation in the ion trap and a pseudo 
MS3 spectrum is produced, which combines the MS2 and MS3 fragmentation spectra. This 
leads to richer fragmentation spectra and maintains fast acquisition speeds (Schroeder et 
al., 2004).  
 
Neutral loss can also be observed with HCD fragmentation. However, the ability for 
multiple collisions leading to additional fragmentation events can produce rich 
fragmentation spectra, allowing for the modified site to be identified. The improvements in 
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instrumentation have led HCD fragmentation and high resolution mass analysis to begin to 
overtake CID (and MSA) methods as the method of choice for phosphoproteomics analysis. 
Alternatively, ETD fragmentation can be utilised for phosphopeptide analysis, as the 
nonergodic nature means that the phosphate group is retained on the modified residue, 
often allowing the site of modification to be identified with greater confidence. However, 
ETD is only available on selected MS platforms, requires longer reaction times, and 
fragmentation is generally much less efficient than collision-mediated dissociation, in 
particular for low charge states (where z = 2). This has limited the benefit of ETD in high-
throughput phosphoproteomics studies.  
 
An additional challenge to performing phosphoproteomics is that phosphorylation is sub-
stoichiometric and phosphoproteins are present in a background of highly abundant non-
modified proteins (Steen et al., 2006). DDA approaches to study phosphorylation will select 
the TopN most abundant ions, which will greatly limit the number of phosphopeptides 
selected for fragmentation. In addition, phosphopeptides are believed to exhibit reduced 
ionization efficiencies and can suffer from ion suppression (Ishihama et al., 2007; 
Marcantonio et al., 2008). Improvements in phosphopeptide analysis have therefore 
involved both offline fractionation methods (e.g. strong anion exchange, HILIC) to enable 
analysis of greater numbers of low abundant ions, and enrichment of phosphopeptides to 
separate them from non-phosphorylated peptides for analysis.  
 
 High pH reversed phase fractionation 
 
Offline peptide fractionation has greatly aided the ability to identify large numbers of 
phosphorylated peptides in a sample. A number of methods have been utilised, including 
ion exchange (IEX) (Beausoleil et al., 2004), hydrophilic interaction chromatography (HILIC) 
(McNulty & Annan, 2008), electrostatic repulsion-hydrophilic interaction chromatography 
(ERLIC) (Alpert, 2008) and high pH reversed phase (high pH RP) (Yang et al., 2012; Batth et 
al., 2014). High pH RP was utilised in the work described in this thesis and is therefore 
described in further detail. 
 
High pH RP fractionation separates peptides based on their relative hydrophobicity, with 
peptides of increasing hydrophobicity eluting as the concentration of solvent increases. The 
high pH of the buffers enables peptide separation that is orthogonal to the low pH RP 
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employed for separation of peptides prior to MS/MS analysis. At high pH, the charge 
distribution within each peptide is radically changed, as the carboxylic and ammonium 
groups within the peptide will be deprotonated (Gilar et al., 2005; Delmotte et al., 2007)). 
This will affect the elution profile compared to low pH RP and enhances the separation of 
peptides to increase overall phosphopeptide identifications. Compared with other 
fractionation strategies, high pH RP has shown to significantly improve phosphopeptide 
identifications, with more than double the number of phosphopeptides identified 
compared with strong cation exchange (Batth et al., 2014).  
 
 Titanium dioxide enrichment 
 
In addition to off-line fractionation, enrichment of phosphopeptides is a prerequisite to 
perform in-depth phosphoproteomics analysis. Traditionally, immobilised metal affinity 
chromatography (IMAC) has been widely used for phosphopeptide enrichment. In IMAC, 
the affinity of immobilised metal ions (e.g Fe3+) for negatively charged groups is exploited 
(Neville et al., 1997). Whilst successfully employed in many experiments, IMAC is limited by 
the affinity for acidic carboxylic acid groups on non-phosphorylated peptides to bind to the 
metal ions (Negroni et al., 2012). These limitations led to the development of novel 
approaches for enrichment, including metal oxide affinity chromatography (MOAC), which 
most commonly utilises TiO2 to bind to phosphopeptides.   
 
TiO2 enrichment is performed at low pH, which helps prevent the unwanted binding of 
acidic groups from non-phosphorylated peptides (Larsen et al., 2005). Additives such as 
glutamic acid can also also be included, to further prevent carboxylic acid groups of non-
phosphorylated peptides from binding (Wu et al., 2007).  The oxygen group of the 
phosphate has a strong affinity to the titanium metal, which binds via a bridging bidentate 
interaction (Figure 1.23). Phosphopeptides can then be eluted with an alkaline buffer such 
as ammonium hydroxide, which disrupts this interaction (Thingholm et al., 2006). 
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Figure 1. 23. Titanium dioxide enrichment of phosphopeptides.  Phosphorylated peptides bind to 
the titanium dioxide resin via the formation of a bridging bidentate interaction between the metal 
and phosphate. Adapted from Larsen et al., 2005. 
 
Combining off-line fractionation with selective phosphopeptide enrichment has greatly 
advanced the study of complex phosphoproteomes by LC-MS/MS. Phosphoproteomics 
experiments can now identify tens of thousands of phosphopeptides and deliver novel 
insights in to the dynamic regulation of phosphorylation within cells. This includes studies in 
to the deregulation of phosphorylation in disease, as well phosphorylation dynamics in 
response to drug treatments. One study, which aimed to comprehensively analyse the 
phosphoproteome of two cancer cell lines (HeLa and K562) identified 16,000 and 24,000 
phosphosites respectively (Zhou et al., 2013).  
 
1.10. Data Analysis 
 
Following LC-MS/MS analysis, the acquired data must be computationally deconvoluted 
and processed to determine peptide identity based on the MS1 and MS2 spectra. Many 
search engines are available, including MASCOT, SEQUEST, Andromeda, PEAKS and MS 
Amanda (Eng et al., 1994; Perkins et al., 1999; Cox et al., 2011; Dorfer et al., 2014). The 
search engines typically use the experimental data (MS1 and MS2) and compare the masses 
to calculated theoretical values based on in silico digests of a proteome. A probability based 
scoring algorithm is used to determine confidence in the matched peptides (Perkins et al., 
1999). There is a requirement to determine the false discovery rate (FDR) of peptides 
identified to filter out false positive results. There are different approaches to calculating 
FDR, with a ‘target decoy’ approach being the most common. This approach reverses the 
sequences present in the database used to search data and the number of matches to the 
reversed database is an indicator of the number of false positives in the data (Elias & Gygi, 
2007).  
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Additional software is required if peptide/protein quantification is required. The two most 
commonly used platforms are Progenesis for label-free data and MaxQuant, which can 
perform both label-based and label free quantification, and was used in the work described 
in this thesis.   
 
MaxQuant is freely available software and is the most widely used platform for processing 
SILAC data (Cox & Mann, 2008). MaxQuant uses feature detection (m/z and intensity of the 
peptide peaks) in each MS scan for quantification and fits Gaussian peak shapes using the 
number of data points per peak. Ion retention time, m/z and intensity are then used to 
create a 3D peak, which is smoothed and used to determine an intensity weighted mass. In 
SILAC experiments, MaxQuant detects heavy and light SILAC pairs if they have the same 
charge and differ by a predefined mass (set in the method as a variable modification) (Cox 
& Mann, 2008). Peptides are identified using the Andromeda search engine implemented in 
to MaxQuant and FDR calculated using a target-decoy approach (Cox et al., 2011). The 
advanced algorithm for quantification and ease of use make MaxQuant a popular choice for 
data analysis. In addition, output files from MaxQuant contain all of the information 
required to interrogate quantitative changes between samples to study biological processes 
(Cox & Mann, 2008).  
 
 Phosphosite localisation 
 
The ability to identify large numbers of phosphopeptides has greatly advanced the 
phosphoproteomics field. However, to truly understand phosphorylation dynamics, the 
exact site of modification within a peptide must be determined. Many bioinformatics tools 
have been developed to apply calculated localisation scores to phosphosites within a given 
peptide sequence. These include A-score, PTM-score, SloMo, LuciPHOr and ptmRS 
(Beausoleil et al., 2006; Olsen et al., 2006; Bailey et al., 2009; Taus et al., 2011; Fermin et 
al., 2013). Each of these tools aims to localise phosphosites by calculating the chance of a 
given peak (capable of being phosphorylated) being matched at random. An alternative 
approach is to compare search engine scores calculated when the phosphosite is localised 
at different residues within the peptide. This is incorporated in the MASCOT search engine 
and is referred to as a MASCOT delta score (Savitski et al., 2011).  
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PTM-score determines sites of modification by first dividing the spectrum in to separate 
m/z ‘bins’. The top N most intense ions within each bin are then used to score the 
probability of a residue being modified. One limitation of this approach is that ions of low 
intensity in bins containing few ions will be used in the calculation, which can affect the 
ability of the algorithm to determine true sites of modification. PTM-score calculates a 
probability score for the peptide with each of the phosphorylatable residues chosen as 
modified site. The scores are then converted to ensure the probabilities equal 100 % (Olsen 
et al., 2006). PTM-score was developed for low-resolution CID data and therefore, the 
strength of the algorithm to correctly localise phosphosites in high-resolution data is likely 
limited. The most recently developed phosphosite localisation tool, ptmRS, is the latest 
development of the PhosphoRS algorithm and is integrated in the Proteome Discoverer 
platform (Taus et al., 2011). It can be therefore be used with data searched in MASCOT and 
SEQUEST. The scoring in ptmRS was developed for high and low resolution data, acquired 
using a range of fragmentation modes (CID, HCD, ETD, EThcD). Compared with PTM-score, 
ptmRS considers the total number of extracted peaks across the full mass range of the MS2 
spectrum, overcoming potential issues of uneven peak distribution in individual m/z bins 
(Chalkley & Clauser, 2012).  
 
The ability to identify high numbers of phosphopeptide identifications using the search 
engines described, along with the ability to assign phosphosite localisation scores to 
residues within a peptide has advanced the phosphoproteomics field. Large-scale 
phosphoproteomics studies can now routinely be performed to study a diverse range of 
biological systems with deep coverage of the post-translationally modified proteome.  
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1.11. Aims and objectives 
 
The aim of this work is to study the PLK4 regulated phosphoproteome to identify cellular 
processes and signalling pathways regulated by PLK4 activity and potentially identify novel 
substrates. The full workflow, including development of biochemical tools to study PLK4 in 
human cells, and the optimisation of MS parameters for phosphopeptide analysis will be 
established. These tools will then be utilised to perform a large-scale SILAC-based 
quantitative phosphoproteomics experiment. Finally, this work aims to establish a novel 
interaction between PLK4 and Aurora A, to aid understanding of the roles of these kinases 
in co-ordinating activities during the cell cycle.  
 
The aims will be met through the following objectives: 
 
 Production and in vitro characterisation of recombinant WT and G95R-PLK4 
proteins  
 Generation of stable isogenic U2OS cells lines transfected with FLAG-WT or 
G95R- PLK4 full-length plasmids 
 Assessment of optimal conditions for PLK4 inhibition with centrinone 
 Optimisation of MS acquisition methods on the Orbitrap Fusion for large-
scale phosphopeptide analysis  
 Performing a large-scale SILAC based quantitative phosphoproteomics 
experiment to investigate PLK4 regulated signalling pathways 
 Assess a possible interaction between PLK4 and Aurora A  
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 Methods:  
 
2.1. Reagents 
 
Unless otherwise stated, general lab reagents were purchased from Sigma Aldrich.  
 
 
2.2. Antibodies 
 
The following antibodies were used: anti-PLK4 clone 6H5 (Millipore, 1/100 for western blot; 
immunofluorescence), anti-Aurora A (Cell Signalling Technologies, 1/5000 for western blot, 
1/500 for immunofluorescence), anti-pericentrin (Abcam, 1/500 for immunofluorescence), 
anti- γ-tubulin (1/500 for immunofluorescence), anti-TAT1 (1/5000, for western blot), anti-
GAPDH (1/5000, for western blot), anti-p21 (Abcam, 1/300 for western blot), anti-CCND2 
(1/100 for western blot), anti-EGFR (1/500 for western blot), anti-pThr669 EGFR (1/100 for 
western blot).  
 
 
2.3. DNA sample preparation 
 
 Polymerase Chain Reaction (PCR) amplification 
 
Full length (1-2913) PLK4 insert (50 ng) was incubated with 1.5 mM MgSO4, 200 µM dNTPs, 
2.5% DMSO, 1 µM forward primer incorporating a Kozak sequence, FLAG tag and Hind III 
and Not I restriction sites at the 5’ and 3’ ends respectively, 1 µM reverse primer, 1x KOD 
buffer and 1 µL KOD polymerase. The PCR cycle was set up as follows: 95 °C for 2 minutes 
followed by 30 cycles of 95 °C DNA denaturation for 20 seconds, 64 °C primer annealing for 
10 seconds and 70 °C extension for 2 minutes, with a 10 minute 70 °C hold after the last 
cycle.  
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 Agarose gel electrophoresis  
 
PCR product was analysed by agarose gel electrophoresis using a 1 % (w/w) agarose gel 
containing 5 µL Midori green nucleic acid stain and run at 100 V for 30 minutes. DNA bands 
were visualised by UV light. 
 
 DNA gel extraction 
 
DNA bands were excised for DNA purification using the QIAGEN QIAquick Gel Extraction Kit 
following the manufacturers protocol. Gel bands were dissolved in buffer QG (volume 3x 
that of the gel band) at 50 °C for 10 minutes followed by the addition of isopropanol 
(volume 1x that of the gel band). DNA was collected in a QIAquick spin column at 15,000 x g 
for 1 minute. The column was washed with 500 µL buffer QG followed by two washed with 
750 µL buffer PE and centrifuged at 15,000 x g after each step. DNA was eluted from the 
column by the addition of nuclease free H2O and DNA concentration determined by 
nanodrop.  
 
 Restriction digestion & ligation 
 
Not I and Hind III restriction enzymes were incubated with FLAG-PLK4 PCR product and 
separately, with pcDNA5 frt/to vector for 2 hours at 37 °C Enzymes were heat deactivated 
at 65 °C for 20 minutes and pcDNA5 was treated with alkaline phosphatase to prevent re-
ligation of the plasmid.  
 
Ligation reactions were set up with 3.5 fold excess PLK4 insert to pcDNA5 vector and 
incubated with 20,000 units/mL T4 ligase and 1x reaction buffer for 15 minutes at room 
temperature. T4 ligase was heat deactivated at 65 °C for 20 minutes. 
 
 Site Directed Mutagenesis 
 
Full length wild type (WT) PLK4 pcDNA5 plasmid (6ng) was incubated with 1.5 mM MgSO4, 
200 µM dNTPs, 2.5% DMSO, 1 µM forward primer incorporating the mutation GGA 
(Glycine) to CGA (Arginine), µM reverse primer, 1x KOD buffer and 1 µl KOD polymerase. 
The PCR cycle was set up as follows: 95 °C for 2 minutes followed by 35 cycles of of 95 °C 
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DNA denaturation for 20 seconds, a temperature gradient between 55 °C and 65 °C for 
primer annealing and a 70 °C extension for 16 minutes.  
 
 Bacterial transformation 
 
5 µL DNA was transformed in to 50 µL Top10 E.coli and incubated on ice for 30 minutes 
followed by heat shock at 42 °C for 35 seconds. 250 µL SOC media was added and 
incubated for 30 minutes at 37 °C, 250 rpm. Cultures were inoculated on agar plates 
containing 50 µg/mL ampicillin overnight at 37 °C. Colonies were extracted and added to 10 
mL LB broth containing 50 µg/mL ampicillin overnight at 37 °C, 250 rpm. Plasmids were 
purified using QIAGEN QIAprep Spin Miniprep kit and Sanger sequenced to confirm the 
presence of the incorporated mutation.  
 
 Plasmid DNA purification 
 
DNA was purified using the QIAprep Spin Miniprep kit following the manufacturers 
protocol. Briefly, the cell pellet was re-solubilised in 500 µL of buffer P1 followed by the 
addition of 500 µL buffer P2 and mixing by inversion then the addition of 700 µL N3. 
Samples were centrifuged at 15,000 xg for 10 minutes and supernatant remove and applied 
to a QIAprep Spin column and centrifuged at 150,000 xg for 1 minute to collect the DNA. 
The columns were washed sequentially with 500 µL buffer PB and buffer PE and centrifuged 
at 15,000 xg for 1 minute after each. DNA was eluted from the column by the addition of 
nuclease free H2O and DNA concentration determined by nanodrop.  
 
 
2.4. Cell-based sample preparation  
 
 Cell culture  
 
U2OS T-Rex Flp-in cells were maintained in DMEM supplemented with 10% (v/v) fetal 
bovine serum, penicillin (100 U/mL), streptomycin (100 U/mL) and L-glutamine (2 mM), at 
37 °C, 5% CO2. At 80 % confluence, cells were washed with PBS, released with trypsin (0.05 
% (v/v)) and centrifuged at 220 x g.  
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 Cell transfection 
 
To generate stable transfected cells, 1 μg plasmid (FLAG or MYC- WT & G95R PLK4) was 
incubated with 1 μL lipofectamine and made up to 500 μL with serum free media. Plasmids 
were co-transfected with a Flp recombinase, pOG44, of which 9 μg was incubated with 9 μL 
lipfoctamine 2000 (Invitrogen) in a 500 μL volume made up with serum free media. The 1:1 
lipofectamine:plasmid mixture was added to the cells. Media was changed 24 hours later 
and after a further 24 hours, media was supplemented with hygromycin. 
For transient transfection of MYC-WT PLK4, the above procedure was followed with the 
following exceptions: 6 μg of plasmid was transfected with 6 μL lipofectamine 2000 and 
pOG44 was omitted to prevent incorporation of the plasmid in to the genome.  
 
 SILAC labelling  
 
U2OS T-Rex Flp-in cells stably transfected with FLAG-WT PLK4 or FLAG-G95R PLK4 were 
grown in DMEM supplemented with 10% (v/v) dialysed fetal bovine serum, penicillin (100 
U/mL) and streptomycin (100 U/mL). Once 80 % confluency was reached, cells were split in 
to DMEM containing heavy labelled, 13C 15N labelled arginine and lysine for ~seven cell 
doublings to permit full incorporation of the label. At each passage, an aliquot of cells were 
removed and analysed by LC-MS/MS (see below) to assess label incorporation. At 80 % 
confluence, cells were washed with PBS, released with trypsin (0.05 % (v/v)) and 
centrifuged at 220 x g.  
 
 Cell Lysis 
 
Cells were lysed with two different lysis buffers depending on whether western blot or MS 
analysis was required. For western blot analysis, cells were lysed with 1 % (v/v) NP-40, 1 % 
SDS in 50 mM Tris pH 8.0, 150 mM NaCL containing with 1x protease inhibitor cocktail 
tablet (Roche) (for western blot analysis). The lysate was sonicated briefly and centrifuged 
at 15,000 x g at 4  °C for 20 minutes. Protein concentration was determined using the 
Bradford assay. 
To preserve protein-protein interactions, cells used for co-immunoprecipitation (IP) 
experiments were lysed with 50 mM Tris pH 8.0, 150 mM NaCl, 0.5 % NP-40, 1 mM DTT, 2 
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mM MgCl2, benzonase supplemented with 1x protease inhibitor (Roche) cocktail tablet. 
Cells were incubated with lysis buffer for 30 minutes and centrifuged at 15,000 x g at 4 °C 
for 20 minutes. Protein concentration was determined using the Bradford assay. 
For MS analysis, cells were lysed with an MS compatible buffer (0.25% (v/v) Rapigest SF 
(Waters) in 50 mM ammonium bicarbonate, supplemented with 1x PhosStop inhibitor 
(Roche) and sonicated (3x 10 seconds on, 1 minute off) to shear DNA. Samples were 
centrifuged at 15,000 x g at 4 °C for 20 minutes. Protein concentration was determined 
using the Bradford assay. SILAC labelled protein lysates (1 μg) were analysed by LC-MS/MS 
(see below) to assess label incorporation and subsequently mixed 1:1.  
 
 Immunofluorescence Microscopy 
 
U2OS MYC-WT PLK4 or MYC-G95R PLK4 stably transfected cells were split in to a 6 well 
plate containing cover slips. At 80 % confluence, 1 µg/mL tetracycline was added to induce 
protein expression for 18 hours. Cells were washed with 2.5 mL PBS and fixed for 20 
minutes with 2.5 mL of 3.7% paraformaldehyde. Cells were washed 3x with 2.5 mL PBS and 
permeabilised with 0.1 % (v/v) triton x-100 for 10 minutes. Cells were washed a further 3x 
with PBS and blocked with 1% (w/v) BSA, 0.3 M glycine for 60 minutes and washed 2x with 
PBS. Primary antibodies, anti-9E10 anti-myc antibody (1/100), anti-γ- tubulin (1/5000) or 
anti-pericentrin in 500 µL of 1% BSA were added to each coverslip and incubated overnight 
at 4 °C in a humidified chamber. Cells were washed 5x 10 minutes with PBS and secondary 
antibodies, rabbit anti mouse-Cy3 and goat anti rabbit-FITC (1/200) were added to each 
coverslip and incubated for 1 hour, room temperature in the dark. Cells were washed 5x 5 
minutes with PBS and incubated with 1 µg/mL DAPI for 3 minutes. Coverslips were 
mounted on to microscope slides with immune-mount and imaged at the Centre for Cell 
Imaging (Institute for Integrative Biology) on a Zeiss LSM 880 confocal microscope using an 
alpha Plan-Apochromat 100x/1.46 DIC grade oil immersion lens. A 405 nm diode, 488 nm 
Argon and 561 nm diode laser were used to excite DAPI, Alexa 488 and Cy3 fluors 
respectively with a transmitted light image also captured. A pinhole of ~1 Airy unit was 
maintained throughout imaging. Spatial sampling was conducted at 2x Nyquist sampling for 
the chosen magnification with four times line averaging used to reduce noise. For each 
condition at least one z-stack through the sample was acquired with slices taken at ~1 µm 
throughout the cell of interest.  
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 Flow Cytometry for DNA analysis (FACS) 
 
U2OS FLAG-WT & G95R PLK4 cells grown in DMEM media were split in to 10cm2 dishes. At 
60 % confluence, cells were incubated with 1 µg/mL tetracycline for 18 hours to induce 
protein expression before incubating with 300 nM centrinone for 4 hours. Cells were 
washed with PBS and released with trypsin (0.05 % (v/v)). Following centrifugation at 220 
xg, PBS was removed and cells were fixed with 70 % (v/v) ethanol, added slowly whilst 
vortexing to avoid aggregation and stored at -20 °C overnight. Fixed cells were washed with 
PBS and incubated with 200 µL Guava cell cycle reagent for 30 minutes in the dark at room 
temperature. Samples were then transferred to a 96 well plate and analysed using a Guava 
easycyte HT cytometer. ANOVA statistical analysis and Tukey post-hoc testing was 
performed in R.  
 
 
2.5. Protein purification 
 
 Expression of PLK4 & Aurora A plasmids 
 
pET30 N-terminal 6His- tagged WT or G95R PLK4 (1-269) plasmids were transformed in to 
Rosetta E.coli as described above (2.3.6). Cultures were plated on agar plates containing 50 
µg/mL kanamycin and 37 µg/mL chloramphenicol overnight at 37 °C. Colonies were 
extracted and added to 100 mL LB broth containing 50 µg/mL kanamycin and 37 µg/mL 
chloramphenicol overnight at 37 °C, 250 rpm. Cultures were transferred to two 2L flasks 
and incubated at 37 °C, 250 rpm until OD600= 0.6 – 0.8 was reached. Protein expression was 
induced upon the addition of 0.4 mM IPTG and incubated overnight at 18 °C, 250 rpm. 
Bacterial cells were harvested by centrifugation at 5000 x g for 10 minutes.  
 
To generate dephosphorylated WT Aurora A, N-terminal pET30 6His-tagged Aurora A 
plasmids was co-transformed with pET30 6His-GST-tagged λ-phosphatase, following the 
procedure described above.  
 
 Bacterial Cell Lysis 
 
Bacterial cells were lysed with 20 mL lysis buffer (50 mM Tris pH 7.4, 300 mM NaCl, 1 mM 
DTT, 10 % glycerol, 1 % Triton x-100, 10 mM imidazole, 0.1 mM EDTA, 0.1 mM EGTA, 
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supplemented with 1x protease inhibitor (Roche)) and sonicated to shear DNA. Samples 
were centrifuged at 14,000 xg for 1 hour and 8 °C to pellet insoluble material. Supernatant 
was filtered with a 0.22 µm filter prior to protein purification.  
 
 Ni2+ - affinity purification 
 
Ni2+ - affinity purification was performed for all expressed proteins used in this thesis. Ni-
NTA affinity resin (Thermo Fisher Scientific) (1 mL) was applied to a gravity flow column, 
washed with milliQ H2O and equilibrated with 25 mL wash buffer (50 mM Tris pH 7.4, 500 
mM NaCl, 10 % glycerol, 20 mM imidazole, 1 mM DTT). The filtered supernatant was then 
applied to the column; the flow through collected and the column was washed with a 
further 25 mL wash buffer. Bound protein was then eluted with increased imidazole 
concentration (500 mM). Elution buffer was added in 2 mL volumes and 500 µL fractions 
were manually collected.  
 
 Glutathione-S-Transferase (GST) affinity purification 
 
To separate 6His-tagged Aurora A plasmids from 6His- GST-tagged λ-phosphatase, samples 
were incubated with 1 mL GST beads (equilibrated with wash buffer (50 mM Tris pH 7.4, 
500 mM NaCl, 20 mM imidazole, 10% (v/v) glycerol, 1 mM DTT) overnight at 8 °C. Proteins 
were eluted with 50 mM Tris-HCl pH 7.4, 10 mM glutathione and 5 mM DTT and 500 µL 
fractions were manually collected.  
 
 Gel filtration chromatography 
 
6His-tagged WT & G95R PLK4 and 6His-tagged WT Aurora were purified by gel filtration 
chromatography, following Ni2+ - affinity purification. Samples were loaded on to an 
equilibrated (50 mM Tris pH 7.4, 100 mM NaCl, 10% (v/v) glycerol, 1 mM DTT) Superdex 16 
600 column attached to an AKTA FPLC system. Flow rate was set at 1.5 mL/min and 
fractions (500 μL) were collected across the run (~2 hours).   
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 Strong Cation Exchange Chromatography 
 
Strong cation exchange chromatography was employed to 6His-tagged Aurora A plasmids 
from 6His- GST-tagged λ-phosphatase based on differences in PI between the two proteins 
(pI of Aurora A = 9.5; pI of λ-phosphatase= 4.5). Samples were diluted in loading buffer (50 
mM Tris pH 7.4, 100 mM NaCl, 10% (v/v) glycerol, 1 mM DTT) and loaded on to a HiTrap SP 
HP cation exchange column at 1 mL/min flow rate, with chromatography controlled by an 
AKTA FPLC system. Bound protein was eluted using an increasing salt gradient from 0 - 100 
% elution buffer (50 mM Tris HCl, pH 7.4, 1 M NaCl, 10% (v/v) glycerol, 1 mM DTT) and 
collected in 500 μL fractions. 
 
 
2.6. Analytical methods 
 
 Bradford assay 
 
Protein concentrations were determined using the Bradford assay. A standard curve was 
generated using BSA standards of known concentration (0-1 mg/mL). Protein samples were 
typically diluted with the appropriate buffer and 5 µL sample (or 5 µL buffer) added to 200 
µL Bradford reagent and incubated for 5 minutes. The absorbance was read using a 
spectrophotometer at 595 nm and protein concentration determined using the calibration 
curve.  
 
 Immunoprecipitation 
 
Anti-FLAG M2 agarose resin (30 µL) was washed 3x with 50 mM Tris pH 8.0, 150 mM NaCl 
wash buffer and incubated with cell lysate overnight at 4 °C. Samples were centrifuged at 
1000 rpm for 1 minute and flow through removed. Beads were washed 5 x with 50 mM Tris 
pH 8.0, 150 mM NaCl wash buffer and proteins were eluted from the antibody by boiling 
with 2x SDS sample buffer.  
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 SDS-PAGE 
 
Proteins were analysed by SDS-PAGE under reducing conditions using 8 % polyacrylamide 
gels for analysis of full length PLK4 (MW- 110 kDa) or 10 % polyacrylamide gels for analysis 
of recombinant proteins (PLK4 1-269, MW- 32 kDa). Samples were centrifuged at 15,000 x g 
for 15 minutes prior to the addition of 5x SDS sample buffer (0.25 M Tris-HCl pH 6.8, 10 % 
SDS, 50 % glycerol, 0.5 M DTT, 0.25 % bromophenol blue) and boiled at 95 °C for 5 minutes. 
Samples were loaded on to the gel and run at 200 V for approximately 45 minutes. Protein 
bands were visualized by Coomassie Brilliant Blue staining (0.1 % Coomassie G250, 45 % 
methanol, 10 % acetic acid). 
 
 Western blot  
 
Proteins were electrotransferred from the gel on to a nitrocellulose membrane at 100 V for 
60 minutes. The membranes were incubated in blocking buffer (5 % (w/v) milk powder in 
TBST) for 1 hour and washed 3x 5 minutes with TBST. Primary antibodies were incubated 
with the membrane overnight at 4 °C. Membranes were washed 3 x 10 minutes with TBST 
and incubated with secondary antibody for 1 hour at room temperature. The antibody-
antigen complex was visualised upon addition of ECL substrate and exposing film to the 
membrane.  
 
 
2.7. In vitro kinase assays 
 
 Differential Scanning Fluorimetry (DSF) 
 
Proteins were diluted with 50 mM Tris pH 8.0, 150 mM NaCl to a final concentration of 5 
µM and incubated with 1 mM ATP +/- 10 mM MgCl2 or 10 mM centrinone/VX-680. Samples 
were incubated at room temperature for 15 minutes before the addition of SYPRO Orange 
fluorescent dye (Invitrogen). The samples were analysed using an Applied Biosystems 
StepOnePlus Real-Time PCR instrument using a DSF thermal-shift protocol developed for 
the analysis of protein kinases (Rudolf et al., 2014). The temperature was increased in 0.3 
°C intervals from 25 °C to 95 °C. DSF assays were performed with three technical replicates.  
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2.8. Enzymatic assays 
 
 PLK4 activity  
 
The Caliper LabChip EZ Reader platform measures enzyme activity by assessing the mobility 
shift of a fluorescently labeled peptide substrate, which changes upon phosphorylation and 
can be quantified by comparative integration of phosphorylated and dephosphorylated 
peptide peaks. To assess WT and G95R PLK4 activity, increasing amounts of PLK4 (0.5 µg to 
10 µg) were incubated with 1 mM ATP (to mimic cellular concentration) and 5 µM of a 
fluorescent kemptide-derived peptide substrate (5-FAM-FLAKSFGSPNRAYKK) in 25 mM 
Hepes, 10 mM MgCl2, and 0.001% (vol/vol) Brij 35 buffer. Reactions were pre-incubated for 
30 minutes at 37 °C and measurements were taken over 4 EZ Reader cycles at room 
temperature.  
 
 PLK4 inhibition 
 
To assess WT and G95R PLK4 inhibition with centrinone, 5 µg of protein was incubated with 
increasing half-log concentrations of centrinone (10 nM to 100 µM), 1 mM ATP (to mimic 
cellular concentration) and 5 µM of the fluorescent kemptide-derived peptide substrate (5-
FAM-FLAKSFGSPNRAYKK) in 25 mM Hepes, 10 mM MgCl2, and 0.001% (vol/vol) Brij 35 
buffer. Reactions were pre-incubated for 30 minutes at 37 °C and measurements were 
taken over 4 EZ Reader cycles at room temperature.  
 
 Aurora A inhibition 
 
To assess WT and G216L Aurora A inhibition with centrinone, 10 ng of protein was 
incubated with increasing concentrations of centrinone (10 nM, 100 nM, 1000 nM) and 2 
µM of the fluorescent kemptide-derived peptide substrate (5FAM-LRRSLG) in 25 mM 
Hepes, 10 mM MgCl2, and 0.001% (vol/vol) Brij 35 buffer. Reactions were pre-incubated for 
15 minutes at 37 °C and measurements were taken over 4 EZ Reader cycles at room 
temperature. 
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 PLK4 : Aurora A activation  
 
To assess the effects of GST, GST-TPX2, WT PLK4, or kinase-dead (D154A) PLK4 on inactive 
Aurora A, a 10-fold molar excess of each protein was incubated with 100 ng λ-phosphatase- 
treated Aurora A with 1 mM ATP (to mimic the cellular concentration) and 10 mM MgCl2 for 
30 min at 30°C.  Aurora A activity was then assessed in kinetic mode by the addition of a 
fluorescent kemptide-derived peptide substrate (5FAM-LRRSLG), with calculation of 
peptide phosphorylation every minute for 30 cycles at 20°C (1 min, approximately one 
cycle). To measure enhanced effects of WT PLK4 (1–285) on the activity of catalytically 
active (non–phosphatase treated) Aurora A, 2 µM of the Aurora A fluorescent kemptide-
derived peptide substrate was incubated with 30 ng PLK4 and 10 ng Aurora A in 25 mM 
Hepes, 10 mM MgCl2, and 0.001% (vol/vol) Brij 35 buffer, with 1 mM ATP. Reactions were 
preincubated for 15 min at 37 °C to permit activation of Aurora A, and measurements were 
taken over 60 EZ Reader cycles at room temperature in kinetic mode. 
 
 In vitro kinase activation assay 
 
Purified “kinase-dead” N-terminally 6His-tagged D274N Aurora A (available in the 
laboratory) (1.5 µg) was incubated with 3 µg of 6His-tagged WT Plk4 (1–285) lacking the 
polo box domains or a catalytically inactive D154A Plk4 (1–264) mutant (±10 µM 
centrinone) at 37°C in 50 mM Tris, pH 7.4, 10  mM MgCl2, 1  mM DTT, and 1  mM ATP. 
Aliquots were removed at 0, 10, 30, 60, 120, and 240 min after reaction initiation and 
stopped by boiling in SDS sample buffer. To evaluate site-specific Aurora A phosphorylation, 
trypsin proteolysis and liquid chromatography–tandem mass spectrometry (LC-MS/MS) 
analysis was performed at the 120-min time point. 
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2.9. Sample preparation for LC-MS 
 
 Trypsin digestion 
 
Proteins were digested in to tryptic peptides as follows: disulfide bonds were reduced by 
addition of 3 mM DTT in 50 mM ammonium bicarbonate and heated at 60°C for 15 
minutes. The resulting free cysteine residues were alkylated with 14 mM iodoacetamide 
(dark, room temperature, 45 minutes) and excess iodoacetamide quenched by addition of 
DTT to a final concentration of 7 mM.  Proteins were digested overnight with trypsin (2% 
(w/w); Promega) at 37 °C.  RapiGest SF hydrolysis was induced by addition of trifluoroacetic 
acid (TFA) to 1 % (v/v) and incubated at 37 °C for up to 2 h, 400 rpm. Insoluble hydrolysis 
product was removed by centrifugation (13,000 x g, 15 min, 4°C).   
 
 Desalting 
 
Peptides generated from U2OS cell lysates were desalted using C18 macro columns 
(Harvard Apparatus, Cambridge, UK). Briefly, columns were conditioned with 100 % 
methanol and washed with H2O and 1% (v/v) TFA. Peptides were loaded on to the column 
and centrifuged for 1 minute at 110 x g. The flow-through was re-applied a total of 5 times 
and peptides were eluted with 80% (v/v) MeCN and 1% (v/v) TFA and dried to completion 
by vacuum centrifugation. 
 
 High pH reversed phase fractionation 
 
Tryptic peptides generated from SILAC labelled protein lysates were dissolved in 94.5 % 
buffer A (20 mM ammonium hydroxide pH 10) and 5.5 % buffer B (20 mM ammonium 
hydroxide in 90% acetonitrile, 10% water) and loaded on to a Extend C18 (3.5 µm, 3mm x 
150 mm) Agilent column. Peptides were eluted following an increase in buffer B up to 30% 
over 25 minutes then 75% B over 12 minutes at a flow rate of 0.5 mL/minute. Sixty 500µL 
fractions were collected, partially dried by vacuum centrifugation and concatenated in to 
twelve pools. Aliquots (5 µg) were removed from each pool for total proteomics analysis. 
Samples were dried to completion by vacuum centrifugation.  
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 Titanium dioxide enrichment 
 
Dried peptides were dissolved in loading buffer (80 % (v/v) MeCN, 5 % (v/v) TFA, 1 M 
glycolic acid), sonicated and incubated with 5 mg titanium dioxide resin (5:1 (w/w) 
beads:protein; GL Sciences) at 1400 rpm for 10 minutes on a thermomixer. Wash steps 
were performed sequentially with 150 μL loading buffer; 150 μL wash buffer 1 (80% (v/v) 
MeCN, 1% (v/v) TFA) and 150 μL wash buffer 2 (10 % (v/v) MeCN, 0.2% (v/v) TFA). 
Phosphopeptides were eluted with increasing pH (1 % (v/v) ammonium hydroxide and 5 % 
(v/v) ammonium hydroxide) and dried to completion by vacuum centrifugation. Peptides 
were re-solubilized in 240 μL of 96 % (v/v) H2O, 3 % (v/v) MeCN, 1 % (v/v) TFA.  
 
 Preparation of phosphopeptide library 
 
The phosphopeptide library (Intavis) containing 180 chemically synthesized phosphorylated 
peptides (~10 pmol) were reconstituted in 10 μL H2O. The phosphopeptides were split in to 
five pools, designed to separate phosphoisomers and thus ensure confidence in 
phosphosite localization.  
 
 
2.10. Mass Spectrometry  
 
 Thermo Orbitrap Fusion 
 
Reversed-phase capillary HPLC separations were performed using an UltiMate 3000 nano 
system (Dionex) coupled in-line with a Thermo Orbitrap Fusion Tribrid mass spectrometer 
(Thermo Scientific, Bremen, Germany). Samples were loaded onto the trapping column 
(PepMap100, C18, 300 μm x 5 mm), using partial loop injection, for seven minutes at a flow 
rate of 9 μL/min with 2% (v/v) MeCN, 0.1% (v/v) TFA and then resolved on an analytical 
column (Easy-Spray C18 75 µm x 500 mm, 2 µm bead diameter column) using a gradient of 
96.2% A (0.1% (v/v) formic acid (FA)): 3.8% B (80%  (v/v) MeCN, 0.1%  (v/v) FA) to 50% B 
over 97 minutes at a flow rate of 300 nL/min.. 
MS(/MS) data were acquired on an Orbitrap Fusion as follows: all MS1 spectra were 
acquired over m/z 350-2000 in the orbitrap (120K resolution at 200 m/z for high-low 
strategies and 60K resolution at 200 m/z for high-high strategies); automatic gain control 
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(AGC) was set to accumulate 2x105 ions, with a maximum injection time of 50 ms.  Data-
dependent tandem MS analysis was performed using a top speed approach (cycle time of 3 
s) with multiple fragmentation methods tested (see Appendix, Supplementary Table S1). 
The normalized collision energy was optimized at 32% for HCD. MS2 spectra were acquired 
with a fixed first m/z of 100. The intensity threshold for fragmentation was set to 50,000 for 
orbitrap methods and 5000 for ion trap methods and included charge states 2+ to 5+. A 
dynamic exclusion of 60 seconds was applied with a mass tolerance of 10 ppm. For neutral 
loss triggered ETcaD/EThcD methods, fragmentation was enabled for all precursor ions 
exhibiting neutral loss of mass 97.9763 Da or 80 Da with a mass tolerance of 20 ppm for 
orbitrap data and 0.5 m/z for ion trap data, where the neutral loss ion was one of the top 
10 most intense MS2 ions. ETD calibrated parameters were applied. AGC was set to 10,000 
with a maximum injection time set at 50 ms for IT and 70 ms for OT; ETD reaction time was 
charge-dependent.  
 
 
2.11. Data Analysis 
 
 Proteome Discoverer 1.4 
 
Data were processed using Thermo Proteome Discoverer (v. 1.4) in conjunction with 
MASCOT (v 2.6). To address the requirement of MASCOT for centroided data, raw data files 
were converted to mzML format in order to perform MS2 de-isotoping prior to processing 
with MASCOT through the Proteome Discoverer (PD) pipeline. Peak lists were searched 
against a database containing either the synthetic phosphopeptide sequences or the 
human UniProt database (downloaded December 2015; 20187 sequences). Parameters 
were set as follows: MS1 tolerance of 10 ppm; MS2 mass tolerance of 0.01 Da for orbitrap 
detection, 0.6 Da for ion trap detection; enzyme specificity was set as trypsin with 2 missed 
cleavages allowed; no enzyme was defined for the phosphopeptide library processing; 
carbamidomethylation of cysteine was set as a fixed modification; phosphorylation of 
serine, threonine and tyrosine, and oxidation of methionine were set as variable 
modifications. Non-fragment filtering was applied to ETD scans to remove the precursor 
peak within a 4 Da window and remove charged reduced precursor and neutral loss ions 
from charged reduced precursor ions within a 2 Da window. ptmRS was run in PhosphoRS 
mode using diagnostic fragment ions and analyzer specific fragment ion tolerances as 
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previously defined in the search. For EThcD data, 'Treat all spectra as EThcD' option was set 
to 'True'. Data was filtered to a 1% false discovery rate (FDR) on PSMs using automatic 
decoy searching with Mascot and a target-decoy search with Andromeda.   
For processing of SILAC data, 15N 13C Arginine and 15N 13C Lysine were set as a variable 
modifications.  
 
 MaxQuant  
 
Phosphopeptide data from the MS acquisition method optimization study were processed 
using Andromeda with PTM-score implemented within MaxQuant (version 1.6.0.16) (Cox & 
Mann, 2008). MS/MS spectra were searched against a database containing the human 
UniProt database (downloaded December 2015; 20187 sequences). Trypsin was set as the 
digestion enzyme and two missed cleavages were permitted. Cysteine 
carbamidomethylation was set as a fixed modification. Variable modifications were set as 
oxidation (M), phospho (STY). Default instrument parameters and score thresholds were 
used: MS1 first search peptide tolerance of 20 ppm and main search tolerance of 4.5 ppm; 
FTMS MS2 tolerance of 20 ppm; ITMS MS2 tolerance of 0.5 Da. A false discovery rate of 1 % 
for peptide spectrum matches (PSM) and proteins was applied.  
For processing of SILAC data, Thermo raw. files were loaded in to MaxQuant (version 
1.6.0.16). Total proteomics (protein expression data) and phosphoproteomics experiments 
were processed separately. The experimental template design separated individual 
bioreplicates in to separate experiments, linking the experiment to the relevant fractions. 
MaxQuant parameters were as described above, with the following additions: ‘multiplicity’ 
was set to 2 and Arg10, Lys8 were selected as labels. For proteomics datasets,the variable 
modifications oxidation (M), acetyl (protein N-term) were included. Both ‘requantify’ and 
‘match between runs’ were enabled. Two peptides were required for protein 
quantification.  
 
 Perseus 
 
Post processing was performed using Perseus (version 1.6.0.7). For proteingroups.txt 
output files, Perseus was used to filter out contaminants, reverse decoy hits and those 
‘matched only by site’. Additionally, data were filtered to include proteins identified in ≥3 
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(out of 4) bioreplicates and Log2 transformed. For phosphosites(STY).txt output files, data 
were filtered as above. In addition, ‘expand site table’ feature was used to separate 
individual phosphosites, and a phosphosites localisation cut-off of ≥0.75 was applied. Ratios 
were Log2 transformed. Statistical analysis was then performed using the LIMMA package 
in R with Benjamini-Hochberg multiple corrections to generate adj. p values (performed by 
Dr. Simon Perkins).  
 
 Arginine to proline conversion 
 
Non-normalised SILAC ratios were used to assess arginine to proline conversion. The 
peptides.txt MaxQuant output files was loaded in to Perseus (version 1.6.0.7) and reverse 
decoy hits and contaminants were removed. Non-normalised SILAC ratios were Log2 
transformed and the density of the SILAC ratios against the proline count observed in the 
identified peptides was calculated. Log2 SILAC ratios were plotted against proline count.  
 
 Manual spectra annotation 
 
MS2 spectra were extracted from the Thermo raw. files and manually annotated using the 
MASCOT output and Protein Prospector (version 5.22.1). Spectra were redrawn in R to 
improve figure quality.  
 
 DAVID 
 
Functional annotation and enrichment analysis of regulated proteins and phosphosites was 
performed using DAVID (version 6.8) (Huang da et al., 2009). Information pertaining to 
enriched cell compartments, molecular functions, biological processes and KEGG pathways 
were exported. Results were filtered to exclude a protein count <10 and redundant GO 
terms. Benjamini-Hochberg adjusted p values were used to determine significance and 
terms with p value <0.05 were highlighted to indicate significance. Unfiltered tables 
exported from DAVID can be found in Appendix 3, Table 9.6 to 9.9. 
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 STRING 
 
Significantly downregulated proteins from the G95R PLK4 SILAC dataset (adj. p value <0.05) 
were submitted to the STRING database (version 10.5) to assess protein-protein 
interactions (Szklarczyk et al., 2015). A high confidence (score 0.7) filter was applied, and 
only ‘experiments’ and ‘databases’ as active interaction sources were included.  
 
  IceLogo 
 
Sequences surrounding Ser phosphorylated peptides identified as downregulated were 
extracted from the ‘sequence window’ column in the MaxQuant phosphoSTY.txt output 
and input into IceLogo (Colaert et al., 2009). Homo sapien Swiss-Prot protein sequence 
database was used as the reference dataset. A P value threshold (p= 0.01) was applied to 
determine motif confidence.  
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 Development of biochemical tools for the functional 
analysis of PLK4  
 
3.1. Introduction 
 
The aim of this work is to understand PLK4-dependent signalling pathways and to identify 
potential PLK4 substrates by phosphoproteomics. This chapter describes the development 
of biochemical tools for the functional analysis of PLK4 in human cells.   
 
Despite the importance of PLK4 in regulating centrosome duplication, very few substrates 
have been identified,  the majority of research having focused on the interactions between 
PLK4 and the centriolar proteins STIL and SAS6, which are involved in centriole duplication 
(Dzhindzhev et al., 2014; Ohta et al., 2014). Despite advances in the understanding of how 
these proteins co-ordinate their activities to regulate centriole duplication, gaps remain in 
the understanding of centriole formation and additional PLK4 substrates have yet to be 
identified. In addition, a wider role for PLK4 and its implications in cell signalling pathways 
has not been explored thus far. 
 
Table 3.1 Known PLK4 substrates.  A list of direct PLK4 substrates reported in the literature to date 
and whether the interaction was determined by in vitro and/or in vivo based methods. 
PLK4 substrate Evidence Reference 
STIL Ser1108, 
Ser1116 
In vitro/in 
vivo 
(Arquint et al., 2015); (Dzhindzhev et al., 2014); (Ohta et 
al., 2014); (Kratz et al., 2015); (Moyer et al., 2015).  
CP110 Ser98 In vitro/in 
vivo 
(Lee et al., 2017) 
PCM1 Ser372 In vitro/in 
vivo 
(Hori et al., 2016) 
GCP6 Ser7, Ser15, 
Ser392, Ser1437, 
Ser1465 
In vitro (Bahtz et al., 2012)  
Cep152/Cep192 
Phosphosites 
unknown 
In vitro (Hatch et al., 2010); (Sonnen et al., 2013) 
FBXW5 Ser151 In vitro (Puklowski et al., 2011) 
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The levels of PLK4 in the cell are kept very low through tight regulation of protein 
abundance via autophosphorylation and proteasomal degradation. Utilising a selected 
reaction monitoring (SRM) mass spectrometry approach, PLK4 was determined to be 
expressed at less than ~4000 copies per cell. This is in comparison to other centrosomal 
proteins such as SAS6 which is expressed at ~20,000 copies per cell (Bauer et al., 2016).  
The low expression of PLK4 in human cells therefore makes it difficult to study endogenous 
protein activity, without chemical arrest of the cycle cycle (Leung et al., 2002). There is, 
therefore, a need to establish a suitable over-expression system in which protein 
expression can be carefully controlled to ensure cellular conditions mimic those of the 
rapidly turned over endogenous protein as closely as possible (Habedanck et al., 2005).  The 
first part of this chapter will discuss the cloning and generation of PLK4 plasmids, their 
transfection into a Tet-inducible U2OS cell line and the analysis of PLK4 protein expression 
and subcellular localisation. 
 
The human bone osteosarcoma U2OS T-Rex cell line was chosen for stable transfection of 
the PLK4 plasmids due to its unique phenotype. U2OS cells contain highly altered 
chromosome numbers, often in the hypertriploid range. However, unlike many other 
cancerous cell lines, the cells do not undergo multipolar mitosis due to functional activities 
of the tumour suppressor proteins p53 and pRB. Consequently, the control of centrosome 
number is maintained and the normal duplication process can be studied (Niforou et al., 
2008). A further advantage of this cell system is conferred by the use of a stable, rather 
than transient, transfection procedure that allows for controlled protein expression at 
levels much lower than that obtained by transient transfection. Transient over-expression 
of PLK4 leads to aberrant activity resulting in over-duplication of the centrioles and 
formation of extra centrosomes (Bettencourt-Dias et al., 2005; Habedanck et al., 2005). 
Expression of the transfected gene is controlled by a TetO2  sequence adjacent to the 
promoter. In the absence of tetracycline, the TetO2 sequence binds molecules of a Tet 
repressor that prevent transcription of the gene. Upon addition of tetracycline, the 
repression at the TetO2 sites is relieved through the binding of tetracycline to the Tet 
repressors. Controlling protein expression through the use of a stable, Tetracycline-
inducible cell line allows the conditions to closely resemble that of the endogenous protein 
with respect to localisation and activity, with a high enough level of expression to study by 
phosphoproteomics.  
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Phosphoproteomics experiments to study protein kinase-based signalling typically utilise 
small molecule inhibitors that can inhibit the activity of the protein of interest, so that 
changes in protein expression or phosphorylation stoichiometry can be assessed. However, 
a key issue with this approach is the known promiscuity of ATP-competitive small molecule 
inhibitors, due to the high degree of conservation of the ATP binding site in protein kinases 
(Hanks & Hunter, 1995; Bain et al., 2007).  This promiscuity can lead to ‘off-target’ effects 
and perturbations of signalling pathways that are not biologically relevant to the protein 
under study (Fabian et al., 2005; Anastassiadis et al., 2011; Klaeger et al., 2017) Inhibitors 
with high levels of selectivity are continuously being synthesised and released to the 
research community and the most recently developed, highly specific PLK4 inhibitor, 
centrinone, was selected for the inhibition experiments described in this chapter. However, 
even a kinase inhibitor with high specificity will likely inhibit additional off-target protein 
kinases. Off-target inhibition greatly complicates downstream analysis and the ability to 
correctly attribute protein and phosphosite level changes to the activity of PLK4 directly 
and, therefore, additional tools to validate phosphoproteomics data are required.  
 
A drug resistant mutant (G95R) that retains WT activity and localises correctly at the 
centrioles represents an ideal approach by which to separate on- and off-target effects of 
centrinone inhibition of PLK4. Gly95 is located at the ‘+6 position’ adjacent to the hinge 
loop of PLK4 and is an important residue for sensitivity to kinase inhibitors such as VX-680 
and MLN8054 (Bailey et al., 2014). PLK1-3 contain an arginine residue at the +6 tetrad 
position and are not sensitive to VX-680-like classes of small molecule inhibitors (Johnson et 
al., 2007). Mutation of Gly95 to Arg results in a catalytically-active protein resistant to 
inhibition by small molecule inhibitors within the ATP-binding site (Sloane et al., 2010).  
 
An additional challenge of a phosphoproteomics approach to studying PLK4 signalling is 
that in addition to PLK4, many other cell cycle proteins are also expressed at very low levels 
in the cell and are likely beyond the limit of detection of current mass spectrometers when 
used for high-throughput proteomics experiments (Choudhary & Mann, 2010; Wilhelm et 
al., 2014). This is exacerbated for phosphopeptides by their often low stoichiometry and 
low ionization efficiency, which interferes with the identification of phosphopeptides from 
proteins of low abundance (Olsen & Mann, 2013; Solari et al., 2015). Pre-fractionation of 
digested cell lysates is therefore crucial for reducing mass spectral sample complexity and 
increasing the analytical dynamic range allowing for greater coverage of the proteome. 
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High pH reversed phase fractionation has emerged as the leading method for maximising 
coverage of the phosphoproteome, with more than double the number of phosphopeptide 
identifications compared with the other common chromatography methods (Batth et al., 
2014). The development of a high pH reversed phase fractionation approach for maximising 
phosphopeptide identifications will also be discussed in this chapter.  
 
As outlined in Chapter 1, stable isotope labelling of amino acids in culture (SILAC) is a 
commonly used labelling technique for quantitative phosphoproteomics studies. SILAC 
based quantification requires cells to be fully labelled prior to sample mixing, as partially 
labelled cells will contribute to the ‘light’ peptide signal upon analysis of the resulting 
peptides by MS, resulting in inaccurate quantification. It is; therefore, of critical importance 
to assess the labelling efficiency over a number of cell divisions to ensure that the heavy 
labels were fully incorporated into the U2OS cell line, which is described in this chapter.  
 
 Aims 
 
The aim of the work described in Chapter 3 was to develop new tools for the proteomic 
analysis of PLK4 activity in human cells. These tools include FLAG-WT and G95R PLK4-
expressing DNA plasmids for stable transfection in to U2OS cells, and the characterisation 
of protein expression and subcellular localisation to ensure the full-length proteins are 
being expressed and are correctly localised. In addition, this work aimed to establish the 
degree of similarity between the activities of WT & G95R PLK4, to confirm that G95R PLK4 
expressing cells can be used as a tool for validating on- and off-target effects of centrinone 
in PLK4 phosphoproteomics studies. Finally, this work aimed to develop and implement 
stages of an experimental workflow to perform phosphoproteomics analysis, including 
offline fractionation by high pH reversed phase chromatography and assessment of the 
incorporation of heavy labelled arginine and lysine in SILAC experiments in U2OS cells.  
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3.2. Results & Discussion 
 
 Generation of WT & G95R PLK4 plasmids  
 
To establish stably transfected T-Rex U2OS cell lines capable of controlled expression of 
PLK4, PCR was used to amplify full-length WT PLK4 cDNA (1-2913 bp), engineered to 
include a Kozak sequence (CCACCATG) required for high level initiation of translation of a 
mRNA in eukaryotic cells, followed immediately by an initiator ‘ATG’ codon. In addition, a 
FLAG peptide sequence (DYKDDDDK) was incorporated at the 5’ end of the PLK4 cDNA to 
generate a small N-terminal tag that acts as an artificial antigen allowing for 
immunoprecipitation of the expressed protein (Figure 3.1A). The resulting DNA construct 
was then sub-cloned in to the pcDNA5 FRT/TO vector specific to the T-Rex cell system via 
the engineered Not I and Hind III restrictions sites (Figure 3.1B, C) and Sanger sequenced to 
confirm the sequence was correct. This pcDNA5 vector contains important features 
required for stable integration in to the host genome. These include a hybrid human 
cytomegalovirus/TetO2 promoter for the controlled expression of the transfected protein in 
mammalian cells via tetracycline binding at this promoter; a FLP Recombination Target 
(FRT) site which binds FLP recombinase to initiate recombination of the vector in to the 
host genome and a hygromycin resistance gene permitting the selection of successfully 
transfected cells using this antibiotic (Figure 3.1B. C).  
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Figure 3.1. Cloning strategy to generate FLAG-PLK4 pcDNA5 constructs  A) Full length wild type PLK4 cDNA was amplified by PCR to introduce unique restriction sites (Hind 
III & Not I), a Kozak sequence required for protein expression in eukaryotic cells and a FLAG tag for immunoprecipitation. A range of primer concentrations were tested and 
analysis of PCR product for the 0.1 µM and 1 µM primer conditions by agarose gel electrophoresis revealed a single band at ~3,000 bp B) PLK4 cDNA was cloned in to 
pcDNA5 vector using T4 ligase. C) To confirm successful ligation, plasmids were restriction digested and analysed by agarose gel electrophoresis, revealing a band at 3,000 
bp and at 5,000 bp representing FLAG-PLK4 cDNA and pcDNA5 vector respectively.  
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Using the FLAG-PLK4 pcDNA5 FRT/TO construct, a drug-resistant PLK4 (G95R) mutant was 
generated by site-directed mutagenesis using overlapping primers incorporating the glycine 
to arginine mutation (Figure 3.2A). Sanger sequencing of the plasmid confirmed successful 
incorporation of the mutation (Figure 3.2B). Both the WT and G95R constructs could then 
be transfected and stably integrated in to the genome of T-Rex U2OS cells.  
 
 
 
 
Figure 3.2. Generation of FLAG-G95R PLK4 by site-directed mutagenesis.  A) Full length wild type 
FLAG PLK4 cDNA was mutated by site directed mutagenesis using forward and reverse primers 
containing a G to R mutation to produce drug resistant PLK4. B) Plasmids were sent for Sanger 
sequencing which confirmed successful incorporation of the mutation.  
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 Transection of plasmids into U2OS cells   
 
U2OS T-Rex Flp-In cells incorporate a pFRT/lacZeo plasmid consisting of a zeocin fusion 
gene under the control of an SV40 promoter and an FRT site downstream of an initiation 
codon. T-Rex cells can therefore be selected for (and the plasmid maintained) using DMEM 
supplemented with an appropriate concentration of zeocin (Figure 3.3A). FLAG-WT and 
G95R PLK4-pcDNA5 plasmids were transfected into T-Rex Flp-In U2OS cells (a kind gift from 
Dr Gopal Sapkota, MRC PPU, University of Dundee) using lipofectamine 2000 transfection 
reagent. The plasmids were co-transfected with a pOG44 plasmid encoding a FLP 
recombinase, which mediates homologous recombination (Figure 3.3B). This integrates 
FLAG-PLK4 between the FRT sites on the pFRT/lacZeo and pcDNA5 plasmids, which brings 
the SV40 promoter and initiation codon next to the hygromycin resistance gene present in 
pcDNA5 and inactivates the zeocin gene (Figure 3.3C). Successfully transfected cells were 
then selected for by supplementing media with hygromycin as they will have acquired 
hygromycin resistance, whereas unsuccessfully transfected cells will remain hygromycin 
sensitive and fail to establish. Successfully transfected cells were propagated to produce 
stably transfected, isogenic cell lines.   
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Figure 3.3. Summary of the U2OS T-Rex Flp-In system.  a) FLAG-PLK4 pcDNA5 plasmids were co-transfected with pOG44 in to U2OS T-Rex Flp-In cells. b) Flp recombinase is 
expressed from the pOG44 plasmid and catalyzes homologous recombination between the FRT sites on pcDNA5 and the U2OS cell line, which integrates FLAG-PLK4 
pcDNA5 in to the host genome. c) Integration of FLAG-PLK4 pcDNA5 confers cell resistance to hygromycin, providing a means to select successfully transfected cells. 
Addition of tetracycline relieves repression at TetO2 sequence and results in expression of FLAG-PLK4 in a controlled manner.  
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FLAG-WT and G95R PLK4 protein expression levels were assessed upon induction of protein 
expression with tetracycline. Cells were also treated with the proteasome inhibitor MG-
132, to prevent degradation of low-abundance PLK4 in proteasomes. As discussed in 
Chapter 1, PLK4 trans-autophosphorylates at residues Ser293 and Ser297 within its 
phosphodegron and subsequently binds the SCF-Slimb/βTrCP-E3 ubiquitin ligase to signal 
the protein for degradation by the proteasome (Holland et al., 2012; Cunha-Ferreira et al., 
2013; Klebba et al., 2013). Therefore, blocking PLK4 degradation results in an accumulation 
of PLK4 in the cell, which can be observed by western blot. Figure 3.4 confirms that both 
full-length WT and G95R FLAG-PLK4 are expressed in U2OS cells; the presence of an 
immunoreactive band at ~110 kDa increases in abundance in the presence of MG-132. The 
presence of faint bands at ~110 kDa in the negative controls is likely due to “leaky” 
expression of the transfected genes, where expression of the gene occurs in the absence of 
tetracycline. This is supported by the detection of a slightly more intense band in the 
‘negative control’ MG-132-exposed cells, which reflects the accumulation of this protein 
due to stabilisation after inhibition of the proteasome.   
 
 
 
 
Figure 3.4. Overexpression of WT & G95R PLK4.  U2OS cells stably transfected with WT or G95R 
PLK4 were incubated +/- 1 μg/mL  tetracycline for 18 hours to induce protein expression, followed by 
+/- 10 μM MG-132 for 4 hours. Lysates were analysed by western blot and probed using the 
indicated antibodies. Full length PLK4 is revealed by the presence of a band at ~110 kDa, which 
increases in intensity following MG-132 treatment.  
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 Immunofluorescence  
 
To confirm that the over-expression of PLK4 was associated with targeting to the correct 
subcellular localisation, U2OS cells were imaged by immunofluorescence with a confocal 
microscope. With an established in-house protocol to study MYC-tagged centrosomal 
proteins by immunofluorescence, MYC- WT & G95R U2OS cells (data available in S.Ferries 
Masters report, 2015) were employed to study subcellular localisation. To confirm that the 
MYC- tagged proteins were expressed at a similar level to FLAG-PLK4, protein expression 
was induced in MYC-WT & MYC-G95R PLK4 or FLAG-WT & FLAG-G95R PLK4 by tetracycline, 
followed by treatment with MG-132. Figure 3.5 reveals the presence of a band at ~110 kDa 
in both the FLAG- and MYC- PLK4 cell lines, showing that both constructs produce full-
length protein. In addition, the MYC-PLK4 proteins also accumulate within the cell when the 
proteasome is inhibited. Slightly increased levels of the MYC-PLK4 proteins can be observed 
compared with FLAG-PLK4 which further justified the use of the MYC cell lines for 
assessment of subcellular localisation.  
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Figure 3.5. Overexpression of FLAG & MYC- WT & G95R PLK4.  U2OS cells stably transfected with 
FLAG or MYC- WT or G95R PLK4 were incubated +/- 1 μg/mL tetracycline for 18 hours to induce 
protein expression, followed by +/- 10 μM MG-132 for 4 hours. Lysates were analysed by western 
blot and probed using the indicated antibodies. Full length PLK4 is revealed by the presence of a 
band at ~110 kDa, which increases in intensity following MG-132 treatment. 
 
To establish unequivocal centrosomal localisation, pericentrin and -tubulin, known 
markers of the centrosome were imaged alongside WT & G95R PLK4. Figure 3.6 shows both 
WT and G95R PLK4 expressed within the cells co-localising with both pericentrin and -
tubulin. The decondensed DNA and the presence of two PLK4 and pericentrin or -tubulin 
puncta within each individual cell confirm that PLK4 is expressed in S phase cells, which is 
consistent with the onset of kinase activity to initiate centriole duplication (Habedanck et 
al., 2005). PLK4 expression in G2/M phase cells has also been reported, with an active form 
of the kinase expressed at M phase, with an assumed role in procentriole assembly and 
elongation (Sillibourne et al., 2010). However, expression of WT or G95R PLK4 in cells at 
later stages of the cell cycle was not observed in this study. Future experiments could test 
the presence of PLK4 at later stages of the cell cycle by arresting the cells in G2/M and 
performing immunofluorescence with a phospho specific antibody directed toward 
pSer305, linked to kinase activity. However, these preliminary results confirm that the 
controlled over-expression of PLK4 using the T-Rex system results in stable expression of 
exogenous PLK4, which demonstrates similar subcellular localisation at the centrioles as 
endogenous PLK4.  
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Figure 3.6. WT & G95R PLK4 localise at the centrosome.  U2OS cells, induced with tetracycline to express A) myc-WT PLK and B) myc-G95R PLK4, were probed with anti-
PLK4 (red) & anti--tubulin or anti-pericentrin (green) antibodies and analysed by immunofluorescence microscopy to confirm co-localisation at the centrosome. 
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 WT & G95R PLK4 activity assays 
 
To confidently employ G95R PLK4 as a drug-resistant control to validate PLK4 substrates 
that are sensitive to inhibition by drugs such as VX-680 and centrinone, the drug-resistant 
mutant must exhibit  similar catalytic activity to the WT kinase. To assess protein activity, 
recombinant 6His tagged- WT and G95R PLK4 catalytic domains (containing the catalytic 
domain; residues 1-269) were expressed in Rosetta E. coli and purified by nickel affinity 
chromatography. Analysis of the 12 eluted fractions by SDS-PAGE revealed a high 
concentration of protein migrating to ~32 kDa, consistent with the size of the catalytic 
domain of PLK4 (Figure 3.7 A) (purification of G95R PLK4 is shown; WT PLK4 purification is 
presented in S. Ferries Masters report). Fractions 2-7, containing the highest concentration 
of protein, were pooled and further purified by gel filtration chromatography on an S200 
column (Figure 3.7 B). Fractions were collected across the eluting peak, and re-analysed by 
SDS-PAGE, which revealed protein of high purity (Figure 3.7 C). The identity of the purified 
protein was confirmed by digestion with trypsin and analysis by LC-MS/MS (data not 
shown). Fractions containing the highest concentration of protein were pooled, and 
characterised using a new in vitro PLK4 activity assay.  
 
 
 
 
 
 
 
 
 
 
 
  Chapter 3 
 
 
78 
 
 
 
Figure 3.7. Purification of 6His-G95R PLK4 (1-269).  A) Following expression in Rosetta E.coli, cell lysate was incubated with nickel resin and bound protein was eluted with 
500 mM imidazole. 12 fractions were collected and analysed by SDS-PAGE. B) Fractions 2-7 (as shown by rectangle in panel A) were pooled and purified by gel filtration 
chromatography using a Superdex 200 column. C) Fractions were collected across the main peak and analysed by SDS-PAGE and stained with Coomassie reagent. The 
rectangle indicates which fractions were pooled for use in in vitro assays.   
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Prior to enzymatic assay, the PLK4 proteins were characterised by a thermal DSF assay to 
analyse unfolding by incubation with a fluorescent dye capable of binding to hydrophobic 
regions which become more accessible as the protein unfolds (Rudolf et al., 2014).  In 
addition, binding of inhibitors and the essential co-factors ATP and Mg2+was also assessed. 
The sensitivity of both the WT and G95R PLK4 catalytic domains to the kinase inhibitors VX-
680 and centrinone was also assessed. Figure 3.8 shows that both proteins are capable of 
binding both Mg2+ and ATP, with a ΔTm of 7 °C for both WT and G95R PLK4. This is due to a 
conformational change to the active site induced by binding of Mg2+ and ATP, resulting in 
an inward rotation of the αC helix that creates a more thermostable structure (Knighton et 
al., 1991; Endicott et al., 2012).  
 
Once bound within the active site, ATP-competitive kinase inhibitors interact through 
hydrogen bonding with key residues within the protein. Hydrogen bonding between PLK4 
and centrinone occurs at residues Met91 within the hinge region and Asp154 of the DFG 
motif (Wong et al., 2015). These contacts also increase the thermostability of the protein, 
which can be observed by DSF. The data shows that WT PLK4  appears to bind strongly by 
both VX-680 and centrinone with ΔTm values of 13 °C and 19 °C respectively (Figure 3.8 A). 
G95R PLK4 showed very little thermal stabilisation with VX-680 and slight thermal 
stabilisation in the presence of centrinone (ΔTm ~ 6 °C, Figure 3.8 B), in line with marked 
drug-resistance in G95R PLK4. 
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Figure 3.8. Thermal shift analysis of recombinant WT & G95R PLK4 using Differential Scanning 
Fluorimetry.  Thermal shift was measured in the presence of ATP, Mg2+ and the potent PLK4 
inhibitors, VX-680 and centrinone. The change in Tm (ΔTm) value is reported from three technical 
replicates of a) WT PLK4 and b) G95R PLK4. 
 
Expression of correctly folded and active protein kinases in E. coli often results in extensive 
autophosphorylation, and PLK4 is known to autophosphorylate in vitro (Shrestha et al., 
2012).  An initial assessment of catalytic activity could therefore be determined for WT & 
G95R PLK4 by analysing the autophosphorylation status of each purified protein following 
tryptic digestion. LC-MS/MS analysis of the enriched tryptic phosphopeptides revealed 
autophosphorylation at 11 sites in WT PLK4, and 10 of the same sites in G95R PLK4, with 
only phosphorylation of T34 not being observed (Figure 3.9 A). One key 
autophosphorylation site that was identified was T170, which is located within the 
activation loop and required for PLK4 activity (Figure 3.9 B) (Swallow et al., 2005; Lopes et 
al., 2015). In cells, Thr170 autophosphorylation results in activation of PLK4, leading to 
phosphorylating of the centriolar assembly protein STIL at Ser1108 and Ser1116 within its 
STAN motif. Phosphorylated STIL then binds SAS-6, initiating centriole duplication (Moyer et 
al., 2015). Identification of Thr170 autophosphorylation in G95R, with essentially identical 
autophosphorylation patterns as WT PLK4, strongly suggests that G95R retains WT activity 
and can therefore be used for the phosphorylation and validation of PLK4 substrates in 
phosphoproteomics experiments.  
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Figure 3.9. Drug-resistant G95R PLK4 retains autophosphorylation activity when expressed in bacteria.  A) Full list of autophosphorylation sites identified in WT and G95R 
PLK4 are depicted with associated m/z values, Mascot & ptmRS scores. B) Purified recombinant WT or G95R PLK4 were digested with trypsin and analysed by LC-MS/MS. 
MS2 spectra generated by HCD shows autophosphorylation at T170 within the activation loop of both WT & G95R PLK4. C) Purified recombinant WT or G95R human PLK4 
(amino acids 1–269) was assayed by quantified mobility shift using EZ Reader technology with a PLK4 fluorescent peptide substrate (5-FAM-FLAKSFGSPNRAYKK) in the 
presence of 1 mM ATP (final concentration), to mimic cellular ATP levels.  
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An independent assessment of G95R PLK4 activity after purification and storage was 
undertaken using a kinetic, non-radioactive in vitro kinase assay. WT and G95R PLK4 were 
first incubated with a fluorescent peptide substrate and 1 mM ATP and Mg2+ ions, to mimic 
cellular levels of these co-factors. Conversion of the substrate (5-FAM-FLAKSFGSPNRAYKK) 
into the phosphorylated product (5-FAM-FLAKSFGSPNRAYKK) was quantified using a 
mobility shift assay on the EZ Reader platform. These activity assays reveal that both the 
WT and G95R protein are active towards a generic PLK4 peptide substrate, with a maximum 
of 13 % conversion observed for WT and 8 % for G95R over the same time-period (Figure 
3.9 C). The very small difference in activity between the two proteins could be due to subtle 
differences in the tertiary structure arising from the mutation subtly altering the active site. 
 
Further characterisation of the drug-sensitivity of G95R PLK4 was performed by assessing 
activity toward the peptide substrate in the presence of centrinone, to evaluate the extent 
of G95R PLK4 drug-resistance. WT & G95R PLK4 were incubated with increasing 
concentrations of centrinone (10 nM to 100 μM). Figure 3.10 reveals complete inhibition of 
WT-PLK4 activity at 1 µM compound and a calculated IC50 of 330 nM. In comparison, only a 
small decrease in G95R PLK4 activity is observed, with a maximum decrease of 15 % 
observed with 100 µM inhibitor. This confirms unequivocally that at high concentrations of 
ATP, catalytically active G95R PLK4 is highly drug-resistant when compared to WT PLK4, as 
expected. 
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Figure 3. 10. G95R PLK4 is highly resistant to inhibition with centrinone.  Purified recombinant WT 
(blue line) & G95R (red line) PLK4 (1-269) were incubated with fluorescent peptide substrate in the 
presence of DMSO (control) or the indicated concentrations of centrinone and 1 mM ATP. Reactions 
were analysed by mobility shift assay on the EZ Reader platform.  
 
 
An additional assay was performed to test Aurora A activity in the presence of centrinone. 
Recombinantly produced WT and a drug resistant mutant (G216L) Aurora A (10 ng of each) 
were assayed against a fluorescent peptide substrate (5-FAM-LRRASLG) in the presence and 
absence of increasing concentrations of centrinone. Figure 3.11 A shows that Aurora A is 
sensitive to centrinone, with near complete inhibition of Aurora A activity with 1 µM 
centrinone. In comparison, a drug resistant Aurora A in which Gly216 has been mutated to 
Leu shows no sensitivity to centrinone at any of the concentrations tested (Figure 3.11 B). 
This data further highlights the requirement of a drug resistant PLK4 mutant for validation 
of PLK4 substrates in a phosphoproteomics study.  
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Figure 3.11. Aurora A is inhibited by centrinone. Recombinant WT (A) or G216L (B) human Aurora A 
was assayed by quantified mobility shift using EZ Reader technology with a fluorescent peptide 
substrate (5-FAM-LRRASLG) in the presence of 1 mM ATP (final concentration), to mimic cellular ATP 
levels. Data shown is an average of two replicates. 
 
 
Taken together, the near identical autophosphorylation sites of WT & G95R PLK4 and the 
activity of G95R PLK4 against the peptide substrate, even in the presence of high 
concentrations of centrinone confirm that G95R is a suitable tool to be used for validation 
of on- and off-target effects of centrinone inhibition of PLK4. 
 
 Cellular PLK4 assays 
 
Following the development of a suitable cell system for controlled over-expression of PLK4 
and characterisation of WT & G95R proteins, the effects of in vivo inhibition with 
centrinone was assessed. Owing to the known promiscuity of kinase inhibitors (Fabian et 
al., 2005; Bain et al., 2007), incubation conditions were optimised so that the cells could be 
incubated for the shortest possible time at an inhibitor concentration which was high 
enough to maximally inhibit PLK4 activity, but that minimises off-target effects.  
 
Initially, U2OS cells expressing WT FLAG-PLK4 were incubated with 150 nM (final 
concentration) centrinone over a time-course from 1 to 4 hours (Figure 3.12). PLK4 
inhibition is reported by its accumulation within the cells, due to the inability of inhibited 
PLK4 to autophosphorylate its own degron and thus be degraded by the proteasome. The 
time-dependent inhibition experiment revealed a level of accumulation similar to the MG-
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132 control after 4-hour compound exposure. This 4-hour incubation time was therefore 
selected for the following experiments, since it satisfied the requirement of exposing the 
cells to centrinone for as short a time as possible to try to limit accumulated off-target 
inhibitory effects. 
 
 
 
 
Figure 3.12. FLAG-WT PLK4 is stabilised by centrinone in a time-dependent manner.  Expression of 
FLAG-WT PLK4 was induced upon incubation with 1 μg/mL tetracycline for 18 hours. Cells were 
incubated with 150 nM centrinone or 10 μM MG-132 for the time points indicated. Total cell lysates 
were analysed by western blotting using the indicated antibodies.  
 
Next, WT PLK4 expressing cells were incubated with increasing concentrations of 
centrinone (150 nM to 1,000 nM) for 4 hours.  When compared with the levels of PLK4 
detected upon treatment with MG-132, an increased accumulation of PLK4 was observed 
with 150 nM centrinone and stabilisation was essentially maximal at 300 nM (Figure 3.13). 
No additional accumulation of PLK4 was observed at the higher concentrations of 500 nM 
and 1,000 nM, when off-target effects are more likely. To confirm these results, total PLK4 
was immunoprecipitated from cells and analysed by western blot, which also revealed PLK4 
accumulation at 150 nM and 300 nM, but with higher levels of PLK4 observed at 150 nM. 
Despite this difference, 300 nM was chosen as the optimal concentration to ensure all of 
the expressed PLK4 was maximally inhibited for phosphoproteomic studies.  
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Figure 3.13. FLAG-WT PLK4 is inhibited by centrinone in a concentration-dependent manner.  
Expression of FLAG-WT PLK4 was induced upon incubation with 1 μg/mL tetracycline for 18 hours. 
Cells were incubated with centrinone at the concentrations indicated, or 10 μM MG-132, for 4 hours. 
PLK4 was immunoprecipitated by virtue of its FLAG-tag. Total cell lysates (TCL) were analysed by 
western blotting using the indicated antibodies 
 
 
Using the conditions established in the WT PLK4 expressing cells, the experiment was 
repeated using G95R PLK4 expressing cells to evaluate whether centrinone was able to 
stabilize the G95R ‘drug resistant’ protein in cells. Figure 3.14 shows the level of G95R PLK4 
accumulation at the drug conditions tested. A slight increase is observed compared to the 
DMSO control at 150 nM and 300 nM. However, no increase was observed at the higher 
concentrations of 500 and 1000 nM compared to the DMSO control. However, a decrease 
compared to the 150 nM centrinone treated cells  was observed This suggested that the 
slight differences were possibly due to uneven transfer of proteins on to the nitrocellulose 
membrane and not that G95R PLK4 was being inhibited. To confirm this, total G95R PLK4 
was immunoprecipitated from cells and analysed by western blot with an anti-PLK4 
antibody, which demonstrated that centrinone did not stabilise G95R PLK4, since no 
accumulation of the protein was observed. Taken together, the time and concentration-
dependent experiments established that 300 nM centrinone incubation over 4-hours were 
suitable conditions to enable a comprehensive analysis of the PLK4 regulated 
phosphoproteome.  
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Figure 3.14. FLAG-G95R PLK4 is resistant to centrinone inhibition in vivo.  Expression of FLAG-G95R 
PLK4 was induced upon incubation with 1 μg/mL tetracycline for 18 hours. Cells were incubated with 
centrinone at the concentrations indicated, or 10 μM MG-132 for 4 hours. PLK4 was 
immunoprecipitated with an anti-FLAG antibody overnight at 4 °C. Total cell lysates and 
immunoprecipitates were analysed by western blotting using the indicated antibodies.  
 
 High pH reversed phase fractionation 
 
As discussed in Chapter 1, the study of low abundance proteins and phosphopeptides by 
LC-MS/MS requires pre-fractionation of the digested peptides as implemented here using 
high pH reversed phase fractionation, to maximise coverage of the phosphoproteome 
(Batth et al., 2014) in combination with phosphopeptide enrichment.  
 
As high pH fractionation is performed using a column chemistry that is highly similar to the 
final chromatographic separation step (low pH reversed phase), a concatenation approach 
for fraction pooling is necessary (Figure 3.15 A). This approach combines fractions collected 
from the beginning, middle and end of the high pH separation resulting in pools which, 
when further separated under low pH reversed phase conditions, most efficiently exploit 
the separation space of this second dimension, maximising the potential number of 
identifications that can be made. From the 2.5 mg loaded, 60 fractions were collected 
across the gradient and concatenated to 12 pools, as shown in Figure 3.15 A. The peptide 
pools were enriched for phosphopeptides bytitanium dioxide enrichment and analysis of 
the pools resulted in the identification of similar numbers of phosphopeptides in each, 
reflecting the success of a concatenation approach to evenly distribute peptides across the 
gradient for optimal downstream LC-MS/MS phosphopeptide identification (Figure 3.15 B). 
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Figure 3.15. Strategy for high pH reversed phase fractionation.  A) 2.5 mg of trypsin digested cell lysate was fractionated by high pH reversed phase fractionation. 60 
fractions were collected across the gradient and pooled using a concatenation approach to create 12 final pools for subsequent TiO2 enrichment of phosphopeptides. B) 
Selected TiO2 enriched phosphopeptide were analysed by LC-MS/MS and processed in Proteome Discoverer using Mascot with the ptmRS node enabled. The number of 
phosphopeptides identified in each of the pools analysed (odd number pools) are shown.  
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  Assessment of SILAC labelling  
 
Full incorporation of heavy labelled amino acids in SILAC medium is a critical step prior to 
downstream proteomic analysis. Mann et al., suggest that most cell lines will fully 
incorporate the label after 5 cell doublings and it is critical to confirm full incorporation of 
the heavy labelled amino acids in to the cells prior to downstream proteomic analysis. WT 
and G95R FLAG-PLK4 cells were grown in light (R0K0) media and at 80 % confluence were 
split in to the heavy labelled arginine (13C6 15N4) and lysine (13C6 15N2) media (R10K8). As the 
cells propagated in the heavy media, aliquots were taken at each cell passage and the cells 
were lysed, digested with trypsin and analysed by LC-MS/MS to assess incorporation of the 
heavy label at each passage (Figure 3.16).  
 
 
 
 
Figure 3.16. Strategy for the assessment of heavy arginine (13C6 15N4) and lysine (13C6 15N2) 
incorporation in to U2OS cells.  Cells grown in ‘light’ media were subcultured into ‘heavy’ media 
containing the stable isotopes arginine and lysine (R10K8). Cell growth and protein turnover results 
in incorporation of the label in to newly synthesised proteins. At each passage, an aliquot of cells 
were removed. Proteins were digested with trypsin to produce lysine and arginine terminating 
peptides and analysed by LC-MS/MS to assess incorporation of the heavy labelled amino acids. 
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Chromatograms were extracted for specific peptides to assess label incorporation. 95 % 
incorporation is required for accurate quantification and considered fully labelled, as 100 % 
cannot be achieved due to impurities in the SILAC medium. Figure 3.17 shows that 
following approximately 4 cell doublings, the heavy arginine label is partially incorporated, 
with the light peptide still being observed (20 %) and identified by MS/MS. This 
incorporation is somewhat slower than suggested by Mann et al., and highlights the 
importance of assessing the rate of incorporation over time for each individual cell line 
prior to undertaking a large-scale proteomics study. After 7 cell doublings, the cells reached 
complete incorporation of the heavy labels. A signal for the light peptide (3.6 % of heavy 
peak) can be observed which is within the accepted range to be considered fully labelled.  
An assessment of lysine terminating peptides was also analysed to confirm complete 
incorporation of 13C6 15N2 lysine (see Appendix 1). This work established the number of 
passages required for full incorporation of the heavy labels in U2OS Flp-In cells, and this 
protocol is therefore suitable for accurate SILAC-based quantitative PLK4 
phosphoproteomics experiments in this system.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
        Chapter 3 
91 
 
 
 
Figure 3.17. Heavy arginine (13C6 15N4) incorporation in U2OS cells.  The extracted ion chromatograms (XIC; top panels) show the ion signals for the indicated peptide. The 
top left panel shows a peptide at m/z 902.98 and represents the presence of the peptide in its light form due to growth in ‘light’ media. MS/MS (bottom left) reveals that 
the peptide is from α-enolase. Following 4 cell doublings in SILAC (R10K8) media, the same peptide is shown as a SILAC pair, with a mass difference of 10 Da. The ‘heavy’ 
peptide is at a higher intensity but still contains sufficient ‘light’ peptide to be identified by MS/MS (bottom, middle panels), reflecting partial incorporation of the label. At 
7 cell doublings, no ‘light’ peptide can be identified reflecting full incorporation of the heavy label.  
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3.3. Conclusions 
 
This chapter describes the successful development and optimization of biochemical tools to 
establish a valid strategy for performing large scale phosphoproteomics to study PLK4 
regulated signalling pathways. PLK4 plasmids were successfully cloned into a pcDNA5 
vector and subsequently transfected in to U2OS cells to produce stable, isogenic cell lines. 
These cell lines enabled the controlled over-expression of PLK4, which was not only 
catalytically active, but was also localised correctly at the centrioles. The generation of 
these cell lines provides a method for performing a large-scale analysis of PLK4 signalling 
which has not previously been feasible due to the low abundance of endogenous PLK4 and 
will permit a true insight in to the activities of PLK4 in the cell.  
 
A key consideration for the work described in this chapter was to establish a viable strategy 
for validation of phosphoproteomics data obtained for WT PLK4 expressing cells. Probing 
the cell line with the kinase inhibitor centrinone will perturbate PLK4 regulated signalling 
pathways but is also likely to cause many off target effects, which could be falsely 
attributed to PLK4 activity. Confirmation that G95R PLK4 retains WT activity through in vitro 
kinase assays against a peptide substrate and assessment of sites of autophosphorylation 
was an important result to show that the use of a drug-resistant mutant to validate on and 
off-target effects of centrinone inhibition of WT PLK4 is a viable strategy.  
 
Finally, optimisation of some of the key stages of the phosphoproteomics workflow, 
including offline high pH reversed phase fractionation, ensured that during PLK4 
phosphoproteomics experiments, relatively high numbers of phosphopeptides could 
potentially be identified for deep coverage of the phosphoproteome. This allows for the 
possibility of identifying low abundance proteins that are either direct substrates of PLK4 or 
implicated in PLK4 regulated signalling. Furthermore, the assessment of SILAC labelling of 
U2OS cells has revealed the number of cell doublings required for full incorporation of the 
heavy labels using this cell line which is critical for ensuring accurate and reliable 
quantification of identified peptides to determine true PLK4 regulated phosphosites and 
proteins.  
 
The basic tools to enable the study of the PLK4-regulated phosphoproteome by SILAC based 
quantitative phosphoproteomics are therefore available for the first time. By combining 
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with a drug-resistance approach, we hoped to use chemical genetics to evaluate PLK4 
substrates that were ‘on-target’ to PLK4. For the most effective exploitation, these tools 
can be aligned with optimised mass spectrometry methods in order to not only maximise 
the number of phosphosites identified, but also to have a high degree of confidence in the 
site of modification. The development and optimisation of this mass spectrometry method 
is the focus of Chapter 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
94 
 
 
 Evaluation of parameters for confident phosphorylation 
site localisation using an Orbitrap Fusion Tribrid mass 
spectrometer 
 
The text and figures in section 4.2.4 to 4.2.7 are reproduced from the paper ‘Evaluation of 
Parameters for Confident Phosphorylation Site Localization using an Orbitrap Fusion Tribrid 
Mass Spectrometer’ published in Journal of Proteome Research by Ferries et al., 2017. I am 
the first author of the paper and a full transcript, along with supplementary material can be 
found in Appendix 4. In addition, the Introduction from the paper has been adapted for 
section 4.1.  
 
4.1. Introduction 
 
Following  the development of tools for the functional analysis of PLK4, the next aspect of 
the project involved optimisation of MS-based methods to maximize coverage of the PLK4 
regulated phosphoproteome and achieve high confidence in the sites of phosphorylation. 
This chapter describes the development and optimization of MS acquisition methods for 
phosphoproteomics using an Orbitrap Fusion, with a primary focus on the use of mass 
analysers, fragmentation modes and downstream data processing for phosphopeptide 
analysis.   
 
Over the past decade, there have been great advances in the analysis of 
phosphoproteomes by MS, due to the development of highly sensitive mass spectrometers, 
improved phosphopeptide enrichment techniques and bioinformatics tools for data 
interrogation. Thousands of phosphopeptides can now be identified in a single analytical 
‘run’. However, a key challenge that remains to be resolved is the ability to unequivocally 
identify the site of phosphorylation on a given peptide. Phosphorylation at different sites 
on a protein can have dramatically different downstream effects, from increasing protein 
activity, to altering substrate specificity or signalling for protein degradation (Manning et 
al., 2002).  Correct interpretation of the cell signalling pathways under investigation cannot 
therefore be obtained if there is ambiguity as to the site of phosphorylation within a 
peptide.  
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The capabilities of the Orbitrap Fusion Tribrid mass spectrometer, (described in detail in 
Chapter 1), including the combination of ion trap and orbitrap mass analysers in addition to 
multiple modes of fragmentation (CID, HCD & ETD) offers significant user flexibility to 
design methods for the analysis of phosphopeptides. To ensure that the Orbitrap Fusion is 
utilized to its maximum capability for this type of analysis, key parameters must first be 
optimized: the HCD collision energy for phosphopeptide fragmentation; maximum fill time 
for ion accumulation in the orbitrap; fragmentation mode and detection of product ions in 
the ion trap versus the orbitrap. The applied collision energy, along with the peptide 
sequence and charge, determines the product ions produced following HCD fragmentation. 
Increased collision energy provides the initial product ions with higher translational energy 
which results in a greater number of abundant product ions being produced from multiple 
fragmentation pathways (Olsen et al., 2007). This is crucial for phosphopeptides, where 
high numbers of product ions are required, not just to identify the peptide but to isolate 
the site of modification. Collision energy must also be controlled to ensure over-
fragmentation does not occur; higher energies can result in multiple fragmentation events, 
decreasing the abundance of the larger b- and y- ion fragments, resulting in spectra that are 
dominated by smaller m/z ions and internal product ions. This can decrease the overall 
quality of the spectra, resulting in fewer identifications (Diedrich et al., 2013). . 
 
In addition to collision energy, the maximum injection times for ion accumulation in the 
orbitrap for MS2 must also be optimised for phosphoproteomics studies to achieve a 
balance between quantity and quality of acquired spectra. Methods are created with 
automatic gain control (AGC) to fill the orbitrap until a set number of ions are reached and 
with a time limit imposed for ion accumulation. Owing to the relatively low abundance and 
reduction in ionization efficiency that can be observed for some phosphopeptides, the AGC 
is unlikely to be reached in most instances without long maximum injection times. This was 
shown in a previous study which revealed that the average injection time for 
phosphopeptides in an orbitrap was 236 ms and as a result, fewer phosphopeptides were 
identified than when using CID based fragmentation in a linear ion trap (Zhang et al., 2009). 
Whilst this is dependent on the material loaded, it does reflect the longer injection times 
required for orbitrap mass analysis. Additionally, a study on the Q Exactive platform, which 
assessed a range of methods with varying injection times for peptide identifications 
revealed that whilst ‘fast’ methods using low injection times produced high scan numbers 
and high quality data for peptide analysis, much longer fill times were required to study 
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post-translationally modified peptides (Kelstrup et al., 2014). Maximum injection time is 
therefore an important parameter to ensure sufficient ion accumulation to obtain high 
quality MS/MS spectra whilst maintaining a high number of phosphopeptide identifications.  
 
Increasing the number of site-determining product ions can be achieved by the exploitation 
of multiple complementary fragmentation modes (described in Chapter 1) (Boersema et al., 
2009a; Kim et al., 2011; Frese et al., 2012; Frese et al., 2013; Lanucara et al., 2014; Lanucara 
et al., 2016). On the Orbitrap Fusion, the benefit of being able to perform both HCD and 
CID, as well as ETD and ETca/hcD, with product ion analysis being performed in either the 
ion trap or the orbitrap (Hebert et al., 2014; Riley et al., 2016; Espadas et al., 2017), means 
that these instruments should be of great benefit to improve phosphoproteome analysis 
and unambiguous phosphosite identification.  
 
The number of potential phosphopeptide MS acquisition strategies, particularly with the 
new generation of versatile tribrid Orbitrap instruments, means that it can be extremely 
complicated and time-consuming to establish an ‘optimal’ phosphoproteomics pipeline. 
There are numerous challenges associated with optimizing instrument settings to maximize 
phosphopeptide identification and crucially, confident site localization. The added 
capability of the Orbitrap Fusion instruments to parallelize acquisition of MS1 in the high 
resolution Orbitrap, while acquiring at a faster rate, lower resolution MS2 in the ion trap (if 
required), means that there can be significant advantages for high throughput proteomics 
using this type of tribrid instrument. The number of possible strategies for MS(/MS) data 
acquisition (orbitrap versus ion trap), as well as potential fragmentation regimes (CID, HCD, 
ETcaD, EThcD, with or without neutral loss considerations that may be used for triggering 
additional MS2 /MS3 acquisition, or multistage acquisition (MSA)) means that the 
combinatorial options for MS data acquisition are vast. 
 
 Aims 
 
The aims of the work described in this Chapter were therefore, to develop and optimize MS 
parameters and a downstream data analysis workflow for the study of the PLK4-regulated 
phosphoproteome.  This included preliminary experiments to ascertain a suitable collision 
energy and MS2 maximum injection time for phosphopeptides, followed by the evaluation 
of eight acquisition modes on the Orbitrap Fusion Tribrid MS platform, using a library of 
synthetic phosphopeptide standards, and a complex phosphopeptide-enriched cell lysate 
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preparation. In addition, this work aimed to identify optimal downstream processing for 
phosphopeptide identifications and phosphosite localization by comparing Proteome 
Discoverer (PD) with MASCOT and phosphoRS (ptmRS), and MaxQuant with Andromeda 
and PTM-score.  
 
 
4.2. Results & Discussion 
 
 Effect of normalized collision energy on phosphopeptide identifications  
 
To assess the effect of HCD collision energy on phosphopeptide identification and confident 
phosphosite localisation, a phosphopeptide enriched U2OS lysate was analysed on the 
Orbitrap Fusion, with both MS1 & MS2 scans being performed in the orbitrap to generate 
high-resolution data. A range of collision energies were tested from 28 to 34 normalised 
collision energy (NCE), and the data processed using Mascot within Proteome Discoverer, 
with the ptmRS node enabled. Table 4.1 shows the total number of phosphopeptide 
identifications for each method tested, with the total number of identifications increasing 
by ~30 % from 28 to 32 NCE. The numbers then decrease at 34 NCE, suggesting that at this 
collision energy, over fragmentation may be reducing MS2 spectral quality resulting in 
fewer phosphopeptide identifications. 
 
Table 4.1. Evaluation of normalised collision energy (NCE) on the number of phosphopeptides 
identified.  For each NCE value tested, the number of PSMs, total number of peptide and 
phosphopeptide identifications, and number of phosphosites is reported.  32 NCE, which identifies 
the highest number of phosphopeptides is highlighted in red. 
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 Effect of normalised collision energy on phosphosite confidence  
 
To assess the effect of collision energy on phosphosite localisation, individual spectra were 
manually annotated to identify the number of site determining ions produced following 
fragmentation at each NCE value tested. Figure 4.1 shows annotated MS2 spectra for the 
peptide HNsESESVPSSMFILEDDR from 28, 30 & 32 NCE. At 28 NCE, the fragment ions 
identified provide evidence for phosphorylation at either the first, second or third serine in 
the sequence. However, insufficient fragment ions are produced to unequivocally isolate 
the phosphosite. This is reflected in the ptmRS score of 33.3 for this peptide. At 30 NCE, the 
b6 ion is produced which eliminates the third serine as the site of modification and 
improves the ptmRS score to 50. However, the exact site of phosphorylation still cannot be 
determined. The b4-H2O product ion observed when 32 NCE is applied isolates the first 
serine in the sequence as the phosphorylated residue and a ptmRS score of 100 is obtained.  
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Figure 4.1. Product ion spectra of a phosphopeptide fragmented with 28, 30, 32 & 34 NCE.   Doubly 
charged ion at m/z 753.65 fragmented at the indicated collision energies: A) 28 NCE; B) 30 NCE; C) 32 
NCE; D) 34 NCE. The sequence is displayed on each mass spectrum showing the product ions 
identified and isolation of the phosphosite. 
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Next, the phosphopeptides identified under all four conditions were compared to assess 
the global distribution of ptmRS scores as NCE increased. Interestingly, the data shows that 
the percentage of high confidence ‘Type I’ phosphosites (ptmRS ≥ 75 %) was relatively high 
across all collision energies tested (~82 %) (Figure 4.2A). Figure 4.2B shows that the 
distribution of ptmRS scores does not change with increased collision energy and that the 
vast majority of phosphosites are given a confidence score above ~98 % or below ~50 %. It 
is likely that the increased number of phosphopeptides identified as collision energy 
increases is due to accessing a wider population of peptides that could be fragmented to 
produce sufficient fragment ions for identification, but the ability to localise phosphosites 
follows the same distribution regardless of the energies tested in this study.  
 
 
 
Figure 4.2. Evaluation of collision energy on ptmRS score.  A) The total number of phosphosites 
identified and those identified with high confidence ptmRS (≥0.75, is indicated. 32 NCE, which 
identifies the highest number of confident phosphosites is highlighted in red. B) Global distribution 
of ptmRS scores for phosphosites identified in all four collision energy methods tested. 
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 Effect of maximum injection time on phosphopeptide identifications & 
phosphosite confidence 
 
Next, an assessment of the effect of maximum injection time of ions into the orbitrap on 
phosphopeptide identifications and phosphosite localisation confidence was performed. A 
range of MS2 fill times from 50 ms to 100 ms were tested and the data processed using 
Mascot/ Proteome Discoverer with phosphosite localisation assessed using ptmRS.  
 
Table 4.3A shows that as the MS2 maximum injection time increases, the number of both 
MS1 and MS2 scans decreases, as expected. However, the number of phosphopeptides 
identified increases 10 % as fill time increases from 50 ms to 80 ms (Table 4.3B), 
demonstrating that despite obtaining fewer spectra, the quality of the acquired spectra is 
higher and therefore more phosphopeptides can be identified with longer fill times.  
 
Interestingly, whilst a slight increase in the number of singly phosphorylated peptides is 
observed as maximum fill time increases, a greater difference is observed for multiply 
phosphorylated peptides (Figure 4.2B). At 100 ms injection time, the number of doubly and 
triply phosphorylated peptides increased by 25 % and 64 % respectively, compared with the 
50 ms injection time method. Whereas reduced ionization efficiency for singly and doubly 
phosphorylated peptides has been disputed (Steen et al., 2006), multiply phosphorylated 
peptides have been shown to suffer disproportionally from ionization suppression. Efforts 
have been made to increase the identification of these multiply phosphorylated peptides, 
including by addition of EDTA and phosphoric acid to LC buffers to aid elution from 
reversed phase columns (Kim et al., 2004; Fleitz et al., 2013). The increase in the number of 
multiply phosphorylated peptides identified with longer injection times without the need 
for additives therefore presents an ideal approach for a global analysis of the 
phosphoproteome, including this subset of phosphopeptides that would not otherwise be 
observed.  
 
Whilst the numbers of identified triply phosphorylated peptides remains low with 100 ms 
injection time (80 phosphopeptides), this is to be expected, as identification of multiply 
phosphorylated peptides requires there to be an equal number of basic residues to 
phosphate groups which does not occur frequently when trypsin is used for digestion. 
Digestion with another enzyme, such as LysC which would only cleave C-terminal to lysine 
residues, resulting in a number of basic peptides including both arginine and lysine to 
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counter the acidic effects of the phosphate on modified residues would allow for potential 
identification of a greater number of multiply phosphorylated peptides.  
 
When considering ptmRS score, the percentage of confidently localised phosphosites (≥ 75 
%) increases from 81 to 84 % for 80 ms, and 86 % for 100 ms fill times. The global 
distribution of ptmRS scores was assessed and clearly shows that with longer MS2 fill times 
the ptmRS score increases up to 80 ms (Figure 4.3C). Again, this is likely due to longer fill 
times permitting the accumulation of sufficient numbers of ions resulting in higher quality 
MS2 spectra upon fragmentation. Overall, 100 ms injection time represents a significant 
improvement from the lower injection time methods tested and allows for a high number 
of quality spectra to be identified and is optimal for a global phosphoproteomics study.  
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Figure 4.3. Evaluation of MS2 fill time maximum injection time on phosphopeptide identification and phosphosite confidence.  A)  MS2 fill times tested and the 
respective number of MS1 and MS2 scans acquired. B) The total number of peptides & phosphopeptides identified is shown in addition to the number of singly, doubly and 
triply phosphopeptides identified. Number of phosphosites and phosphosite confidence is indicated. 100 ms injection time, which identified the highest number of 
confident phosphosites is highlighted in red. C) Global distribution of ptmRS scores is shown for each method. 
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Taken together, the results show that for high numbers of phosphopeptide identifications, 
including doubly and multiply phosphorylated peptides, and high confidence in the site of 
modification, a collision energy of 32 NCE and a maximum MS2 fill time of 100 ms provides 
optimal parameters for large-scale phosphoproteomics analysis.  
 
 Comparison of fragmentation methods and MS2 resolution settings for 
identification and site localization of phosphopeptide standards 
 
To evaluate the advanced capabilities of the Orbitrap Fusion tribrid mass spectrometer for 
site-specific phosphopeptide identification, a series of MS acquisition methods were 
designed to assess the benefits of using either the high resolution orbitrap or the lower 
resolution ion trap mass analysers. In the first instance a commercially available synthetic 
library of phosphopeptides was analysed, (Marx et al., 2013) that comprised tryptic 
peptides previously observed in multiple large-scale phosphopeptide studies. The library 
was designed such that the typical composition and length observed in bottom-up 
proteomics is represented, with a natural occurrence of unmodified and phosphorylated 
serine, threonine and tyrosine residues.  
 
As well as differing in resolving power, there are significant differences in speed and 
sensitivity between the orbitrap (OT) and ion trap (IT) mass analysers. HCD, EThCD and 
neutral loss (NL) triggered ETD-mediated fragmentation strategies, where ions exhibiting 
precursor neutral loss of 98 amu (arising due to the characteristic loss of H3PO4 from 
phosphorylated peptide ions (DeGnore & Qin, 1998; Boersema et al., 2009a; Lanucara et 
al., 2014)) or 80 amu (arising due to loss of HPO3) following HCD, were also compared 
(Table 4.2; Table S1).  
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Table 4.2. MS data acquisition methods evaluated.  IT: ion trap; OT: orbitrap; nl: neutral loss. See 
Appendix 4, Table S1 for full details of MS data acquisition parameters. All MS1 analysis was 
performed in the orbitrap. 
Method 
Resolution 
(MS1) 
Mass analyzer 
(MS2) 
Resolution 
(MS2) 
HCD OT 60K Orbitrap 30K 
HCD IT 120K Ion Trap Rapid 
EThcD IT 120K Ion Trap Rapid 
EThcD OT 60K Orbitrap 30K 
HCD OT nl EThcD IT  60K Orbitrap 30K 
HCD OT nl ETcaD IT 60K Orbitrap 30K 
HCD IT nl EThcD IT 120K Ion Trap Rapid 
HCD IT nl ETcaD IT 120K Ion Trap Rapid 
 
The phosphopeptide library, containing 175 unique phosphopeptides (191 phosphorylation 
sites), was divided into five pools for LC-MS/MS analysis (see Appendix 2). Isomeric 
phosphopeptides (where the same peptide sequence is modified on a different residue) 
were allocated to different analytical pools to ensure that site localization could be defined 
absolutely. The five pools of synthetic phosphopeptide standards were each analysed in 
duplicate using the eight MS acquisition methods, assessing both phosphopeptide 
identification and phosphosite localization (Table 4.2, Appendix 4 , Supp. Fig 1).  
 
As an extension of previously published studies (Marx et al., 2013; Wiese et al., 2014) the 
ability of two commonly used phosphoproteomics data analysis platforms, MASCOT 
integrated into Proteome Discoverer (PD) using ptmRS (a slightly modified version of 
phosphoRS (Taus et al., 2011)) for phosphosite localization, and Andromeda with 
MaxQuant and PTM-score (Olsen et al., 2006) was also assessed, to identify the synthetic 
phosphopeptides from all eight datasets (Table 4.3).
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Table 4.3. MS acquisition and data analysis methods evaluated using synthetic phosphopeptides.  For each of the eight orbitrap Fusion MS acquisition methods (Table 1, 
Supplementary Table 1) the number of peptide spectrum matches (PSMs) are presented (n = two technical replicates), together with the number of unique peptides (out of 
a total of 175) and phosphosites (total 191), as well as the number and percentage of correctly localized phosphosites using either Andromeda with PTM-score (top), or 
MASCOT and ptmRS (bottom), according to the top-ranked PSM.  aMean values are presented ± S.D. 
Search 
Engine  
  HCD OT HCD IT EThcD OT EThcD IT 
HCD OT    
nl EThcD 
HCD OT   
 nl ETcaD 
HCD IT     
 nl EThcD 
HCD IT      
nl ETcaD 
Andromeda # PSMa 705 ± 4 984 ± 16 407 ± 18 515 ± 88 625 ± 194 650 ± 30 838 ± 37 745 ± 36 
  # unique phosphopeptides  154 159 146 152 156 154 154 155 
  # phosphosites 168 173 160 166 170 168 168 170 
  
# phosphosites correctly 
localized with PTM-score  
155 150 155 156 152 154 147 150 
 
% phosphosites correctly 
localized with PTM-score   
92% 87% 97% 94% 89% 92% 88% 88% 
MASCOT  # PSMa  889 ± 1 1497 ± 11 417 ±1 654 ± 52 866 ± 107 868 ± 13 1029 ± 30 940 ± 29 
  # unique phosphopeptides  164 168 149 156 162  160 159 157 
  # phosphosites 179 183 163 165 180 175 173 171 
  
# phosphosites correctly 
localized with ptmRS  
172 151 154 151 167 163 154 144 
 
% phosphosites correctly 
localized with ptmRS  
96% 83% 94% 92% 93% 93% 89% 84% 
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Implementation of either the Andromeda or MASCOT search algorithms resulted in notably 
fewer PSMs using EThcD compared to HCD, independent of whether MS2 was performed in 
the orbitrap or the ion trap (Table 4.3). This result can be explained by the increase in duty 
cycle for this mixed mode fragmentation regime. Consequently fewer phosphopeptides 
were identified with EThcD OT compared with the analogous HCD OT, and likewise for 
EThcD IT compared with HCD IT (Table 4.3). However, the higher percentage of PSMs with 
correctly localized phosphosites following EThcD IT (94% compared with 87% for 
Andromeda/PTM-score; 92% compared with 83% for MASCOT/ptmRS for EThcD IT or HCD 
IT respectively) translated to the same or higher numbers of correctly site localized 
phosphosites being characterized overall with EThcD IT than HCD IT (Table 4.3; Figure 4.4A; 
Appendix 4 Supp. Figure 2). These findings are in agreement with previous observations on 
different instrument platforms, which highlight the benefit of mixed mode fragmentation 
for improved phosphosite localisation (Frese et al., 2013). For the high resolution OT data, 
there was a notable difference in the performance of the two search engines. 
Consequently, while phosphosite localization confidence increased with EThcD compared 
with HCD (resulting in the same numbers of correctly localized phosphosites) using 
Andromeda/PTM-score, this was not the case with MASCOT/ptmRS. 172 phosphosites were 
correctly identified with HCD OT, whereas EThcD OT yielded only 154 correctly localized 
phosphosites. The benefits of high resolution MS2 acquisition therefore appear to outweigh 
the increased duty cycle associated with EThcD when using MASCOT/ptmRS for this 
phosphopeptide library. 
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Figure 4.4. Fragmentation method-specific phosphosite localization.  (A) Number of correctly 
assigned (HCD OT: red; HCD IT: blue; EThcD OT: green; EThcD IT: purple) and incorrectly assigned 
(white) phosphosites from the synthetic phosphopeptide library (Table 1; Supplementary Table 1). 
(B, C) False localization rate (FLR) determination for the four different basic MS2 acquisition 
strategies using either Andromeda/PTM-score (B) or MASCOT/ptmRS (C). (D, E) Distributions of PTM-
score (D), or ptmRS (E) for each of the four MS2 methods. *Site localization scores equivalent to 0.7% 
FLR 
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When considering HCD fragmentation, with or without NL-triggered ET(hc/ca)D, 
phosphosite localization with both bioinformatics platforms was optimal (higher 
percentage) with high resolution orbitrap MS2 analysis, likely due to the improved 
confidence afforded by the enhanced mass accuracy as compared with low resolution ion 
trap MS2 measurements (Table 4.3; Figure 4.4A; Appendix 4 Supp. Figure 1). Interestingly, 
Andromeda/PTM-score yielded fewer numbers overall, both of unique phosphopeptides 
and correctly localized phosphosites, compared with MASCOT/ptmRS, irrespective of MS 
method.  A maximum of 159 unique phosphopeptides (155 correctly localized 
phosphosites) were identified from the pool of 175 synthetic phosphopeptides with 
Andromeda/PTM-score, compared with 168 phosphopeptides (172 correctly localized 
phosphosites) when the same data were interrogated using MASCOT/ptmRS. 
 
With both search algorithms, HCD IT was optimal for both PSMs and the numbers of unique 
phosphopeptide identified, as might be expected given the possibility for parallelization of 
MS1 data acquisition in the orbitrap and concurrent MS2 analysis in the ion trap. However, 
site localization confidence, the critical parameter from the point of view of biological 
inference, was either optimal (ptmRS) or of equal performance (PTM-score) using the HCD 
OT method.  
 
Upon further examination of the workflows exploiting neutral loss-triggered ETcaD, the vast 
majority (89 – 93%) of correctly site localized phosphopeptides were derived from the HCD 
spectra rather than the ETcaD spectra triggered following precursor neutral loss. The 
additional incorporation of ETcaD in this regime thus appeared to offer no benefit for either 
phosphopeptide identification or site localization over that achieved with HCD alone. 
Indeed, the number of PSMs was compromised due to the increase in duty cycle for the 
EThcD component of this multi-stage acquisition method. The HCD IT/OT nl ETcaD IT 
methods are therefore not discussed in subsequent analytical comparisons. 
 
A significant advantage of using synthetic phosphopeptides of known sequence is the ability 
to define false localization rates (FLRs) specific to the MS acquisition method employed, by 
counting the numbers of correct and incorrectly site localized PSMs (Marx et al., 2013) 
(Figure 4.4 B-E). The distribution of site localization scores for each of the four unique 
fragmentation modes, HCD OT, HCD IT, EThcD OT, EThcD IT, with each of the two 
informatics pipelines is presented in Figure 4.4. Akin to previous observations on different 
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MS platforms with both synthetic phosphopeptides (Marx et al., 2013) and a complex 
phosphopeptide enriched cell lysate (Wiese et al., 2014), both site localization tools require 
MS acquisition method specific scores to yield a 1% FLR, (Figure 4.4 B, C).  It is of interest to 
note that although fewer phosphosites were incorrectly localized overall with HCD OT 
compared to HCD IT with both search engines, this does not correlate with a lower site 
localization score. ptmRS exhibits a bimodal distribution for high-resolution MS2 data, with 
clustering of values around ptmRS = 100 and ptmRS = 50, indicating either ‘certainty’, or 
lack of discriminatory evidence between two possible sites, respectively. In contrast, PTM-
score values are more evenly distributed (red plots in Fig. 4.4D and 4.4E). This difference is 
likely due to how the two algorithms were developed; while phosphoRS was optimized with 
both high and low resolution data (Taus et al., 2011), PTM-score was originally developed 
for phosphosite localization using low mass accuracy ion-trap generated CID data (Cox et 
al., 2011). Unlike phosphoRS, PTM-score treats all observed MS2 peaks as integer masses 
(Taus et al., 2011; Chalkley & Clauser, 2012), meaning that there is limited benefit using 
PTM-score when high resolution data has been acquired.  Furthermore, while PTM-score 
searches the “n” most intense peaks within a bin of 100 m/z to identify site-determining 
product ions, ptmRS considers the total number of extracted peaks across the full mass 
range of the MS2 spectrum, overcoming potential issues of uneven peak distribution in 
individual m/z bins (Taus et al., 2011; Chalkley & Clauser, 2012), and is thus better suited 
for data generated with high resolution mass analysers.  
 
Both localization tools underestimated the true FLR for EThcD IT data (Fig. 4.4B and C), 
demonstrating the additional benefit of generating site determining c/z as well as b/y ions 
within a single spectrum.  A 1% FLR could not be computed for the EThcD OT dataset, as 
insufficient incorrectly localized phosphopeptides were identified from the library. Instead, 
the scores defined for this fragmentation mode (PTM-Score = 0.9; ptmRS = 99.4, Figure 
4.4B, C) represent an FLR of 0.8%. The other PTM-score and ptmRS values computed for 
phosphosite localization at a 1% FLR are broadly in agreement with those previously 
defined for a larger synthetic phosphopeptide library using a different orbitrap-based MS 
platform, demonstrating that the MS acquisition methods and the associated 
bioinformatics platforms are largely transferable between similar platforms (Marx et al., 
2013). 
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In addition to the 1% FDR filtering, ‘default settings’ in Andromeda apply a score cut off of 
40 for post-translationally modified peptides. To investigate whether this artificially 
reduced the numbers of phosphopeptides identified from our library, all eight datasets 
were searched again with Andromeda, having removed the requirement for scores to 
exceed 40 (Supplementary Table 2).  An analogous threshold for comparison with MASCOT 
could not be set since there is not a perfect linear relationship between the two scoring 
algorithms (Cox et al., 2011). Upon removal of this score filter in Andromeda, the numbers 
of confidently identified phosphorylation sites was broadly similar, with the exception of 
the high resolution HCD OT and HCD OT nl EThcD datasets, where an additional seven and 
six phosphosites were identified respectively. The resultant minimal change in confidently 
assigned phosphosites (max. 4% with HCD OT; 2% decrease with EThcD IT) meant that 
amendment of the default settings in Andromeda did not warrant further investigation.  
Default settings for both search engines were thus used in subsequent investigations, these 
also being the parameters that most end-users will typically apply. 
 
 Phosphopeptide identification from a phosphopeptide enriched complex 
human cell lysate 
 
Having evaluated the eight MS acquisition methods using the phosphopeptide library, six 
methods for this tribrid MS platform worthy of further investigation based on the numbers 
of correctly site localized phosphopeptides were defined. Performance of these six MS 
acquisition strategies for phosphopeptide identification and phosphosite localization was 
then evaluated using a larger dataset derived from a more complex, biologically relevant 
sample. Phosphopeptides were enriched from a U2OS cell lysate using TiO2, and aliquots (6 
µl, equivalent to 100 µg from 4 mg digested cell lysate) of the same phosphopeptide 
enriched sample were analysed in duplicate by LC-MS/MS using HCD OT, HCD IT, EThcD OT, 
EThcD IT, HCD OT nl EThcD IT or HCD IT nl EThcD IT (Table S1).  
 
The number and overlap of unique phosphopeptide identifications using either 
Andromeda/PTM-score or MASCOT/ptmRS is presented for each of the MS acquisition 
methods (Table 4.4, Figure 4.5, Appendix 4 Figures S2, S3). Of the six methods assessed, 
HCD IT exhibited the least overlap between technical replicates, with up to 44% of 
phosphopeptides being unique to a single LC-MS/MS run. Other methods exhibited 
between ~80% (HCD OT nl EThcD IT) and 75% (HCD OT) overlap (Figure S1). 
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The highest total number of unique phosphopeptides from the enriched U2OS cell lysate 
(6877 phosphopeptides above a 1% FDR) was identified using HCD IT and Andromeda 
(Table 4.4, Figure 4.5, Appendix Figures S4, S5, S6). This regime maximizes on the capability 
of the Orbitrap Fusion to parallelize high resolution MS1 acquisition in the orbitrap whilst 
simultaneously acquiring MS2 data in the ion trap. Interestingly, there was little difference 
in the numbers of unique phosphopeptides identified using MASCOT when MS2 was 
performed in the OT versus the IT; 4957 phosphopeptides were confidently identified for 
HCD OT compared with 4920 phosphopeptides using HCD IT (Table 4.4). This is almost 
certainly due to the enhanced confidence in phosphopeptide identification that results 
when MS data are acquired with higher mass accuracy, as is the case with HCD OT. 
However, it is particularly interesting to note how Andromeda and MASCOT differentially 
handle high resolution and low resolution MS2 data (discussed in more detail below). 
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Table 4.4. MS acquisition and data analysis methods evaluated using phosphopeptide enriched human cell lysate.  For each of the six Orbitrap Fusion MS acquisition 
methods (Table 1, Table S1) the number of peptide spectrum matches (PSMs) at 1% FDR are presented together with the total number of unique phosphopeptides and 
phosphosites using either Andromeda with PTM-score (top) or MASCOT and ptmRS (bottom). The number of phosphosites with an FLR ≤ 1% is also presented. aMean 
values are ± S.D., n = 2. 
 
 
 
Search Engine    HCD OT HCD IT EThcD OT EThcD IT 
HCD OT  
nl EThcD 
HCD IT  
nl EThcD 
Andromeda/ 
PTM-score  
# Unique phospho 
PSMsa 
5414 ± 197 6396 ± 728 1947 ± 1 3321 ± 42 5452 ± 88 5506 ± 659 
  
# unique 
phosphopeptides  
4214 5632 1730 3315 3702 3494 
  # phosphosites 4808 6877 1928 3995 4345 4145 
  
# phosphosites  
≤ 1% FLR  
2422 
(50%) 
2550 
(37%) 
1468 
(76%) 
3037 
(76%) 
2472 
(57%) 
2045 
(49%) 
MASCOT/ ptmRS  
# Unique phospho 
PSMsa  
5118 ± 45 4705 ± 269 2084 ± 26 2847 ± 197 4966 ± 45 4297 ± 69 
  
# unique 
phosphopeptides  
4957 4920 2148 2947 4153 3398 
  # phosphosites 5733 5501 2413 3409 4880 3933 
  
# phosphosites  
≤ 1% FLR  
4337 
(76%) 
3294 
(60%) 
2078 
(86%) 
2841 
(83%) 
3837 
(79%) 
2717 
(69%) 
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Figure 4.5. Comparison of method-dependent phosphorylation site localization.  Confidently localized phosphorylation sites (FLR ≤1%, green) or ambiguous phosphosite 
assignments (white, grey) from a TiO2-enriched U2OS cell lysate, using either (A, B) Andromeda/PTM-score, or (C, D) MASCOT/ptmRS for each of the six Orbitrap Fusion MS 
acquisition methods. Phosphosites assigned by virtue of neutral loss (NL)-triggered EThcD are also presented. Number (A, C) or percentage (B, D) of phosphosites identified 
is indicated for each condition. 
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An important reason for undertaking this study was to evaluate confidence in phosphosite 
localization. Under the conditions examined, phosphosite localization was optimal when 
utilizing HCD OT and MASCOT/ptmRS searching. Of the 5733 phosphosites identified, 76% 
(4337) were confidently site localized under these conditions (Table 4.4, Figure 4.5, Figures 
S4, S5, S6). For the same dataset, 4808 phosphosites were defined using Andromeda/PTM-
score, of which 50% failed to meet the 1% FLR cut-off for confident site localization using 
the previously defined PTM-score of 0.994. Although the proportion of confidently site 
localized phosphopeptides is optimal overall with the EThcD regimes (both OT and IT), as 
was observed with the phosphopeptide library dataset, the numbers of phosphosites was 
compromised compared with either the equivalent HCD method, or the neutral-loss driven 
strategies. Even considering that the site localization scores applied to the EThcD OT data 
was slightly more conservative (equating to 0.7% FLR, rather than 1% FLR), the distribution 
of phosphosite localization scores demonstrates that total numbers of phosphosites is still 
significantly lower with this MS2 method, irrespective of search engine (Fig. S4). Not 
surprisingly, site localization confidence generally decreased as the number of 
phosphorylation sites per peptide increased, irrespective of the search algorithm employed 
(Figures S5, S6). The exception was EThcD OT: ~76% of phosphosites were confidently 
localized with PTM-score independent of the number of phosphate groups; doubly 
phosphorylated peptides yielded a higher number of confidently localized phosphosites on 
average (93%) with ptmRS site than singly (86%) or triply (83%) phosphorylated peptides.  
The performance of Andromeda/PTM-score was uniformly weaker across all datasets 
compared with MASCOT/ptmRS. The exception was the EThcD IT data for singly 
phosphorylated peptides, where the percentage of confidently localized sites was more 
comparable for the two search algorithms (78% for Andromeda/PTM-score, 83% for 
MASCOT/ptmRS). 
 
Although the trend in confident phosphosite identification is similar to that observed for 
the phosphopeptide library, the proportion of incorrect or ambiguous assignments is much 
higher in the lysate-derived peptides, possibly due the greater diversity of peptide size, and 
the true/false nature of the manner that the phosphopeptide library was used to define 
correct/incorrect site localization. In contrast, Andromeda/PTM-score performed much 
better than MASCOT/ptmRS with EThcD IT (but not EThcD OT) data, identifying 12.5% more 
phosphopeptides, and ~7% more phosphosites with confidence (Table 4.4, Figure 4.5).  
 
Chapter 4 
116 
 
For both the HCD OT and HCD IT regimes where nl EThcD IT is triggered, the percentage of 
confidently assigned phosphosites increases with Andromeda/PTM-score compared to HCD 
alone, particularly for HCD IT. This reflects the high performance of Andromeda/PTM-score 
with EThcD IT data. However, the total numbers of phosphosites identified with HCD IT are 
much lower when neutral loss EThcD is triggered due to the increased time required for 
ETD. Interestingly, although 42% of HCD IT spectra contained precursor neutral loss product 
ions (either 98 or 80 amu, at ≥10% base peak signal), a significant number of these were 
not within the top 10 ions that triggered EThcD, and only 16% of HCD IT spectra 
precipitated the acquisition of EThcD.   
 
The high proportion of confidently localized phosphosites with EThcD IT (76% and 83% from 
Andromeda/PTM-score and MASCOT/ptmRS respectively), combined with the fact that the 
two data analysis platforms yielded a high proportion of algorithm unique identifications 
(Figure 4.6) suggests that this mixed mode fragmentation regime would likely benefit from 
data interrogation using multiple informatics pipelines: 31% of Andromeda/PTM-score 
identifications were unique, while 23% were unique to MASCOT/ptmRS. Perhaps not 
unexpectedly, the utility of EThcD OT for high-throughput phosphosite identification was 
severely compromised due to the additional time required for both ETD and OT-based 
product ion analysis, resulting in much slower overall acquisition speeds for this high 
resolution mixed mode fragmentation method.  Consequently, there was a ~40-50% 
decrease in the numbers of confidently localized phosphosites using EThcD OT compared to 
HCD OT.  
 
The difference in site localization confidence for HCD IT versus HCD OT data for the two 
algorithms becomes much more apparent for the complex cell lysate derived 
phosphopeptide sample compared to the synthetic phosphopeptide library, with site 
localization confidence decreasing from 76% to 60% for MASCOT/ptmRS and 50% to 37% 
for Andromeda/PTM-score (Figure 4.5B, D), again emphasizing the benefits of high 
resolution MS2 over the reduction in duty cycle afforded by analysis in the ion trap.  
 
Evaluation of the distribution of site localization scores for all phosphopeptides facilitates a 
better understanding of how the two site localization algorithms handle the different 
fragmentation modes for this complex phosphopeptide sample (Figure S4). Scoring of 
EThcD IT data, particularly with ptmRS, yields a much shallower distribution of scores than 
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those for HCD IT. Consequently, large changes in score result in relatively small changes in 
the number of confidently localized phosphosites. The distribution of scores for HCD OT 
data is notably distinct between the two algorithms. The elevated mass accuracy of the 
orbitrap allows ptmRS to maximize its ability to pinpoint the correct site of modification, 
with ~4000 phosphosites having a ptmRS score of 100. In contrast, PTM-score consistently 
scores low resolution ion trap data higher, where the increased ion current and enhanced 
duty cycle likely yields benefits that are not compensated by the inability of this scoring 
system to handle high resolution data. 
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Figure 4.6. Overlap of phosphopeptide identification between search engines.  Venn diagrams showing the number and overlap of phosphopeptides identified with either 
Andromeda/PTM-score (blue, left) or MASCOT/ptmRS (red, right) for each of the six MS acquisition methods applied to TiO2-enriched U2OS cell lysate. 
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 Confident phosphosite localization is dependent on the number of 
potential sites of phosphorylation 
 
To avoid potential confusion when examining the effect of multiple potential sites of 
phosphorylation (Ser, Thr or Tyr) within a single peptide on site localization confidence, 
singly phosphorylated peptides only were considered for investigation (Figure 4.7; Figures 
S7, S8). Unsurprisingly, as the number of Ser/Thr/Tyr residues increases, i.e. the number of 
potential sites of modification increases, the numbers of confidently site localized 
phosphopeptides decreases with both ptmRS and PTM-score. For HCD OT generated 
tandem mass spectra, this decrease in confident phosphosite localization is much more 
apparent with PTM-score than with ptmRS. For those phosphopeptides containing two 
Ser/Thr/Tyr residues, the phosphosite is confidently localized in 92% of cases using ptmRS, 
while only 72% are correctly localized with PTM-score. This decreases to 39% for PTM-score 
when a peptide contains four Ser/Thr/Tyr residues, but only 73% for the same cohort when 
searched using ptmRS. The trend is consistent for HCD OT incorporating neutral loss 
triggered EThcD, with 80% of the peptides containing 4 Ser/Thr/Tyr residues from the 
ptmRS search having confident site localization, but only 49% being confidently localized by 
PTM-score (Figure 4.7; Figures S7, S8). For both scoring algorithms, the numbers of 
confidently assigned sites with HCD OT nl EThcD IT was intermediary between the numbers 
observed with either HCD OT and EThcD IT, showing potential benefit of the dual 
fragmentation approach when considering peptides with multiple possible sites of 
phosphorylation.  Under all tandem MS conditions examined, MASCOT/ptmRS performed 
as well as, or better than Andromeda/PTM-score for confident site localization, irrespective 
of the number putative sites of phosphorylation (Figure 4.7, Figures S7, S8). 
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Figure 4.7. Number of confidently localized phosphosites as a function of the number of common putative phosphorylatable residues.  Percent correctly site localized 
phosphopeptides (FLR ≤1%, green) or site ambiguous phosphopeptides (FLR >1%, white) is presented as a function of the number of Ser (S), Thr (T) or Tyr (residues) within 
the peptide. Data generated by either HCD OT (left), EThcD IT (middle) or HCD nl EThcD OT (right) was search with either (A) Andromeda/PTM-score or (B) MASCOT/ptmRS 
as previously described.  Percentage is indicated for each condition; the number of unique phosphosites is in parentheses. Data for all six MS acquisition methods is 
presented in Figures S7 and S8. 
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 Effect of charge state on phosphosite assignment 
 
It is known that the efficiency of ETD is dependent on charge density and is thus optimal for 
tryptic peptides in which the charge state is 3 (Good et al., 2007). Given that EThcD is a 
dual fragmentation mechanism, generating both b/y (HCD) and c/z ions (ETD), the total 
number of ions generated using this fragmentation regime will thus be dependent on 
charge state, impacting the number of site-determining product ions. The effect of charge 
state on phosphosite localization confidence was therefore evaluated (Figure 4.8, Figures 
S9, S10). Unsurprisingly, the ability to pinpoint the site of modification was notably 
improved with EThcD IT compared with HCD IT alone for precursor ions where z=3, with 
either 84% (MASCOT/ptmRS) or 75% (Andromeda/PTM-score) of phosphosites being 
defined by EThcD, compared with 53% or 29% respectively for HCD IT. The same is true for 
EThcD OT compared with HCD OT, with 77% or 42% respectively of 3+ peptide ions being 
correctly site localized with PTM-score, c.f. 87% (EThcD OT) and 66% (HCD OT) with ptmRS 
(Figs. S9, S10). EThcD IT also outperformed both HCD OT and HCD IT for confident site 
localization for ions of charge states 2+ and 4+, albeit with significantly fewer phosphosites 
being identified in total with EThCD IT than with either HCD method for 2+ ions (Figure 4.7, 
Figs. S9, S10). 
 
Both of the MS acquisition strategies invoking EThcD as a consequence of precursor neutral 
loss (HCD IT nl EThcD; HCT OT nl EThcD) were compromised in terms of the efficiency and 
total number of phosphosites identified for 3+ and 4+ ions, with no apparent benefit. 
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Figure 4. 8. Phosphosite localization as a function of peptide ion charge state.  Confidently localized phosphorylation sites (FLR ≤1%, green) or 
ambiguous phosphosite assignments (FLR >1%, white) presented as a function of precursor ion charge state for data searched with 
Andromeda/PTM-score (A, B) or MASCOT/ptmRS (C, D). Number (A, C) or percentage (B, D) of phosphosites identified is indicated for each 
condition. Data for all six MS acquisition methods is presented in Figures S9 and S10. 
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 Assessment of a charge-dependent HCD/EThcD method 
 
Following the publication of the 8 acquisition methods and showing the limited benefit of a 
neutral loss triggered EThcD method for phosphoproteomics studies due to the relatively 
small number of ions triggered for ETD fragmentation, an additional method was 
considered with the aim of combining the benefits of both HCD and EThcD. In this charge 
dependent method, ions with a charge (z= 2+) were fragmented with HCD whereas ions 
with a charge (z= 3+ to 5+) were fragmented with EThcD.  ETD of 2+ peptide ions is 
inefficient due to electron transfer being less exothermic for 2+ peptides than 3+ or 4+ ions, 
and that the singly charged cation formed from a 2+ ion following electron transfer has 
greater kinetic stability than the doubly/triply charged cation formed from 3+ and 4+ 
peptide ions. The Coloumb repulsion is therefore absent in the singly charged cation 
following electron transfer and so non-dissociative electron capture occurs leading to highly 
inefficient fragmentation (Pitteri et al., 2005; Swaney et al., 2007).  However, as the 
majority of peptides produced by trypsin digestion are doubly charged following 
electrospray ionization, it is crucial to obtain high quality data for these peptides and so a 
charge-dependent HCD/EThcD method represents an ideal approach for obtaining high 
numbers of identifications and maximising confident phosphosite localisation.  Similar to 
the methods described in section 4.3, the HCD fragment ions were detected in the orbitrap 
and EThcD fragment ions detected in the ion trap. The method was compared against the 
HCD OT NL EThcD IT method to evaluate the possible benefits of this approach.  
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 Assessment of phosphopeptide identification & phosphosite confidence  
 
A phosphopeptide enriched U2OS lysate was analysed in duplicate and revealed 15 % fewer 
unique phosphopeptides identifications with the charge dependent method compared with 
the neutral loss triggered method and this is likely due to a higher number of ETD events 
resulting in a longer reaction times and fewer spectra acquired (Table 4.5).  
 
Table 4. 5. MS acquisition methods evaluated using phosphopeptide enriched human cell lysate.  
For both methods, the number of peptide spectrum matches (PSMs) at 1% FDR are presented 
together with the total number of unique phosphopeptides and phosphosites identified using 
MASCOT with ptmRS. The number of phosphosites with an FLR ≤ 1% is also presented.  
 
 
When considering phosphosite localisation, 82 % of phosphosites were confidently 
localised (≤ 1% FLR) with the charge state-dependent regime compared with 75 % for the 
NL triggered method. This is comparable to the EThcD OT & IT methods described in section 
4.3. However, when considering the total number of high confidence phosphosites 
identified, fewer sites were identified using the charge state-dependent method (2116 vs 
2279) suggesting additional optimization (e.g. ETD reaction times) to increase spectral 
acquisition would be required to maximize the benefits of this method (Table 4.5; Figure 
4.9). With further development, this method could be usefully implemented in 
phosphopeptide studies requiring EThcD spectra where it is most beneficial (z = 3+) whilst 
obtaining high quality HCD spectra for 2+ ions.  
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Figure 4.9. Comparison of method-dependent phosphorylation site localization.  Confidently localized phosphorylation sites (FLR ≤1%, green) or ambiguous phosphosite 
assignments (white, grey) from a TiO2-enriched U2OS cell lysate, using Mascot with ptmRS to process data from both HCD OT nl EThcD IT (A) and HCD OT (2+) EThcD IT (3+ 
to 5+) acquisition methods. Phosphosites assigned by EThcD are also presented (light green). The number (A) and percentage (B) of phosphosites identified is indicated for 
both methods tested 
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 Effect of number of phosphorylatable residues (S/T/Y) on phosphosite 
assignment 
 
Next, the ability to localize phosphosites as the number of possible phosphorylatable sites 
(Ser/Thr/Tyr) increased was assessed. Compared with the NL triggered method, the charge-
dependent method identified more sites with high confidence. With 5 possible sites of 
phosphorylation, the charge-dependent method confidently localized 81 % of 
phosphosites, compared with 69 % for the NL triggered method and for peptides containing 
9 possible phosphosites, the charge dependent method confidently localized 58 %, 
compared with 40 % for the NL triggered method (Figure 4.10). This is most likely due to 
the method utilizing HCD and EThcD fragmentation where each is most beneficial (for 2+ 
ions and >3+ respectively) which increases the quality of the resulting MS2 spectra, 
allowing for greater confidence in the site of modification. This further highlights the 
potential benefits of this method for phosphoproteomics studies.  
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Figure 4.10. Number of confidently localized phosphosites as a function of the number of common putative phosphorylatable residues.  Percent correctly site localized 
phosphopeptides (FLR ≤1%, green) or site ambiguous phosphopeptides (FLR >1%, white) is presented as a function of the number of Ser (S), Thr (T) or Tyr (residues) within 
the peptide. Data generated by either HCD OT (2+) EThcD IT (3+ to 5+) (A) or HCD OT nl EThcD IT (B) was searched using Mascot with ptmRS and the percentage is indicated 
for each condition; the number of unique phosphosites is in parentheses. 
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 Effect of charge state on phosphosite assignment 
 
Similarly, the charge-dependent method also outperformed the NL triggered method when 
considering phosphosite localization of peptides as a function of charge state. There was 
little difference between the percentage of confidently assigned phosphosites for 2+ ions 
(87% for the charge dependent method vs 85 % for the NL triggered method) which is 
expected, as the majority of 2+ ions in the NL method, and all in the charge dependent 
method were identified with HCD, rather than EThcD (Figure 4.11).  
 
For 3+ peptide ions, the charge dependent method outperformed NL triggered method, 
with 84 % confidently localized compared with 73 % (Figure 4.11). This is due to all 3+ 
peptides being fragmented with EThcD using this method, allowing for high quality MS2 
spectra to be acquired. However, higher total numbers of phosphosites for >3+ peptide 
ions were identified with the NL method and this again highlights the requirement of 
further development of the charge dependent method to utilize cycle time most efficiently 
to acquire higher numbers of high quality MS2 spectra.  
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Figure 4.11. Phosphosite localization as a function of peptide ion charge state.   Confidently localized phosphorylation sites (FLR ≤1%, green) or ambiguous phosphosite 
assignments (FLR >1%, white/grey) presented as a function of precursor ion charge state for data searched MASCOT with ptmRS. The number (A) and percentage (B) of 
phosphosites identified is indicated for both methods tested. 
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Taken together, the charge dependent method for phosphoproteomics studies represents 
an ideal method for confidently identifying sites of phosphorylation with EThcD 
fragmentation where most beneficial (z= 3+ to 5), and HCD for 2+ ions, to obtain a balance 
between number of identifications and confident phosphosite localisation. Similar to the 
methods described in section 4.3, the total numbers of identifications decrease due to a 
greater number of ETD events compared with the NL triggered methods and therefore, this 
method is likely to be most beneficial for studies requiring ETD fragmentation whilst aiming 
to increase identifications with HCD fragmentation for 2+ peptide ions.  
 
 Conclusions 
 
The work described in this chapter aimed to develop and optimize MS acquisition methods 
for large-scale phosphoproteomics studies and assess downstream processing tools to 
maximize phosphopeptide identifications with confident phosphosite localization.  
 
An assessment of both collision energy and ion injection time for MS2 led to the 
optimization of these parameters for the analysis of phosphopeptides. Eight MS acquisition 
strategies on the Orbitrap Fusion mass spectrometer were subsequently tested, for their 
ability to confidently identify and, crucially, to pinpoint sites of modification on 
phosphopeptides. In addition, the relative efficiency of two of the most widely used 
phosphoproteomics data analysis platforms for optimal phosphosite identification: 
MASCOT integrated into Proteome Discover using ptmRS, and Andromeda with PTM-score 
was examined.   
 
Using a synthetic phosphopeptide library, MS method-specific scores for Andromeda/PTM-
score and MASCOT/ptmRS that yielded a 1% FLR were defined. When applied to a complex 
biologically-derived phosphopeptide mixture, even small changes in the applied scores may 
yield significant changes in the numbers of phosphosites identified for HCD-mediated 
fragmentation, and the marked difference in site confidence for the different MS methods 
at any given value cannot be ignored. 
 
The findings are largely in agreement with previous observations made using other 
orbitrap-based MS platforms, which demonstrate that phosphosite localization confidence 
is optimal with EThCD where a dual ion series is generated (Frese et al., 2013). However, 
the total number of unique phosphopeptides identified, as well as the number of 
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confidently localized phosphosites, is optimal when high resolution analysis of HCD 
fragment ions for MS2 is employed. MS acquisition strategies invoking neutral loss-
mediated ETD-based fragmentation is hampered by both the additional time taken to 
perform this type of fragmentation in a second round of MS2, as well as the surprisingly 
few phosphopeptide ions that generate neutral loss product ions and thereby invoke this 
second round of MS2 analysis.  
 
Differences in the ways that the two bioinformatics platforms handle distinct types of 
tandem MS data and the number of unique phosphopeptides identified, means that there 
is likely to be benefit in searching data acquired using a single acquisition strategy using 
both data analysis pipelines. This is particularly apparent with EThcD, where 31% and 23% 
of phosphopeptides respectively are unique to either Andromeda/PTM-score or 
MASCOT/ptmRS. The relatively few unique phosphopeptide identifications with 
Andromeda for HCD OT data, and the overall reduction in confident site localization using 
Andromeda/PTM-score for regimes exploiting fragmentation strategies other than EThcD, 
means that multi-algorithm searching may not be of significant benefit with other types of 
data.  
 
Whilst EThcD methods provides the highest confidence in sites of phosphorylation, the 
total numbers of identifications were much lower due to the long reaction times required 
for efficient fragmentation and therefore, it was concluded that EThcD methods were 
unsuitable for a large-scale phosphoproteomics study where high number of identifications 
are required to gain a global assessment of the phosphoproteome under study. However, 
future advances in MS platforms and ETD fragmentation will undoubtedly permit the use of 
ETD for large-scale phosphoproteomics studies. (Riley et al., 2015).  
 
The data also highlights that there are likely to be additional benefits in terms of increased 
numbers of confidently localized phosphosites, by implementing EThcD for ions with charge 
state of 3+ and the employment of a multiple algorithm search strategy. Moreover, the 
‘high-definition ETD’ (ETD HD) permissible with the Orbitrap Fusion Lumos, which is 
reported to facilitate ETD on larger precursor ion populations, will likely result in even 
greater benefits when applied to such a charge-state mediated data acquisition strategy for 
phosphoproteomics.  
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Currently, HCD OT methods on the Orbitrap Fusion represent the best approach for large-
scale phosphoproteomic studies, with high numbers of phosphopeptides identified with 
high confidence in the site of phosphorylation. This method will therefore be used for the 
large-scale phosphoproteomics analysis of the PLK4 regulated phosphoproteome. In 
addition to this analysis, the unenriched peptides will also be analysed to study protein 
level changes upon PLK4 inhibition with centrinone. Although the HCD IT method produced 
the lowest phosphosite confidence, the ability to parallelize MS1 in the orbitrap and, thus, 
obtaining high resolution data required for quantification with MS2 scans in the ion trap, 
does, however, provide a method capable of generating high numbers of peptides and this 
method will therefore be used to study the unenriched proteome. This analysis will be the 
focus of the next chapter.  
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 Investigating Polo-like kinase 4-regulated signalling by 
SILAC-based quantitative phosphoproteomics 
 
5.1. Introduction 
 
Following the development of new tools for the functional analysis of PLK4 in human cells 
(described in Chapter 3), and the optimisation of mass spectrometry acquisition methods 
for phosphopeptide analysis, a large scale (phospho)proteomics study was undertaken to 
identify PLK4 substrates and PLK4-regulated signalling pathways.  Whilst a greater 
understanding of the function of PLK4 during centriole biogenesis has been achieved in 
recent years, no global assessment of the roles of PLK4 in the cell, including its full 
substrate repertoire, has been undertaken thus far.  
 
As discussed in Chapter 1, PLK4 is the master regulator of centriole biogenesis, with the 
activities of PLK4, STIL & SAS6 being carefully co-ordinated to ensure that each centrosome 
is duplicated once per cell cycle (Dzhindzhev et al., 2014; Kratz et al., 2015; Moyer et al., 
2015). Dysregulation of PLK4 leading to overexpression results in supernumerary 
centrosomes and mis-segregation of chromosomes, which is a hallmark of many cancers. 
PLK4 has therefore been identified as a viable target for the development of 
chemotherapeutics to inhibit protein activity and has led to one compound, CFI-400945, 
reaching phase I clinical trials (Mason et al., 2014). Therefore a comprehensive insight in to 
the activities of PLK4 is crucial, to help understand its multiple roles at the centrosome and 
perhaps wider roles in the cell cycle, so that the potentially complex effects of PLK4 
inhibition by compounds such as centrinone can be understood (Wong et al., 2015). A 
large-scale analysis of the PLK4 regulated (phospho)proteome was therefore deemed a 
suitable approach  to globally assess cellular PLK4 activity. 
 
Global (phospho)proteomics analysis has previously been performed to study the activities 
of another polo-like kinase family member, PLK1, and revealed regulated phosphosites 
linked to PLK1 activity via their roles in mitotic progression. In addition, novel substrates 
were identified, which implicated PLK1 in the DNA damage response and cohesin release 
from chromosomes (Grosstessner-Hain et al., 2011). Similarly, a global assessment of the 
Aurora A regulated (phospho)proteome revealed roles in RNA processing, splicing and DNA 
damage repair in addition to identifying known substrates implicated in mitosis 
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(Kettenbach et al., 2011b). This further highlights the benefits of a discovery MS approach 
to study global phosphorylation events, as this is the only method capable of analysing the 
full range of activities of a particular protein kinase in an untargeted manner.  
 
The results presented in this chapter represent the first global assessment of PLK4 
signalling in human cells, with the identification of a number of PLK4-regulated proteins 
and phosphosites. The regulated sites were mapped on to known pathways, implicating 
PLK4 in activities beyond that of centriole biogenesis.   
 
 Aims 
 
The aims of the work in this chapter were to perform a high-throughput SILAC-based 
quantitative phosphoproteomics investigation to uncover PLK4 regulated signalling 
pathways. This involved the analysis of both the total proteome and enriched 
phosphopeptides to assess changes in protein expression and phosphorylation state in 
response to PLK4 inhibition with centrinone. This work also attempted to validate potential 
PLK4 substrates through the parallel analysis of a ‘drug-resistant’ G95R PLK4 allele, which 
could be inducibly expressed in stable cells treated with and without centrinone. Finally, 
this work aimed to validate possible PLK4 substrates by western blotting, and generate new 
information relevant to cellular PLK4 substrate specificity, which has only previously been 
analysed in vitro relative to the PLK1-3 consensus motif (Johnson et al., 2007; Leung et al., 
2007). 
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5.2. Results & Discussion 
 
 Strategy for the phosphoproteomics analysis of PLK4 signalling   
 
U2OS cells stably transfected with either FLAG-WT or G95R PLK4 (developed in Chapter 3) 
were used for the work described in this chapter. Cells grown in light (Arg0 Lys0) or heavy 
(Arg10 Lys8) media were treated with DMSO and centrinone respectively (Figure 5.1). Four 
bioreplicates were prepared (following separate cell expansions from the same aliquot of 
cells) and analysed by western blotting, which confirmed the successful overexpression of 
WT and G95R PLK4 in all four bioreplicates. An accumulation of WT PLK4 is observed 
following treatment with centrinone, reflecting the inhibition of PLK4 activity, preventing 
trans-autophosphorylation within the degradation motif to signal for proteasomal 
degradation. No accumulation of G95R PLK4 was observed, confirming the drug-resistant 
phenotype (Figure 5.2).   
 
The cell lysates were mixed 1:1, digested with trypsin and fractionated by high pH reversed 
phase chromatography. Fractions were concatenated in to 12 pools and an aliquot of each 
(5 μg) was removed for total proteomics analysis using the HCD IT acquisition method on 
the Orbitrap Fusion described in Chapter 4. The remaining samples were phosphopeptide 
enriched and analysed using the HCD OT method. Following MS acquisition, the data were 
processed in MaxQuant. The full workflow is shown in Figure 5.1. 
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Figure 5.1. Workflow for SILAC-based quantitative (phospho)proteomics.  FLAG-WT and G95R PLK4 
cells were grown in light (R0K0) and heavy (R10K8) media. Light cells were treated with DMSO and 
heavy cells were treated with 300 nM centrinone for four hours. Cells were lysed and heavy and 
light samples were mixed 1:1. Lysates were digested with trypsin and fractionated by high pH 
reversed phase chromatography. The 60 fractions collected were concatenated to generate 12 
pools. Aliquots were removed for analysis of the total proteome by LC-MS/MS and the remaining 
sample was phosphopeptide enriched. Data were processed in MaxQuant.  
 
 
Chapter 5 
137 
 
 
 
Figure 5.2. Analysis of overexpressed and centrinone-treated FLAG-WT & G95R U2OS cells.  
Expression of PLK4 was induced upon incubation with 1 μg/mL tetracycline for 18 hours. Cells were 
treated with 300 nM centrinone or 0.1 % (v/v) DMSO control for 4 hours. Total lysates were 
analysed by western blot using the indicated antibodies.  
 
Whilst SILAC is a robust method for quantification, labelling efficiency can be reduced by 
the metabolic conversion of arginine to proline during cell culture. This conversion greatly 
affects the accuracy of quantification, as it lowers the intensity of the heavy labelled peak 
and introduces additional satellite peaks containing heavy proline that will not be 
considered for quantification (Ong et al., 2003; Blagoev & Mann, 2006). It is therefore 
important to assess arginine to proline conversion before proceeding with statistical 
analysis of the acquired data. Figure 5.3 confirms that no arginine to proline conversion 
occurred during metabolic labelling of cells as the density remains centred on the Log2 H/L 
ratio of 0, and no drift toward the light peptide is observed as the number of proline 
residues increases. This provided confidence that H/L ratios had been accurately quantified 
and could therefore be used to determine significantly changing proteins and 
phosphosites. 
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Figure 5.3. Assessment of Arg to Pro conversion.  Density plots were generated to assess the 
metabolic conversion of Arg to Pro in WT PLK4 (A) and G95R PLK4 (B) expressing cells. Non-
normalised H/L ratios were plotted against the total proline count from the identified peptides. The 
data points are colour coded based on density. No global drift toward the light peptide was 
observed in either cell line, confirming that metabolic conversion had not occurred.  
 
An initial assessment of the overlap between the four bioreplicates was performed to 
check reproducibility. A high degree of overlap was obtained for protein identifications, 
with 96 % of proteins identified in ≥3 WT bioreplicates and 94 % of proteins identified in ≥3 
G95R bioreplicates. Much greater variability was observed for the phosphopeptide data, 
which is expected due to the stochastic nature of peptide identifications when data is 
acquired using a DDA approach. A total of 13,816 phosphopeptides were identified in the 
WT dataset, with 54 % identified in ≥3 bioreplicates. In the G95R dataset, a total of 13,060 
phosphopeptides were identified, with 48 % identified in ≥3 bioreplicates (Figure 5.4).   
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Figure 5.4. Overlap between biological replicates.  The overlap between proteins (A, C) and 
phosphopeptides (B, D) identified between the four bioreplicates for both WT and G95R PLK4 
overexpressing U2OS cells. 
 
 Assessment of protein expression 
 
Statistical analysis of the H/L ratios of proteins quantified in ≥3 bioreplicates was 
performed using an empirical Bayesian approach; with the Benjamini-Hochberg procedure 
used for multiple comparisons correction to generate FDR adjusted p values (Kammers et 
al., 2015). Figure 5.5 A & B show the Log2 fold changes of proteins quantified in WT and 
G95R PLK4 cell lines plotted against adj. p value. Proteins with adj. p value ≤0.05 are 
labelled and highlighted in red. In the WT PLK4 dataset, 87 proteins were identified as 
significantly changing, with 67 downregulated upon centrinone treatment, and 20 
upregulated. WT PLK4 was identified with a H/L ratio of 1.8 and an adj. p value of 0.052. 
The H/L ratio reflects the accumulation of PLK4 in the cell upon inhibition with centrinone 
and corroborates the data in Figure 5.2. In the G95R dataset, only one PLK4 peptide was 
identified, in one bioreplicate and therefore the protein was not quantified. This could be 
due to the lower expression of G95R PLK4 compared to WT, as shown by western blot 
analysis in Figure 5.2.  Compared with the WT dataset, a much greater number of proteins 
were identified as significantly regulated in the G95R PLK4 expressing cells. In total, of the 
7492 proteins identified in this dataset, 5949 were quantified, and 1791 proteins were 
identified as significantly changing, with 1240 downregulated and 551 upregulated 
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following treatment of the cells with centrinone (adj. p value ≤0.05) (Figure 5.5 B; Figure 
5.6 B).  
 
 
 
Figure 5.5. Proteomics analysis of centrinone treated WT- and G95R PLK4 expressing cells.  H/L 
ratios were tested for significance using a Bayesian statistical approach. Log2 fold change of 
identified proteins was plotted against –Log2 Benjamini-Hochberg FDR adj. p values for both the WT 
(A) and G95R (B) PLK4 datasets. Proteins with an adj. p value ≤0.05 are highlighted in red.  
 
Functional annotation and enrichment analysis of the significantly regulated proteins in the 
G95R PLK4 dataset was performed using DAVID. Figure 5.6 A shows an enrichment of 
dysregulated proteins localised at mitochondrion, focal adhesions and within the cell-cell 
adherens junctions. In addition, an enrichment of proteins involved in the regulation of 
metabolic pathways, amino acid biosynthesis and ribosome biogenesis was observed, 
which would suggest a cellular response to stress upon inhibition with centrinone (Tennant 
et al., 2010; Cairns et al., 2011; Poliakova et al., 2018). Dysregulated proteins were also 
implicated in activities at later stages of the cell cycle, such as cytokinesis and metaphase 
plate congression, whereby chromosomes are aligned at the metaphase plate. Mitotic 
proteins including Aurora A, TPX2, cyclin B1, and FOXM1 were all identified as significantly 
downregulated upon treatment with centrinone. Functional network analysis using STRING 
revealed the connection between these downregulated G2/M phase proteins (Figure 5.6 
C), suggesting the possibility that centrinone treatment of this cell line resulted in G2/M 
phase arrest.   
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Figure 5.6. Enrichment and network analysis of significantly regulated proteins in the G95R PLK4 
dataset.  A) GO term enrichment analysis of significantly regulated proteins. Proteins enriched with 
an FDR adj. p value ≤0.05 (using the Benjamini-Hochberg procedure) are shown above the dotted 
line and labelled. BP= biological processes; CC = cellular compartment; MF= molecular function. B) 
The total number of proteins identified in the G95R PLK4 dataset is shown, along with the total 
number quantified and proteins identified as significantly regulated (p ≤ 0.05). C) STRING interaction 
analysis revealed a network of mitotic proteins identified as downregulated.  
 
 Cell cycle analysis 
 
To test whether centrinone had led to mitotic arrest in the G95R PLK4 cells, U2OS cells 
were incubated +/- tetracycline to induce WT or G95R PLK4 expression. The cells were then 
incubated +/- centrinone for four hours, to match the conditions used for the 
phosphoproteomics study and the cell cycle distribution for each condition was assessed by 
flow cytometry. Figure 5.7 shows the percentage of cells in G0/G1, S, or G2/M. The overall 
cell cycle profile for both WT and G95R cells is consistent with the reported profile for 
asynchronous U2OS cells (Di et al., 2014). The observed shift in profile between WT and 
G95R cells may be due to the differential effect on growth rates arising from expression of 
exogenous proteins in this U2OS cell system.  
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Figure 5.7. Cell cycle analysis by flow cytometry.  Expression of PLK4 was induced upon incubation 
with 1 μg/mL tetracycline for 18 hours. Cells were treated with 300 nM centrinone or 0.1 % DMSO 
for 4 hours cell cycle distribution was analysed by FACs. The bar chart reflects the percentage of cells 
in each cell cycle phase for WT (A) and G95R (B). The data is plotted as the mean ±SD for three 
biological replicates. ANOVA generated p values are shown above each phase and the * indicated on 
the chart represents significant differences between individual samples determined using Tukey 
post-hoc testing (adj. p value ≤0.05).  
 
Statistical analysis using ANOVA revealed no statistically significant differences between 
cell cycle phases at G1 or G2. However, a significant difference was observed in S phase for 
both WT and G95R cells. In the WT cells, the induction of PLK4 and the presence of 
centrinone revealed a statistically significant increase of cells in S phase, compared with all 
other conditions (Figure 5.7 A). Similarly, G95R PLK4 expressing cells incubated with 
centrinone revealed a significant increase in S phase compared with the negative control (-
Tet/+DMSO) (Figure 5.7 B). A significant increase in the percentage of cells in S phase 
should be accompanied by a statistically significant difference in the percentage of cells in 
G1 or G2 phase, however, this was not observed. It is possible that the small difference 
(~2.5 %) is split between G1 and G2, distributing the effect across both, resulting in neither 
being determined to be statistically significant. The numbers of cells in S phase also show 
less variance than the other two cell cycle phases between replicates, which allows smaller 
differences to be identified as significant. Overall, the results are inconclusive and the 
experiment would need to be repeated to confirm whether there is a true difference in cell 
cycle distribution between the different conditions for both cell lines.  
 
The typical cell doubling time of U2OS cells is ~29 hours (Musa, 2013), therefore, the four 
hour incubation of cells with centrinone was unlikely to be sufficient to induce full mitotic 
arrest that is observable by cell cycle analysis. The reasonably small ~1.5 fold decrease in 
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mitotic proteins identified in the STRING network suggests that the centrinone treated 
G95R PLK4 expressing cells may be at the onset of mitotic arrest. However, cell cycle 
profiling following longer centrinone incubation times would be required to confirm this. 
 
 Assessment of WT PLK4 regulated proteins  
 
The comparatively fewer proteins exhibiting differential expression (1 % of total) in the WT 
dataset suggested that the inhibitor exhibited high specificity toward WT PLK4, with few 
off-target effects (as seen in the G95R dataset). As this was a discovery experiment aiming 
to identify novel PLK4 regulated proteins and phosphosites, where very few substrates are 
currently known, the decision was made to relax the adj. p value to ≤0.075.  
 
DAVID functional annotation analysis of the significantly regulated WT proteins (adj p value 
≤0.075) revealed an enrichment of proteins at a number of cellular compartments including 
exosomes, mitochondria and focal adehesions. In addition, dysregulated proteins were 
involved in biological processes including rRNA processing and negative regulation of 
apoptosis (Figure 5.8 A). It is likely that a four-hour incubation period is insufficient to allow 
for an accurate assessment of PLK4 regulation of protein expression due to the varied rates 
of protein turnover in the cell. However, a number of individual cell cycle-regulated 
proteins, including cyclin D2, p21 and CDK4 were identified as significantly regulated and 
are discussed in more detail in section 5.2.5. 
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Figure 5.8. Enrichment analysis of significantly regulated proteins in the WT PLK4 dataset.  A) GO 
term enrichment analysis of significantly regulated proteins. Proteins enriched with an FDR adj. p 
value ≤0.05 (using the Benjamini-Hochberg procedure) are shown above the dotted line and 
labelled. BP= biological processes; CC = cellular compartment; MF= molecular function. B) The total 
number of proteins identified in the WT PLK4 dataset is shown, along with the total number 
quantified and proteins identified as significantly regulated (p ≤ 0.075).   
 
 Assessment of phosphosite regulation 
 
The work in Chapter 4 described a false localisation rate cut-off to be employed for data 
sets acquired with various fragmentation modes to ensure high confidence in phosphosite 
localisation. For HCD OT methods, this cut off was set as 0.994 when phosphosites have 
been localised using PTM-score. However, as this was a discovery experiment, with the aim 
of exploring the PLK4-regulated phosphoproteome, a 0.994 cut-off was considered too 
stringent. Therefore, the widely used PTM-Score of ≥0.75, used to describe highly confident 
‘class I’ phosphosites was employed (Olsen et al., 2006). To exploit the greater capability of 
ptmRS to confidently localise phosphosites compared with PTM-score, ptmRS scores are 
also included for the regulated phosphosites discussed in this chapter. The phosphopeptide 
lists were expanded to assess quantification at the phosphosite level. This is important, as 
multiply phosphorylated peptides may be differentially regulated and two or more 
phosphosites within a single peptide may have distinct cellular functions (Lanucara et al., 
2016). 
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Bayesian statistical analysis revealed 140 phosphosites significantly changing with an 
adjusted p value ≤0.05 in the WT dataset (Figure 5.9 A). Similar to the proteomics data, a 
much greater number of significantly regulated phosphosites were identified in the G95R 
PLK4 dataset, with 1501 identified with an adj. p value ≤0.05 (Figure 5.9 B; Figure 5.10 B).  
 
 
 
Figure 5.9. Phosphosite analysis of centrinone treated WT- and G95R PLK4 expressing cells. H/L 
ratios were tested for significance using a Bayesian statistical approach. Log2 fold change of 
identified phosphosite was plotted against –Log2 Benjamini-Hochberg FDR adj. p values for both the 
WT (A) and G95R (B) PLK4 datasets. Proteins with an adj. p value ≤0.05 are highlighted in red. The 
horizontal grey lines represent adj. p values of ≤0.05 (top), ≤0.075 (middle), and ≤0.1 (bottom).  
 
The phosphosites that changed significantly upon centrinone treatment in the G95R PLK4 
expressing cells were found to be enriched in proteins localising to a diverse range of cell 
compartments, including focal adhesions, the cytoskeleton, kinetochores, nuclear envelope 
and the midbody of dividing cells. In addition, an enrichment of biological processes, 
including cytoskeletal organisation, sister chromatid cohesion, spindle organisation and 
nuclear envelope assembly was observed. This enrichment of late mitotic events 
corroborates the protein expression data, which revealed significantly regulated proteins 
with roles in the G2/M phase of the cell cycle (Figure 5.10 A; Figure 5.5 B). The distribution 
of Ser, Thr and Tyr downregulated phosphosites was compared against the global 
distribution of identified phosphosites (Figure 5.10 C). As expected, the majority of 
phosphosites observed were at Ser residues (92.6 %), followed by Thr (7.1 %), with very 
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few pTyr residues (0.3 %) (Olsen et al., 2006). The regulated phosphosites followed this 
same trend, with the majority being located on Ser residues (90.9 %).    
 
 
 
Figure 5.10. Enrichment analysis of significantly regulated phosphosites in the G95R PLK4 dataset.  
A) GO term enrichment analysis of significantly regulated phosphosites. Phosphoproteins enriched 
with an FDR adj. p value ≤0.05 (using the Benjamini-Hochberg procedure) are shown above the 
dotted line and labelled. BP= biological processes; CC = cellular compartment; MF= molecular 
function. B) The total number of phosphosites identified in the G95R PLK4 dataset is shown, along 
with the total number quantified and phosphosites identified as significantly regulated (p ≤ 0.075). 
C) Global distribution of Ser/Thr/Tyr residues and the distribution of significantly downregulated 
Ser/Thr/Tyr residues (inset).  
 
Taken together, the G95R PLK4 proteomics and phosphoproteomics datasets strongly 
suggest that in the presence of overexpressed drug-resistant PLK4, centrinone treatment 
results in a high concentration of unbound inhibitor, which acts off-target, causing 
widespread changes in the cell. An overlap between the regulated proteins and 
phosphosites may therefore be identified between the WT and G95R datasets but have 
occurred via different pathways, with redundancy in the proteins involved. Therefore, the 
G95R PLK4 dataset cannot be used to validate WT PLK4 substrates and regulated pathways.  
 
 Assessment of WT PLK4 regulated phosphoproteins  
 
As only ~1.8 % of phosphosites were significantly regulated in the WT dataset and this was 
a discovery experiment, the adj. p value was relaxed to ≤0.075, with the same justification 
as that used for the proteomics dataset.  The adj. p value for each phosphosite quantified is 
listed in Appendix 3 (Table 9.4, 9.5). The distribution of Ser, Thr and Tyr downregulated 
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phosphosites was compared against the global distribution of identified phosphosites 
(Figure 5.11 C). The regulated phosphosites followed this same trend as the global 
distribution, with the majority of regulated phosphosites being located on Ser residues 
(90.7 %). Functional annotation and enrichment analysis of the significantly regulated 
phosphoproteins in the WT PLK4 dataset was performed using DAVID. An overview of the 
enriched terms within the dataset is shown in Figure 5.11 A. Regulated phosphoproteins 
were identified as localising at the cytoskeleton, chromosomes, and the centrosome. An 
enrichment of biological processes including cell-cell adhesion, transcription, mRNA 
processing and regulation of the cell cycle was observed. 
 
 
 
 
Figure 5. 11. Enrichment analysis of significantly regulated phosphosites in the WT PLK4 dataset.  
A) GO term enrichment analysis of significantly regulated phosphosites. Phosphoproteins enriched 
with an FDR adj. p value ≤0.05 (using the Benjamini-Hochberg procedure) are shown above the 
dotted line and labelled. BP= biological processes; CC = cellular compartment; MF= molecular 
function. B) The total number of proteins identified in the WT PLK4 dataset is shown, along with the 
total number quantified and proteins identified as significantly regulated (p ≤ 0.075). C) Global 
distribution of Ser/Thr/Tyr residues and the distribution of significantly downregulated Ser/Thr/Tyr 
residues (inset). 
  
The MAPK signalling pathway was identified as misregulated with five members of the 
pathway identified (Figure 5.12 A, B). Total EGFR protein and pThr669 EGFR were identified 
as upregulated with centrinone treatment. EGFR Thr669 is located in the juxtamembrane 
domain and is a substrate of ERK. ERK is activated upon phosphorylation of Tyr204, located 
within its activation loop and this phosphorylation site was also identified as upregulated in 
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this study (Butch & Guan, 1996). ERK phosphorylation of pThr669 EGFR results in negative 
feedback control of EGFR tyrosine kinase activity, preventing autophosphorylation 
(Nishimura et al., 2009; Sato et al., 2013). An increase in active ERK, along with an increase 
in pThr669 EGFR suggests that centrinone treatment resulted in increased activity of ERK 
toward pThr669 EGFR leading to an inhibition of EGFR activity with downstream effects on 
the MAPK signalling pathway. SOS1 pSer1275 and MEK2 Ser23 also identified in the MAPK 
pathway have only been identified previously in high-throughput phosphoproteomics with 
their biological function not yet known. This work implicates PLK4 inhibition in regulation of 
the MAPK pathway, which is directly linked to regulation of the cell cycle (Wilkinson & 
Millar, 2000) 
 
Regulated phosphosites and proteins were manually mapped on to the cell cycle, which 
revealed proteins and phosphoproteins implicated in G1 and S phase (Figure 5.12 A, B). 
This included downregulated cyclin D2, CDK4, CDK6 and p21 proteins (adj. p value ≤0.075). 
The activity of cyclin D2- CDK4 complexes are suppressed by p21, which prevents 
phosphorylation of RB1 required for G1/S progression (Xiong et al., 1993). Paradoxically, 
p21 can also act as an adaptor of cyclin D-CDK4 complexes, assembling the active complex 
in the nucleus to promote cell proliferation (LaBaer et al., 1997). The lower expression of 
these proteins upon centrinone treatment is likely to exert an anti-proliferative effect on 
the cells, mediated by PLK4 inhibition.  
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Figure 5.12. Pathway analysis of significantly regulated phosphosites in the WT PLK4 dataset.  A) 
Bar chart representing significantly regulated (adj. p value ≤0.075) phosphoproteins implicated in 
MAPK and cell cycle pathways. Bar charts represent the mean Log2 fold change (H/L) for four 
bioreplicates ±SD. B) significantly regulated (adj. p value ≤0.075) proteins/phosphoproteins were 
identified as components of the MAPK signalling pathway. Additionally, significantly regulated 
proteins/phosphoproteins (adj. p value ≤0.075) were manually mapped on to the cell cycle and were 
implicated in G1/S phase. Green outline= phosphosite upregulated; red outline= phosphosite 
downregulated; block green= protein upregulated; block red= protein downregulated. 
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Interestingly, two RB1 phosphosites were identified as differentially regulated, with a 
decrease in pSer37 and increase in pThr821 observed. RB1 protein was identified with no 
significant change in expression and therefore, the two identified phosphosites reflect 
differential regulation of phosphorylation.  Whilst pSer37 has only been previously 
identified in high-throughput phosphoproteomics studies, pThr821 has established roles in 
RB1 activity. RB1 binds to proteins with a specific LxCxE motif to prevent cell growth and 
this binding is dependent on dephosphorylation of Thr821. Phosphorylation of Thr821 
inhibits RB1 binding to proteins and therefore, the increase in phosphorylation observed in 
this study suggests a positive effect on cell proliferation (Knudsen & Wang, 1997).  
 
Cdc6 Ser74 was significantly downregulated 1.3 fold with centrinone treatment. Cdc6 is a 
substrate of PLK4 and has a role in negatively regulating the PLK4-STIL-SAS6 complex 
required for centriole duplication. During G2 phase of the cell cycle, Cdc6 is recruited to the 
centrosomes and binds to SAS6, blocking its interaction with STIL and preventing 
centrosome overduplication. This interaction is disrupted in S phase by PLK4 
phosphorylation of Cdc6 at two sites, pSer30 in its N-terminal domain and pThr527 (not 
identified in this study). In this way, PLK4 and Cdc6 antagonistically control centrosome 
amplification to ensure the centrioles are duplicated once per cycle (Xu et al., 2017). The 
observation of downregulated pSer74 Cdc6 suggests that this could be a novel target of 
PLK4 within the N-terminal domain. 
 
 Identification of PLK4 phosphorylation sites 
 
Three PLK4 phosphosites, Ser421, Ser665 and Ser817 were identified as upregulated upon 
treatment with centrinone, with H/L ratios of 1.8, 2.3 and 3.9 respectively (Figure 5.13). For 
pSer421 and pSer665, the H/L ratios match the change observed in protein expression, 
suggesting that there was no stoichiometric increase in phosphorylation at these sites. A 
stoichiometric increase is observed for pSer817, suggesting that this phosphosite is 
targeted by an upstream protein kinase. The identified phosphosites are located in the C-
terminus, with Ser421 located in the PB1 domain and Ser665 located in PB3. Ser817 is 
located at the extreme C-terminus, outside of PB3. While all three sites have been 
previously observed in high-throughput proteomic studies, no functional role of 
phosphorylation at these sites is currently known.  
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Figure 5.13. Identification WT PLK4 phosphosites in vitro.  Three significantly upregulated (adj. p value ≤0.075) PLK4 phosphosites were identified. The peptide sequence 
and the identified phosphosite is detailed on each mass spectrum. A) Doubly charged ion at m/z 935.74, identifying pSer421. B) Doubly charged ion at m/z 647.65, 
identifying pSer665. C) Doubly charged ion at 845.89, identifying pSer817. D) PLK4 schematic highlighting the location of the identified phosphosites. 
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 Identification of previously described PLK4 substrates & interactors 
 
To date, only a limited number of PLK4 substrates have been identified. Protein substrates 
STIL and PCM1 were identified in the total protein dataset. However, neither were 
identified as significantly regulated following centrinone treatment of WT PLK4 expressing 
cells (Table 5.1). Cep192, a key PLK4 scaffold protein was identified as significantly 
downregulated, with an adj. p value of ≤0.072. Phosphorylated forms of CP110, PCM1, 
Cep152/Cep192 and FBXW5 were identified however, none of the identified phosphosites 
were significantly regulated and the phosphosites that were identified are not known to be 
phosphorylated by PLK4. 
 
Table 5.1. Identification of previously described PLK4 substrates.  Known PLK4 substrates are 
shown, that were identified at the protein or phosphosites level. Associated adj. p values and H/L 
ratios are listed. For phosphosites ID’s, PTM-score and ptmRS site localisation scores are also shown.   
 
 
In addition, the BioGRID database was searched for known PLK4 interactors and cross-
referenced against the list of significantly regulated proteins and phosphoproteins. A 
number of PLK4 interactors were identified as significantly changing, including BTRC, 
MAGED1, NEDD1 and phosphorylated MYCBP2 (Ser3467) (Table 5.2) (Firat-Karalar et al., 
2014).  
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Table 5.2. Identification of previously described PLK4 interactors.  Known PLK4 interactors in the 
BioGrid database are shown if they were identified as significantly regulated at the protein or 
phosphosites level (adj. p values ≤0.075). Adj. p values, H/L ratios and associated PTM-score and 
ptmRS site localisation scores are listed.   
 
 
NEDD1 is a component of the PCM and binds to CEP192. At the centrosome, NEDD1 
recruits -tubulin to nucleate the microtubules in interphase (Manning et al., 2010). It is 
therefore possible that PLK4 interacts with NEDD1 via their interaction with the Cep192 
scaffold. MYCBP2 is an atypical RING E3 ubiquitin ligase that adds ubiquitin groups to Thr 
rather than Lys residues (Pao et al., 2018) and has a role in cell growth via regulation of 
mTOR pathway through the ubiquitylation of target proteins (Han et al., 2012). MAGE 
proteins can assemble with RING ubiquitin ligases to regulate ligase activity and alter 
subcellular localisation (Lee & Potts, 2017). The identification of MYCBP1 and MAGE as 
significantly upregulated in this study suggests they are not direct PLK4 substrates but do 
have potential roles at the centrosome that may be regulated by PLK4 activity. 
 
BTRC (also known as β-TrCP), the substrate recognition component of the SCF E3 ubiquitin 
ligase complex required for PLK4 degradation was identified as significantly regulated at 
both the protein and phosphosite level (Guderian et al., 2010). Protein expression was 
downregulated upon centrinone treatment; with a 1.2 fold decrease observed. At the 
phosphosite level, pSer237 of β-TrCP was identified as a novel phosphosite, with a 4-fold 
increase upon centrinone treatment, reflecting a stoichiometric increase in 
phosphorylation (Table 5.2). Inhibition of PLK4 activity with centrinone prevents 
autophosphorylation within the degradation motif and protects the protein from β-TrCP 
mediated proteasomal degradation. Therefore, the reduced expression of β-TrCP 
expression when PLK4 activity is inhibited is expected. The identification of increasing 
levels of a novel phosphosite is unexpected and requires further investigation to elucidate 
its biological function.  
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 Enrichment of PLK4 regulated phosphoproteins at the centrosome 
 
As the major function of PLK4 is at the centrosome to co-ordinate centriole biogenesis, it 
was not surprising that centrosome localisation was revealed as an enriched term in Figure 
5.11 A. In total, 22 significantly regulated phosphoproteins were identified as enriched at 
the centrosome, with 14 downregulated and 8 upregulated (Figure 5.14 A). The full list of 
centrosomal regulated phosphoproteins and their associated adj. p value can be found in 
Appendix 2.  
 
 
 
 
Figure 5.14. Identification of centrosomal-associated phosphoproteins.  A) Analysis of significantly 
regulated (adj. p value ≤0.075) phosphosites in DAVID revealed an enrichment of phosphoproteins 
localised at the centrosome. Bar charts represent the mean Log2 fold change (H/L) for four 
bioreplicates ±SD. B) Schematic to highlight the roles of the identified phosphoproteins in 
centrosome biology. Red outline= downregulated with centrinone treatment; green outline= 
upregulated with centrinone treatment. 
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NCKAP5L (also known as Cep169) pSer567 was identified as significantly downregulated 
following treatment of the cells with centrinone (Figure 5.14 A, B). Cep169 binds to the 
microtubule plus-end tracking protein, CDK5RAP2, which is responsible for recruiting -
TuRC complexes to the centrosome to nucleate growing microtubules (Mori et al., 2015a). 
Phosphorylation at Ser567 has only been previously identified in high-throughput 
phosphoproteomics studies, although this work suggests that this is potentially regulated 
by PLK4. Adenomatous polyposis coli (APC), a tumour suppressor, which localizes to the 
centrosomes, was downregulated at Ser1436. APC functions at interphase centrosomes 
and interacts with -tubulin to stimulate growth of the nascent microtubules (Lui et al., 
2016). Whilst a functional understanding of the role Ser1436 has not yet been defined, 
downregulated APC phosphorylation at the centrosome suggests that this is also a possible 
substrate of PLK4. 
 
Phosphorylated CHD4 (pSer531), a component of the multiprotein nucleosome remodelling 
deacetylase (NuRD) complex, was also identified as downregulated (Figure 5.14 A, B). CHD4 
localises at centrosomes and has been shown to negatively regulate the centrosomal 
localisation of pericentrin, a key component of the PCM responsible for anchoring proteins, 
including γ-TuRC complexes to the centrosome (Doxsey et al., 1994) (Sillibourne et al., 
2007). Ser531 phosphorylation is frequently observed in high-throughput 
phosphoproteomics studies, although no functional analysis has been undertaken. 
Downregulated phosphorylation of Tyr239 in Rho guanine nucleotide exchange factor 
ARHGEF10 was also identified in this study. ARHGEF10 localises at the centrosome during 
G1/S and regulates RhoA signalling which is believed to have a role in centriole duplication 
(Aoki et al., 2009).  
 
Phosphorylated NPM1 (pSer10) was identified as significantly upregulated, although the 
protein level was also significantly upregulated, which suggests that there was no 
stoichiometric increase in the level of phosphorylation. NPM1 has established roles at the 
centrosome in negatively regulating centriole duplication (Okuda et al., 2000). NPM1 is a 
substrate of the Ran-Crm1 network, which regulates NPM1 centrosomal localisation via 
binding at its nuclear export sequence to prevent unscheduled centriole duplication (Wang 
et al., 2005). Phosphorylated RANBP1 (Ser60) was also identified in this study although no 
functional role has been attributed to this phosphosite. RANBP1 is also linked to the Ran-
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crm1 complex as it dissociates Crm1 from Ran which prevents the centrosomal localisation 
of NPM1, leading to unscheduled centriole duplication (Budhu & Wang, 2005).  
 
NPM1 also interacts with RPGR, a possible guanine-nucleotide release factor, which is 
suggested to be involved in dissociating NPM1 from the centrioles (Shu et al., 2005). RPGR 
phosphorylation at Ser961 was identified as significantly upregulated and therefore 
unlikely to be a direct substrate of PLK4. Similarly, NPM1 is unlikely to be a direct substrate 
of PLK4, as pSer10 is upregulated following PLK4 inhibition. As NPM1 is a negative regulator 
of centriole duplication, it may be upregulated to maintain suppression of centriole 
biogenesis in the absence of active PLK4.   
 
 PLK4 consensus motif analysis 
 
Next, the motifs surrounding the significantly downregulated phosphosites were examined 
to assess whether a PLK4 phosphorylation consensus sequence could be identified. The 
seven residues either side of the phosphosite were searched using the iceLogo tool (Colaert 
et al., 2009). This analysis revealed a motif enriched for proline residues. This included the 
enrichment of Pro at the +1 position.  
 
Figure 5.15. Identification of novel PLK4 phosphorylation motifs.  Downregulated PLK4 
phosphosites were analysed using iceLogo to identify phosphorylation consensus motifs. This 
analysis identified a proline directed phosphorylation motif (p = 0.01).  
 
The autophosphorylation analysis of PLK4 catalytic domain presented in Chapter 3 revealed 
autophosphorylation at Ser232, which contains a Pro at the -1 position.  In addition, the 
FLAKSFGSPNRAYKK peptide substrate (P32) used as our standard PLK4 substrate for in vitro 
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kinase assays (Chapter 3) also already includes a Pro at the +1 relative to the 
phosphorylation site, providing further evidence that PLK4 phosphorylates proline-directed 
motifs. To further evaluate PLK4 phosphorylation of sites similar to the enriched motif 
identified as centrinone-sensitive in cells, the peptide substrate termed P32 (see Chapter 3, 
Figure 5.16 A) was modified at a number of positions, and the phosphotransferase activity 
of recombinant PLK4 assessed using them as substrates (Figure 5.16 A). The rate of 
phosphorylation by PLK4 towards the +1 NT (+1 meaning 1 extra Pro at the N-terminus) 
peptide was essentially identical to that of the original SP motif-containing peptide (Figure 
5.16 B), confirming that the PXP motif is phosphorylated by PLK4 in vitro. Importantly, PLK4 
exhibited very little activity toward the +1 CT (+1 meaning 1 extra Pro at the C-terminus) 
peptide. This confirmed that the +1 proline is critical for PLK4 phosphorylation of this 
peptide sequence. Strikingly, if an additional proline was incorporated at the -2 position to 
generate a PPSP motif (+2 NT), PLK4 activity was completely abolished (Figure 5.16 B), and 
this sequence motif was also excluded in cellular substrates sensitive to centrinone. An ATP 
titration experiment was performed to determine Km values for the P32 peptide and the 
+1NT peptide. The Km[ATP] values for peptide 32  (GXP) and +1NT (PXP) were calculated to 
be 12.8 μM and 10.8 μM respectively (Figure 5.16 C).  
 
As Aurora A is also inhibited by centrinone in vitro (Chapter 3) an additional assay was 
performed to measure whether the proline-directed motif in P32 peptide was 
phosphorylated by Aurora A. Figure 5.16 D shows that Aurora A has extremely low activity 
against the 5-FAM-FLAKSFGSPNRAYKK peptide, and no detectable activity toward the +1NT 
peptide. This provides further evidence that PLK4 activity is directed toward proline motifs 
and suggests that the downregulated cellular phosphosites observed in this study are due 
to inhibited PLK4 (rather than Aurora A) activity. Taken together, the in vitro kinase assays 
provide strong evidence PLK4 phosphorylates a proline-directed consensus motif, which 
will be useful in the future for trying to understand PLK4 substrates in cells. 
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Figure 5.16. Validation of PLK4 phosphorylation consensus motif.  A) The commercially available P32 peptide substrate was used to design peptides incorporating or 
removing additional prolines residues to test the phosphorylation motif. NT= N-terminal to the phosphosites; CT= C-terminal to the phosphosites. B) WT PLK4 (1-269) was 
assayed by quantified mobility shift using EZ Reader technology with a fluorescent peptide substrate in the presence of 1 mM ATP (final concentration), to mimic cellular 
ATP levels. C) Km of WT PLK4 (1-269) was determined for both P32 and the +1 NT following titration of increasing concentrations of ATP. D) Recombinant WT Aurora A and 
PLK4 (1-269) were assayed to test Aurora A activity toward the P32 and +1 NT Pro peptides in the presence of 1 mM ATP. The activity assays shown were performed by Dr. 
Dominic Byrne at the University of Liverpool.  
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 Validation of selected regulated proteins & phosphosites 
 
Validation of selected PLK4 regulated proteins and phosphosites was performed by western 
blot analysis. Cyclin D2 and p21 expression was analysed to assess whether downregulation 
following centrinone treatment could be observed by this method. Figure 5.17 shows that 
for cyclin D2 (CCND2), a decrease in band intensity is observed when the cells are incubated 
with centrinone. The data becomes less clear however, as a decrease is also observed with 
centrinone treatment without induction of expression of PLK4. This could be due to off-
target effects also resulting in down regulation of cyclin D2. Alternatively, the ‘leaky’ 
expression of PLK4 (shown previously in Chapter 3) may be sufficient to induce an effect. 
Centrinone does not appear to have any effect on the levels of CCND2 observed with or 
without G95R PLK4 expression. If decreases in CCND2 were due to off-target effects then 
this should also be observed in the G95R PLK4 U2OS cells with and without induction of 
protein expression. However, as no decrease in CCND2 levels can be observed, it is likely 
that the downregulation observed is directly linked to the inhibited activity of PLK4. No 
decrease in the intensity of p21 can be observed in WT or G95R PLK4 expressing cells 
treated with or without centrinone. This is unexpected; p21 was identified as significantly 
downregulated, with a 1.8 fold decrease in expression in the proteomics dataset. It is 
possible that this fold change is too small to be observed by western blot. This experiment 
would need to be repeated to validate p21 as a downstream target of PLK4 activity and may 
require longer incubation times with centrinone to reduce p21 levels, such that a decrease 
can be observed by western blot.  
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Figure 5.17. Cellular analysis of potential downstream PLK4 substrates.  Expression of WT & G95R 
PLK4 was induced upon incubation with 1 μg/mL tetracycline for 18 hours. Cells were incubated with 
300 nM centrinone, or 0.1 % DMSO for four hours. Total lysates were analysed by western blot using 
the indicated antibodies. 
  
Next, upregulation of total EGFR and pThr669 was evaluated by western blotting, using 
total and phospho-specific EGFR antibodies (Figure 5.18). As the fold change observed in 
the MS data was reasonably small (1.2 fold increase for total EGFR and 1.5 fold for 
pThr669), cells were induced to express PLK4 and treated with centrinone for 4, 16 and 24 
hours in an attempt to amplify the effect of centrinone treatment. No changes in total EGFR 
band intensity could be observed, which may indicate that the fold change is too small to 
observe by western blot, or that EGFR is regulated only at the level of phosphorylation.  
 
 
Figure 5.18. Analysis of potential PLK4 substrates in U2OS stable cells.  Expression of WT PLK4 was 
induced upon incubation with 1 μg/mL tetracycline for 18 hours. Cells were incubated with 300 nM 
centrinone, or 0.1 % DMSO for four hours. Total lysates were analysed by western blot using the 
indicated antibodies.  
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A decrease in pThr669 band intensity was observed following incubation of cells with 
centrinone for four hours (lanes 3 and 4) compared with the untreated cells (Figure 5.18). 
However, the decrease was observed irrespective of PLK4 overexpression, suggesting this is 
an off-target effect of centrinone inhibition. At 16 hours (lanes 5 and 6), an increase in 
pThr669 is observed compared to inhibition at 4 hours, although the levels are slightly 
lower than those observed in the untreated cells (lanes 1 and 2). At 24 hours (lanes 7 and 
8), the levels of Thr669 phosphorylation observed in WT PLK4 overexpressing cells treated 
with centrinone is again lower than those observed in the untreated cells, although an 
increase in phosphorylation is observed at 24 hours in non-PLK4 overexpressed cells 
treated with centrinone. Taken together, the data highlights the true complexity of cell 
signalling mechanisms and illustrates the likelihood of redundancy in the number of protein 
kinases capable of phosphorylating and regulating this residue in EGFR.  
 
 
5.3. Conclusions 
 
The aim of this work was to identify novel PLK4 substrates and regulated signalling 
pathways to provide a deeper understanding of the role of PLK4 in co-ordinating cellular 
activities. Utilising both total proteomics and phosphoproteomics led to the identification 
of a number of significantly changing proteins and phosphosites, implicating PLK4 activity in 
a range of biological functions, including those beyond centrosome biogenesis.  
 
Treatment of G95R PLK4 expressing cells with centrinone led to the identification of a much 
greater number of regulated proteins and phosphosites compared with the WT dataset, 
with the possibility that the cells had begun to initiate mitotic arrest. The differential effects 
of centrinone on the two cell lines may be explained by the inability of drug-resistant G95R 
PLK4 mutant to bind centrinone, leading to an increase of unbound drug (300 nM) in the 
cell which could then potently inhibit off-target proteins. This includes Aurora A, which in 
Chapter 3 was shown to be inhibited by centrinone. Inhibition of Aurora A by small 
molecule inhibitors such as VX-680 and MLN8237 have been shown to lead to mitotic arrest 
(Gorgun et al., 2010; Li et al., 2010). This offers the possibility that the effects observed in 
the G95R PLK4 cell line arise from Aurora A inhibition, leading to negative effects on cell 
proliferation. Reduced expression of mitotic proteins, including cyclin B upon G2/M arrest 
has been reported previously, which matches the observation of downregulated mitotic 
proteins in the G95R PLK4 dataset (Singh et al., 2004). It is therefore possible that off-target 
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inhibition by centrinone has resulted in the onset of G2/M phase arrest in the G95R PLK4 
cell line through off-target inhibition of Aurora A.  
 
This chapter described a number of PLK4 regulated proteins with established roles in the 
early phases of the cell cycle, including RB1, cyclin D, CDK4 and p21. PLK4 expression has 
been implicated in the regulation of expression of these G1/S phase proteins at the level of 
transcription. Deficiencies in PLK4 expression in a PLK4 +/- mouse model, resulted in the 
delayed activation of cyclin D and CDK4, and suppressed the expression of p21 (Ko et al., 
2005). This led to delays in cell cycle progression, spindle defects and an increase in 
hepatocellular carcinomas. The work described in this chapter provides further evidence 
that PLK4 regulates the expression of these interphase proteins and highlights the 
importance of studying the wider roles of PLK4 in the cell cycle.  
 
One interesting observation was the identification of significant differential regulation of 
the two RB1 phosphosites. Particularly, upregulated pThr821 suggests that RB1 is exerting a 
positive effect on cell growth, as dephosphorylation of this residue is required for protein 
binding downstream to suppress cell cycle progression. The majority of other G1/S phase 
proteins and phosphosites were downregulated to suggest a negative effect on cell growth, 
and this conflict highlights the complexity of cell signalling and its effect on cell cycle 
regulation. Although RB1 pThr821 dephosphorylation is required to bind a subset of 
proteins to exert an inhibitory effect, it is inconsequential for binding to E2F proteins, which 
are the major downstream binding partners of RB1 (Knudsen & Wang, 1997). RB1 is 
phosphorylated at a number of residues, with different combinations mediating RB1 
activity in a variety of cellular functions (Rubin, 2013). Therefore, the identification of 
upregulated pThr821 RB1 alone may not be sufficient to confer a positive effect on cell 
growth. Overall, the trend toward downregulated G1/S phase proteins/phosphosites 
following WT PLK4 inhibition with centrinone suggests that inhibited PLK4 activity leads to a 
negative effect on cell growth during G1 phase.  
 
This work also revealed three potential PLK4 phosphosites, all located at the regulatory C-
terminal domain. Although the phosphosites have been identified in shotgun 
phosphoproteomics studies previously (Hornbeck et al., 2015), no function has yet been 
attributed to them. PLK4 Polo Box 1 (PB1) has been implicated in binding to target proteins 
and, along with PB2, is necessary for correct localisation at the centrioles and for forming 
PLK4 homodimers (Slevin et al., 2012). Therefore, it is possible that pSer421, located in PB1 
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is involved in these functions. PB3 has been shown to relieve linker 1 (L1) mediated PLK4 
auto inhibition (Klebba et al., 2015). In addition, it is required for binding to STIL to initiate 
centriole biogenesis (Ohta et al., 2014). Therefore, the identification of pSer665 located 
within PB3 may be implicated in either of these functions.  
 
Finally, this work revealed a potential novel PLK4 phosphorylation consensus motif. The 
currently accepted PLK4 consensus was derived through screening PLK4 against a library of 
peptides derived from known human phosphorylated peptides. This determined that the 
PLK4 consensus sequence included as basic residue at -3, an acidic residue at -2, Tyr or a 
hydrophobic residue at +1 and +2 and Ser or Thr at +4 (Leung et al., 2002; Johnson et al., 
2007). Interestingly, Leung et al., showed that proline at the +1 position was not tolerated. 
However, the data in this thesis provides evidence to support PLK4 phosphorylation of 
proline-directed motifs both in vitro and in cells. The data in Figure 5.16 shows the 
importance of the +1 proline for PLK4 activity and may support the identified centrosomal 
proteins being direct targets of PLK4.  
 
Overall, the work in this chapter describes the first large-scale phosphoproteomics study to 
investigate the global activities of PLK4. The data described reveal potential roles for PLK4 
in the regulation of a wider range of centrosomal proteins than previously reported. In 
addition, the data supports a role of PLK4 in regulating the early stages of the cell cycle. 
Beyond this, PLK4 activity was implicated in a number of additional biological processes 
including gene expression and DNA repair. Taken together, this work highlights important 
novel aspects of PLK4 activity and demonstrates the utility of large-scale 
phosphoproteomics to investigate the global roles of PLK4, enhancing the understanding of 
this critical protein kinase.  
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 Phosphorylation and activation of Aurora A by PLK4 
 
6.1. Introduction 
 
The previous chapter discussed a large-scale analysis of the PLK4 regulated 
phosphoproteome, which identified a number of up- and down-regulated proteins and 
phosphosites with roles in the cell cycle. However, not all previously identified PLK4 
substrates could be identified with this approach due to difficulties in identifying low 
abundance proteins and transient phosphorylation events by shotgun phosphoproteomics 
(Solari et al., 2015).  
 
Recent work has identified a potential interaction between PLK4 and Aurora A in the 
formation of acentriolar spindles in mammalian oocytes (Bury et al., 2017). Inhibition of 
both kinases, with the inhibitor VX-680, resulted in loss of microtubule nucleation, whereas 
expression of a drug-resistant Aurora A mutant (G216L) restored the spindle structures. 
Expression of G95R PLK4 failed to rescue the phenotype, however, expression of both drug-
resistant mutants together enhanced the rescue of spindles beyond that of G216L Aurora A 
alone. This strongly suggested a combinatorial role of the activities of PLK4 and Aurora A, 
although there was no evidence to confirm that the two kinases directly interacted with 
each other to co-ordinate spindle formation.  
 
In somatic cells, no direct interaction between Aurora A and PLK4 has been previously 
defined. However, it has been reported that Aurora A directly interacts with another polo-
like kinase family member, PLK1 to co-ordinate activities at the centrosome (Asteriti et al., 
2015). This highlights the possibility that Aurora A might interact with other members of 
the family, including PLK4.   
 
As discussed in Chapter 1, Aurora A activity is controlled by phosphorylation at Thr288 
within its T-loop, although the mode of activation is complex. Binding partners TPX2, Bora 
and Ajuba act to induce specific conformational changes that enhance the activity of 
distinct pools of Aurora A at varying stages of the cell cycle (Eyers et al., 2003; Hirota et al., 
2003; Hutterer et al., 2006; Bai et al., 2014). Active Aurora A plays a number of major roles 
in the cell cycle, including mitotic entry, centrosome maturation, and chromosome 
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segregation (Giet & Prigent, 1999) with many of these activities requiring interplay with the 
polo-like kinase family  (Asteriti et al., 2015).  
 
Aurora A and PLK1 co-localise during G2 phase and directly interact via Aurora A 
phosphorylation of PLK1 at Thr210, within the T-loop, leading to activation of PLK1 and 
mitotic entry (Macurek et al., 2008). This process is greatly enhanced by the Aurora A 
cofactor, Bora, which interacts with PLK1 to make Thr210 more accessible (Figure 6.1). 
PLK1 then directs the degradation of Bora via a feedback mechanism dependent on 
phosphorylation of a DSGxxT motif, promoting binding of the E3 ubiquitin ligase SCF-βTrCP 
(Seki et al., 2008).  
 
 
Figure 6.1. PLK1 regulation by Aurora A.  A) Schematic of PLK1 showing the kinase domain (KD) & 
polo-box domains (PBD1- residues 417-480 & PBD2- residues 515 to 584). B) Schematic showing the 
activation of PLK1 by Aurora A in the presence of Bora. Adapted from the figure in Seki et al., 2010.  
 
 
Once Bora levels have decreased, PLK1 and Aurora A co-localise with the scaffold protein 
Cep192, bringing both proteins in close proximity (Joukov et al., 2010). This also permits 
phosphorylation of PLK1 by Aurora A, with an additional role in centrosome maturation 
through recruitment of tubulin to the centrosome to nucleate the microtubules (Gomez-
Ferreria et al., 2007; Joukov et al., 2010; Joukov et al., 2014).  
 
PLK4 is also recruited to Cep192, in addition to another scaffold protein, Cep152. An alpha 
helical region, present in both Cep152 and Cep192, ensures the specificity of binding to 
PLK4 whilst a neighbouring motif consisting of acidic residues results in electrostatic 
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interactions to anchor PLK4 to these proteins (Sonnen et al., 2013). The interaction of both 
PLK4 and Aurora A with Cep192, and their key roles at the centrosome, suggests that these 
two kinases could also interact with each other.  
 
No Aurora A phosphopeptides were identified as significantly regulated in the PLK4 
phosphoproteomics study in Chapter 5 to support the possibility of PLK4 regulation of 
Aurora A in somatic cells. However, the established link between the activities of Aurora 
and PLK1, along with the recent work revealing an interplay between Aurora A and PLK4 in 
forming acentriolar spindle fibres in oocytes strongly suggests that these two kinases 
interact. The work in this chapter therefore aimed to assess a direct interaction between 
PLK4 and Aurora A in vitro, and an assessment of co-localisation in somatic cells.  
 
 Aims 
 
The aim of the work described in this chapter was to provide evidence of a direct 
interaction between PLK4 and Aurora A, and to evaluate the inter-regulation of the 
catalytic activity of these two enzymes in vitro to support the work by Bury et al., 2017.  
Finally, the work in this chapter aimed to confirm an interaction in somatic cells through 
both co-immunoprecipitation and immunofluorescence experiments and identify at which 
phase of the cell cycle an interaction occurred.   
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6.2. Results & Discussion 
 
 Aurora A phosphorylation by PLK4 
 
To determine whether PLK4 phosphorylates Aurora A in vitro, recombinant WT PLK4 
catalytic domain (1-269) (presented in S. Ferries MRes Report, 2015) was incubated with a 
recombinantly produced inactive Aurora A, in which the catalytic aspartic acid (D274) was 
mutated to asparagine to prevent autophosphorylation (made by Dr. Dominic Byrne in the 
Eyers’ laboratory). Phosphorylation of Aurora A observed under these conditions can thus 
be directly attributed to the activities of PLK4. Following digestion with trypsin, the 
peptides were analysed by LC-MS/MS, revealing 5 sites of phosphorylation (Figure 6.2 A). 
One of the phosphosites identified (Ser54) was located at the N-terminus, whilst four were 
located within the T-loop (Figure 6.2 B). Of particular interest is the identification of 
phosphorylation at T-loop residue Thr287/288. The sequence surrounding this site 
conforms to the relaxed PLK4 phosphorylation consensus motif as previously determined 
using a peptide spot array, which suggests PLK4 preferentially phosphorylates peptides 
with a basic residue at -3, a Tyr or a hydrophobic residue at +1 and +2 and Ser or Thr at +4 
(Johnson et al., 2007; Leung et al., 2007). This therefore suggests a potential role for PLK4 
in the regulation of Aurora A activity (Figure 6.2 C).  
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Figure 6.2. WT PLK4 phosphorylates catalytically inactive Aurora A.  Purified recombinant WT PLK4 
was incubated with catalytically inactive (D274N) Aurora A for 2 hours at 37 °C. Reactions were then 
digested with trypsin and analysed by LC-MS/MS. A) List of Aurora A phosphorylation sites identified 
are depicted with associated m/z values, Mascot & phosphosite confidence determined using 
Mascot delta score (%). B) Schematic of Aurora A showing the location of the identified 
phosphosites. C) Relaxed PLK4 consensus phosphorylation motif and the Aurora A activation loop 
consensus sequence. ɸ = hydrophobic residue.  
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Figure 6.3 A to F shows the manual annotation of the product ion mass spectra for each of 
the identified phosphosites. HCD product ion spectra for the peptide ‘VLCPSNSSQR’ 
contains three phosphorylatable residues and insufficient product ions are detected to 
identify which site is phosphorylated. However, the EThcD spectrum of the same peptide 
with one missed cleavage provides a c- and z- ion series, which unequivocally defines Ser54 
as the site of modification (Figure 6.3 A & B). Assignment of the HCD product ions in the 
mass spectrum for the pThr288 containing phosphopeptide identified b3 and b5 ions to 
pinpoint the phosphorylated residue as either Thr287 or Thr288 but the exact site of 
modification could not be determined (Figure 6.3 D). This ambiguity arises as these two 
residues are adjacent and located at the extreme N-terminus of the peptide, and the 
MS/MS spectra lack the y17 site determining ion.  The inability of collision-induced 
fragmentation techniques to produce a b1 ion (due to the lack of a carbonyl group at the N-
terminus required for nucleophilic attack to induce peptide cleavage) further prevented the 
identification of Thr287 or Thr288 as the site of phosphorylation (Schlosser & Lehmann, 
2000). Ser245, Thr292 and Thr347 were all identified with high confidence as shown by the 
manual annotation of HCD product ion spectra (Figure 6.3 C, E & F).  
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Figure 6.3. PLK4 phosphorylates D274N Aurora A.  Tandem mass spectra generated by HCD or 
EThcD of tryptic phosphopeptides derived from kinase-dead (D274N) Aurora A phosphorylated by 
PLK4 (1-269). The peptide sequence and the identified phosphosite is detailed on each tandem mass 
spectrum. A) Doubly charged ion at m/z 614.2, generated by HCD suggesting pS54 as a possibly 
phosphosite; B) Triply charged ion at m/z 665.0, generated by EThcD, providing additional evidence 
for pS54; C) triply charged ion at m/z 708.3, generated by HCD, identifying pS245; D) doubly charged 
ion at m/z 1074.0, generated by HCD, identifying the either pT287 or activating T-loop residue, 
pT288. E) doubly charged ion at m/z 1073.5, generated by HCD identifying pT292; F) doubly charged 
ion at m/z 847.9, generated by HCD, identifying pT347.  
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Owing to the ambiguity surrounding phosphosite localisation at Thr287 or Thr288, further 
validation was required to confirm that PLK4 phosphorylated Aurora A at the activating 
residue. Recombinant WT PLK4 (1-269)  (presented in S. Ferries MRes Report, 2015) was 
incubated with catalytically inactive D274N Aurora A over a time course (0 – 2 hours) and 
proteins were analysed by western blot using a pThr288 specific antibody. This analysis 
confirmed that PLK4 phosphorylated Aurora A at the critical Thr288 residue in a time-
dependent manner. The levels of phosphorylation increase over time, up to 120 minutes 
and then a decrease in phosphorylation is observed at 240 minutes. This could be due to 
the proteins becoming unstable and denaturing after incubation at 37 °C for this length of 
time or possibly due to delayed phosphorylation of Thr287 which would mask that 
antigenic epitope. Two negative controls were included: a catalytically inactive PLK4 
(D154A) incubated with D274N Aurora A, and the inclusion, in one reaction, of the PLK4 
specific inhibitor, centrinone. The two negative controls together confirmed that the 
observed phosphorylation was due to the activities of PLK4 (Figure 6.4).  
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Figure 6.4. PLK4 phosphorylates D274N Aurora A at Thr288.  Catalytically inactive Aurora A (D274N) 
was incubated alone and in the presence of WT PLK4 (1-269), D154A PLK4 (1-269), or in the 
presence of 10 μM centrinone with 1 mM Mg-ATP. Reactions were analysed at the indicated time 
points by western blotting using an anti-pThr288 antibody. Equal loading of proteins was confirmed 
by Ponceau staining.  
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The identified phosphosites were mapped on the crystal structure of Aurora A using PyMol 
(Nowakowski et al., 2002). The crystal structure begins at Arg126 and therefore, pSer54 
could not be mapped. This site has however, been shown to flank an α-helix motif in the 
middle of a calmodulin interaction domain and phosphorylation at this site has been 
implicated in the activities of Aurora A at the basal body in ciliary disassembly and re-
absorption during G1/S phase (Plotnikova et al., 2010). Phosphorylation at Ser54 was 
shown to be important for this process as calmodulin binding to Aurora A resulted in 
autophosphorylation at Ser54, which is located within the calmodulin binding motif. 
Mutation of Ser54 prevented binding of Ca2+-calmodulin, preventing mitotic progression 
and reabsorption of cilia, highlighting the importance of phosphorylation at this residue 
(Plotnikova et al., 2012).  
 
Phosphorylated Ser245, located on the C-terminal α-helix has been identified as a substrate 
of GSK3β. This interaction is required to recruit FBXW7, the substrate recognition 
component of SCF- E3 ubiquitin ligase complex, which mediates the ubiquitination of 
Aurora, A to signal the protein for degradation (Kwon et al., 2012). Mutation of Ser245 to 
Ala (along with Ser387) resulted in loss of binding to GSK3β and prevented degradation of 
Aurora A. This reveals an important regulatory role for phosphorylation at this site, 
although the implications with regard to possible phosphorylation of this site by PLK4 are 
unknown.  
 
No functional analysis of phosphorylation at Ser347 has been reported in the literature 
thus far. Figure 6.5 shows that this residue is located in an unstructured region of the C-
lobe. Sequence alignment between different species reveals that this residue is poorly 
conserved, with lysine more frequently observed at this position (Bayliss et al., 2003). 
Phosphorylation in intrinsically disordered regions of proteins is common, with the 
suggestion that phosphorylation in these regions can act as a switch to reveal functionally 
relevant sites nearby (Iakoucheva et al., 2004; Travers et al., 2015) However, it is possible 
that the location of this residue in human Aurora A makes it readily accessible for 
phosphorylation by PLK4 when the two proteins are incubated in vitro and may not be 
biologically relevant.  
 
 
 
Chapter 6 
176 
 
Figure 6.5 depicts pThr288 and pSer292 on the activation loop, as has been shown 
previously. No functional analysis of pSer292 has been performed. However, recent work 
has shown that structurally, when Aurora A is bound to TPX2, Ser292 forms hydrogen 
bonds with Asp256 of the HRD motif, positioning this aspartic acid to activate the hydroxyl 
group of the protein substrate. Ser292 therefore appears to aid in the increased activation 
of TPX2 bound Aurora A (Zorba et al., 2014). The identification of phosphorylated T288 
within the T-loop implicates PLK4 activity in the activation of Aurora A and was investigated 
further.  
 
 
 
Figure 6.5. Aurora A residues phosphorylated by PLK4.  A) The activating residue Thr288 (red) and 
Thr292 (blue), phosphorylated by PLK4 are located within the T-loop. Ser347 (blue) is located in an 
unstructured region on the C-lobe. B) Ser245 (blue) is located within a C-terminal alpha helix. 
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 Aurora A activation by PLK4 
 
As phosphorylation at Thr288 is critical for Aurora A activity, the effect of phosphorylation 
at this residue by PLK4 on activity was assessed. Recombinantly produced WT Aurora A is 
active due to extensive autophosphorylation in E. coli and in the presence of ATP in vitro 
(Enami & Ishihama, 1984; Shrestha et al., 2012) (data presented in S.Ferries MRes, 2015). 
Incubation of Aurora A with a fluorescent peptide substrate (5-FAM-LRRASLG) revealed 30 
% conversion of substrate into phosphorylated product after 60 cycles (~75 minutes), with 
the assay performed at room temperature. However, when WT Aurora A was incubated 
with WT PLK4 catalytic domain, the activity of Aurora A increased dramatically, leading to a 
50 % conversion of the substrate into phosphorylated product (Figure 6.6). The results of 
this assay confirmed that phosphorylation of Thr288 by PLK4 has a direct impact of Aurora 
A activity. However, the use of auto-activated Aurora A precluded the early stages of PLK4 
activation from being observed.  A different approach was therefore required to analyse 
the onset of Aurora A activation by PLK4. 
 
 
 
 
Figure 6.6. Aurora A hyperactivation by PLK4.  WT Aurora was assayed for hyperactivation in the 
presence or absence of WT PLK4 (1-269). Reactions were incubated for 15 minutes at room 
temperature in the presence of 1 mM ATP to mimic cellular levels prior to evaluating Aurora A 
activity against the peptide substrate (5-FAM-LRRASLG). Activity was analysed in kinetic mode for 60 
cycles (75 minutes) and converted to total peptide phosphorylation. Data are presented as the mean 
± SD for triplicate reactions. 
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To overcome the issue of Aurora A autophosphorylation and activation, 6His-tagged WT 
Aurora A and 6His- and GST-tagged λ-phosphatase were co-expressed in E. coli. Co-
expression of these proteins results in the rapid enzymatic dephosphorylation of Aurora A 
by λ-phosphatase, resulting in a wild type, inactive Aurora A, capable of becoming re-
activated upon phosphorylation within its T-loop. The purification steps required to 
separate the expressed Aurora A from λ-phosphatase are shown (Figure 6.7, taken from S. 
Ferries MRes Report, 2015). Following nickel affinity and glutathione S-transferase 
purification, the flow through (expected to contain purified Aurora A) contains a 
contaminant corresponding to the molecular weight of 6His- GST tagged λ-phosphatase 
(Figure 6.7 A, B). Therefore, strong cation exchange chromatography was employed to 
exploit the differences in PI between the two proteins (pI of Aurora A = 9.5; pI of λ-
phosphatase= 4.5) as a final purification step. Fractions 1-7 (Figure 6.7 C) were pooled and 
analysed by LC-MS/MS to confirm the identity of dephosphorylated WT Aurora A (data not 
shown).  
 
 
 
 
Figure 6.7. Purification of dephosphorylated WT Aurora A.  A) Following co-expression of 6His- 
tagged Aurora A & 6His-GST λ-phosphatase in Rosetta E. coli, cell lysate was incubated with nickel 
resin and bound protein was eluted with 500 mM imidazole. Eleven fractions were collected and 
analysed by SDS-PAGE. B) Fractions 1-11 were pooled and Aurora A was separated from λ-
phosphatase by GST affinity purification. Nine fractions were collected and analysed by SDS-PAGE. C) 
The flow through from B) was purified further by strong cation exchange and collected fractions 
were analysed by SDS-PAGE. Fractions 1-6 were pooled and analysed by LC-MS/MS to confirm 
protein identity.  
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To assess the early stages of Aurora A activation by PLK4, the purified, dephosphorylated 
Aurora A was incubated with and without WT PLK4 (1-269) for 2 hours at 37 °C. The kinase-
inactive D154A PLK4 (1-269) mutant was incubated with Aurora A as a negative control and 
GST-tagged TPX2, the allosteric activator of Aurora A, was included as a positive control. 
Figure 6.8 shows the onset of activation of dephosphorylated Aurora A, with low activity 
toward the peptide substrate. A maximum of 3.5 % conversion of the substrate was 
observed after 60 assay cycles. The overall activity was much lower than that observed in 
Figure 6.6 and this may be due to a slow rate of reaction or due to the dephosphorylated 
Aurora A having an altered conformation. Phosphorylation regulates protein stability in 
many instances and therefore, a dephosphorylated protein kinase may be less stable and 
therefore less active (Nishi et al., 2014).  However, a clear increase in the activity of Aurora 
A against the peptide substrate is observed when incubated with PLK4 and is similar to that 
observed with TPX2 (10 % vs 12 % respectively), representing a ~3 fold increase in activity. 
To confirm that the effect observed with TPX2 was not due to the presence of a GST tag, 
GST alone was incubated with Aurora A as an additional negative control.  
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Figure 6.8. Dephosphorylated Aurora A activation by WT PLK4.  λ-phosphatase treated WT Aurora 
was assayed for WT PLK4, catalytically inactive D154A PLK4, or TPX2-mediated hyperactivation. 
Reactions were incubated for 30 minutes at 37 °C in the presence of 1 mM ATP to mimic cellular 
levels. Aurora A activity was assayed upon the addition of the peptide substrate (5-FAM-LRRASLG) in 
kinetic mode for 60 cycles (75 minutes) and converted to total peptide phosphorylation. Data are 
presented as the mean ± SD for triplicate reactions. 
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 Aurora A & PLK4 co-immunoprecipitation 
 
Taken together, the data show that in vitro, PLK4 phosphorylates Aurora A and that 
phosphorylation within the T-loop leads to an increase in activity. Whilst these data are 
encouraging, validation in cells is required to confirm that this interaction is biologically 
relevant. To test this, co-immunoprecipitation experiments were performed to assess 
whether PLK4 and Aurora A co-purified from cells. Expression of a FLAG-tagged Aurora A 
and transiently transfected MYC-PLK4 was induced and Aurora A was immunoprecipitated 
by virtue of its FLAG tag. Analysis by western blot shows the successful transient 
transfection and expression of MYC-PLK4 alongside the expression of FLAG-Aurora A in the 
total cell lysate. However, following immunoprecipitation of Aurora A, no PLK4 was 
observed in the pull-down, suggesting that Aurora A and PLK4 do not co-
immunoprecipitate, at least under the conditions employed (Figure 6.9 A).  
 
As an alternative approach, co-immunoprecipitation was tested in FLAG-PLK4 stably 
transfected U2OS cells.  FLAG PLK4 was immunoprecipitated by virtue of its FLAG tag and 
co-purification of endogenous Aurora A was assessed. Owing to the low expression levels 
of stably transfected PLK4, the proteasome inhibitor MG-132 was included to permit the 
accumulation of PLK4 levels in the cell. Figure 6.9 B shows the enrichment of PLK4 
following immunoprecipitation. However, co-purification with Aurora A was not observed.  
 
Taken together, Figure 6.9 A & B show no evidence of interaction between PLK4 and 
Aurora A in cells therefore, an alternative approach was required to investigate a possible 
interaction.  
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Figure 6.9. PLK4 & Aurora A do not co-immunoprecipitate.  A) HeLa cells stably transfected with WT 
Aurora A were co-transfected with MYC- WT PLK4 and incubated +/- 1 μg/mL tetracycline for 18 
hours to induce protein expression. Aurora A was immunoprecipitated with anti-FLAG resin. Lysates 
and pull down samples were analysed by western blot and probed using the indicated antibodies. B) 
U2OS cells stably transfected with FLAG-PLK4 were incubated +/- 1 μg/mL tetracycline for 18 hours 
to induce protein expression followed by +/- 10 μM MG-132 for 4 hour. PLK4 was 
immunoprecipitated with anti-FLAG resin. Lysates and pull down samples were analysed by western 
blot and probed using the indicated antibodies  
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 Aurora A & PLK4 co-localisation 
 
As an alternative to co-immunoprecipitation, U2OS cells expressing MYC-PLK4 were imaged 
by immunofluorescence to assess whether PLK4 and Aurora A co-localised in the cell. 
Figure 6.10 shows WT PLK4 co-localised with Aurora A within the nucleus, in an interphase 
cell, as indicated by the decondensed DNA.  The presence of two puncta reflects that the 
cell has duplicated its centrosome and so is either in S phase or progressed in to G2. The 
exact phase cannot be determined without imaging markers distinct to different phases of 
the cell cycle. This assay would therefore need to be repeated and fluorescently probed 
with a cell cycle marker such as Cyclin B1 to determine whether this interaction has 
occurred following progression in to G2 (Scott et al., 2003).  
 
Aurora A could be observed in cells across the cell cycle. However, as expected, co-
localisation with PLK4 was not observed in cells in the later stages of mitosis. PLK4 trans-
autophosphorylates and is degraded by the 26S proteasome following centriole duplication 
and is not believed to function in mitosis. Studies investigating the subcellular localisation 
of Aurora A have shown that low levels of Aurora A can be observed in G1 which then 
accumulate at duplicated centrosomes from late S phase through mitosis, which is 
consistent with the data shown here (Dutertre et al., 2002).  
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Figure 6.10. PLK4 and Aurora A co-localise in U2OS cells.  U2OS cells, induced with tetracycline to 
express MYC-WT PLK4, were probed with anti-PLK4 (red) & anti-Aurora A (green) antibodies and 
analysed by immunofluorescence microscopy to confirm co-localisation. 
 
Next, co-localisation of PLK4 with active, Thr288 phosphorylated Aurora A was assessed. 
Using a pThr288 specific antibody, MYC-WT PLK4 expressing U2OS cells were imaged by 
immunofluorescence. Cells at varying stages of the cell cycle were imaged to identify at 
which stages phosphorylated Thr288 could be identified and possibly interact with PLK4. 
Figure 6.11 shows that pThr288 Aurora A can be identified at each of the stages of the cell 
cycle indicated, consistent with the literature (Walter et al., 2000). Figure 6.11.B shows 
pThr288 Aurora A within a metaphase cell. Active Aurora A (pThr288 phosphorylated) has 
recently been shown to play an unexpected role in kinetochore attachment in metaphase 
cells when the chromosomes reside near spindle poles. This occurs via phosphorylation of 
the Hec1 subunit from the NDC80 complex, which associates with the kinetochore to 
control attachment to the microtubules (DeLuca et al., 2018). Figure 6.11 C shows a cell in 
late anaphase/telophase, where active Aurora A can be identified at the spindle mid-zone 
and centrosomes, which has been shown previously (Marumoto et al., 2003). This reflects 
the roles of Aurora A in the later stages of the cell cycle, including the completion of 
cytokinesis. As expected, co-localisation with PLK4 was not detected in the cells at later 
stages of the cell cycle due to PLK4 expression being tightly regulated in interphase cells.  
 
However, co-localisation of pThr288 Aurora A with PLK4 was observed in the early stages of 
the cell cycle (G1/S). Figure 6.11 A shows two cells that have recently undergone 
cytokinesis and re-entered G1. In these two cells, low levels of pThr288 Aurora A can be 
observed as single puncta, co-localised with PLK4. Previous studies showing Thr288 
phosphorylation across the cell cycle revealed that pThr288 levels increase from G1 
through to G2 and then decrease during mitosis, before elevating again upon re-entry in to 
Chapter 6 
185 
 
G1 (Walter et al., 2000). This suggests an active role for pThr288 Aurora A in the earlier 
phases of the cell cycle (G1/S) and the data shown here suggests that this activity could 
potentially be regulated by the catalytic activity of PLK4.  
 
 
 
 
Figure 6.11. PLK4 and pT288 Aurora A co-localise in U2OS cells.  U2OS cells, induced with 
tetracycline to express MYC-WT PLK4, were probed with anti-PLK4 (red) & anti-pThr288 Aurora A 
(green) antibodies and analysed by immunofluorescence microscopy to assess co-localisation in cells 
A) early G1 phase B) metaphase C) late anaphase/telophase.   
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6.3. Conclusions 
 
This chapter describes the attempt to identify an interaction between PLK4 & Aurora A for 
the first time, demonstrating that PLK4 acts upstream of Aurora A, regulating its activity by 
phosphorylation. This work showed that PLK4 is capable of phosphorylating Aurora A in 
vitro at 5 sites, including Thr288, the activating residue located within the T-loop. Of the 5 
observed phosphosites, only Thr288 has been studied extensively to understand its 
biological function, with two other phosphosites (Ser52 and Thr292) having been observed 
in high-throughput proteomic analysis, but lacking information on functional roles. Future 
studies should therefore aim to understand the possible biological relevance of these PLK4 
directed phosphosites through approaches such as chemical genetics to mutate these 
residues and transfect in to cells and observe the phenotypic effect. This approach has been 
used frequently in the study of protein kinases, including PLK4 and Aurora A to probe their 
biological functions (Scutt et al., 2009; Holland et al., 2010; Sloane et al., 2010).  
 
Following confirmation that PLK4 phosphorylates Aurora A at Thr288, in vitro kinase assays 
showed that this phosphorylation resulted in hyperactivation of Aurora A. Given the known 
complexity of Aurora A activation through regulation by multiple cofactors (TPX2, Bora, 
Ajuba), it is possible that this work has revealed a novel regulatory mechanism of Aurora A 
activation, via phosphorylation by PLK4.  
 
The immunofluorescence images indicated that the co-localistion of the two kinases 
occurred only at earlier stages of the cell cycle (G1/S) where potential roles of pThr288 
Aurora A have yet to be elucidated. This could provide an exciting opportunity to uncover 
novel roles for Aurora A in the earlier stages of centriole biogenesis.  
 
Although PLK4 and Aurora A co-localised in the cell, co-purification could not be achieved. 
Co-immunoprecipitation experiments are challenging and require a level of optimisation to 
ensure conditions are suitable to co-purify two interacting proteins. Factors such as buffer 
components (pH, salt concentration, detergent concentration) and total number of washes 
performed can affect the stability of an interaction (Masters, 2004). In addition, it is unlikely 
that all of the protein expressed is bound to just one interacting partner and the 
interactions that do occur are likely to be transient and occur only at distinct phases of the 
cell cycle. This will further decrease the probability of observing an interaction by 
techniques such as western blotting.  
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Overall, this work has identified Aurora A as a possible substrate of PLK4 in vitro and 
revealed co-localisation at early phases of the cell cycle, supporting the findings of Bury et 
al., which showed overlapping functions of PLK4 and Aurora A in forming acentriolar 
spindles in oocytes. This work, along with the in vitro and U2OS cell-based experiments 
described in this chapter, poses the possibility that in addition to a role in meiosis in 
oocytes, PLK4 and Aurora A may also interact in somatic cells to co-ordinate activities in the 
early stages of the cell cycle.  This preliminary work provides evidence of a direct 
interaction. However, a more comprehensive study of this interaction in cells is required to 
unravel the possible interplay of these two important mitotic protein kinases.  
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 General Discussion and Future Perspectives 
 
The work in this thesis aimed to uncover PLK4 signalling and identify novel PLK4 substrates. 
PLK4 is the master regulator of centriole biogenesis, with tightly controlled activity to 
ensure that each centriole is duplicated once per cell cycle. Despite its critical importance, 
few PLK4 substrates have been identified thus far, and much remains to be understood 
about its role at the centrosomes and its wider role regulating activities in the cell. The 
work in this thesis has revealed a number of novel PLK4 regulated signalling pathways, 
identified a new PLK4 phosphorylation consensus sequence and confirmed PLK4 as an 
activator of Aurora A activity.  
 
The first results chapter (Chapter 3) described the development of biochemical tools to 
study the PLK4 regulated phosphoproteome, including characterisation of recombinant WT 
and G95R PLK4, and assessment of their inhibition by centrinone. This work confirmed the 
drug-resistant phenotype in vitro prior to analysis of both proteins in cells. Chapter 3 also 
described the successful creation of stable isogenic U2OS cell lines, transfected with either 
WT or G95R PLK4, where protein expression and correct subcellular localisation was 
confirmed. This was critically important, as the work in this thesis aimed to study the 
activities of PLK4 in the cell and therefore, the overexpression system had to mimic 
endogenous conditions as closely as possible. Finally, the work in Chapter 3 assessed the 
efficiency of SILAC labelling in U2OS cells to confirm the cell doublings required for full 
incorporation of the labels, and established the high pH reversed phase fractionation 
strategy to be employed for improved (phospho)peptide coverage. Together, this work 
permitted a comprehensive analysis of the PLK4 regulated phosphoproteome.  
 
Chapter 4 details how mass spectrometry acquisition methods were optimised for large-
scale confident phosphopeptide and phosphosite analysis. A number of instrument and 
informatics parameters were tested, with a key focus on mode of fragmentation and mass 
analysers for product ion detection. HCD fragmentation, with detection of both precursor 
and product ions in the orbitrap was identified as the optimal method for identifying high 
numbers of phosphopeptides, with high confidence in position of the phosphosite. Whilst 
EThcD fragmentation with product ion detection in the orbitrap provided the highest 
phosphosite confidence compared with HCD (orbitrap or ion trap detection), the total 
number of phosphopeptide identifications was lowest. This is likely due to the longer 
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reaction times required for efficient ETD fragmentation. Further advances in ETD 
technology are required for it to achieve the same numbers of identified phosphopeptides 
compared with HCD in large-scale phosphoproteomics studies, including improved reagent 
ion sources and advances in supplemental activation. Currently there is a balance between 
numbers of phosphopeptides identified and numbers of phosphosites confidently localised 
which needs to be taken into consideration when designing an analytical strategy for 
phosphoproteomics. 
 
Recent improvements with ETD supplemental activation have included the development of 
an activated ion- negative ETD (AI-NETD) fragmentation approach for peptides. Negative 
mode ETD, in which peptides are oxidized with reagent cations leading to cleavage of the C-
Cα bond has been shown to produce interpretable MS2 spectra for peptide identification. 
However, product ions can form intramolecular non-covalent interactions that do not 
separate (McAlister et al., 2012; Riley et al., 2015). In AI-NETD, infrared photon 
bombardment occurs at the same time as the ETD reaction, resulting in dissociation of the 
non-covalent interactions and richer MS2 spectra. Combined with a multipurpose 
dissociation cell implemented in a quadrupole ion trap-orbitrap hybrid mass spectrometer, 
this negative ETD fragmentation method identified ~7600 peptides in a single run from a 
tryptic digest of Saccharomyces cerevisiae (Riley et al., 2015). As phosphopeptides 
preferentially ionize to form anions, future developments with this approach could lead to 
the ability to implement AI-NETD for large-scale phosphoproteomic studies.  
 
The implementation of ETD for high-throughput analysis will also benefit from practical 
considerations such as improved reaction cells for optimised ETD reactions. Improvements 
in this area could allow more efficient storage of precursors and reagent ions and reduced 
ion-ion reaction times. In addition, concurrent supplemental activation as opposed to two 
separate reactions would lead to faster reaction times and permit the acquisition of more 
ETD spectra leading to larger numbers of phosphopeptide identifications (Riley & Coon, 
2018). 
 
Following on from the development of biochemical tools and optimised MS parameters, a 
large-scale phosphoproteomics investigation was performed to study PLK4-regulated 
signalling via the analysis of differential protein expression and changes in phosphorylation 
state upon inhibition of PLK4 activity. This work revealed that PLK4 was implicated in 
regulating MAPK signalling and the early phases of the cell cycle. In addition, PLK4 activity 
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was implicated in roles outside of the cell cycle, including rRNA processing, cadherin 
binding involved in cell-cell adhesion, and negative regulation of apoptosis.  
 
A number of dysregulated phosphoproteins were also identified as enriched at the 
centrosome. As the centrosome cycle is strictly linked to DNA replication at S phase, it is not 
surprising that downregulated proteins/phosphosites were observed with roles in both of 
these processes. CDKs are known to play a role in mediating centrosome biogenesis and the 
downregulation of CDK4 and 6 with roles in both G1/S and at the centrosome highlights this 
link. A gene knockout approach confirmed the importance of CDK4 in the centrosome cycle 
as Cdk4-/- MEFs failed to undergo centrosome duplication (Adon et al., 2010). Similarly, RB 
(identified with up and down regulated phosphosites) is also involved in the centrosome 
cycle, as release of E2F following RB phosphorylation leads to the regulation of genes 
involved in centriole duplication, including cyclin D, cyclin A, CDK2 and RanBP (Ishida et al., 
2001; Ren et al., 2002). This work may have therefore provided further evidence of the 
cross-talk between proteins regulating both centrosome duplication and progression 
through G1/S phase of the cell and showed them to be regulated by PLK4 signalling.  
 
As PLK4 is localised at the centrosome, a more focused approach to studying PLK4 signalling 
could be to isolate and analyse the centrosomal phosphoproteome. Subcellular 
phosphoproteomics permits a greater insight in to the intricate regulation of 
phosphorylation dynamics and isolation of one subcellular compartment allows for lower 
abundance proteins to be identified (Trost et al., 2010). This approach was taken to study 
the PLK1 regulated phosphoproteome of the mitotic spindles. Compared to analysis of the 
global proteome, this study provided a comprehensive assessment of regulated proteins at 
the spindle fibres, and identified a number of novel PLK1 regulated phosphosites on spindle 
associated proteins such as INCENP and Bub1 (Santamaria et al., 2011).  
 
In addition, future work could include arresting the cells in G1 phase of the cell cycle and 
analysing the regulation of proteins/phosphosites with roles in the early phases of the cell 
cycle where PLK4 is most active. Proteomics datasets can also be coupled to RNA-
sequencing data to assess the effects of drug-treatment on transcript levels. This was 
performed for a large-scale study, which aimed to identify mediator kinase substrates using 
the specific CDK8 and CDK19 inhibitor cortistatin A. RNA-sequencing data correlated with 
the targets identified in the proteomics study and provides additional depth in the 
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understanding of kinase inhibition at the transcript, protein and PTM level (Poss et al., 
2016). 
 
These approaches to studying the activity of PLK4 at the centrosome could aid the 
identification of increased numbers of PLK4-regulated centrosomal proteins, including the 
known PLK4-regulated phosphosites in STIL, CP110 and Cep192/152 not seen in this work.  
 
One noteworthy observation is that the fold changes observed in the phosphoproteomics 
study were typically relatively small (<2 fold). Many large-scale phosphoproteomics studies 
implement an arbitrary fold change cut off (typically 2-fold) to determine significance and 
employ a t-test to assess statistical significance of the calculated ratios for SILAC data. The 
t-test has a number of limitations when used in proteomics studies. Firstly, the sample size 
in this type of experiment is typically small, (3 to 5 bioreplicates) and this results in issues in 
estimating the true variability in the data. This is exacerbated for phosphoproteomics 
datasets, where SILAC ratios determined for single peptides, compared with protein 
quantification where a minimum number of peptides are required for quantification. As the 
variability estimates are used in the t-test statistic, proteins and peptides can be declared 
as not significant due to high variability.  
 
Empirical Bayesian approaches have been the gold standard for gene microarray data, 
although its use in the proteomics field has lagged behind. Bayesian statistics allow for a 
realistic distribution of variance by using the full dataset to shrink the variances observed 
toward a pooled estimate (Kammers et al., 2015). In this way, Bayesian statistics can 
determine statistical significance, even with small sample sizes and was therefore an ideal 
solution to determine significance in the phosphoproteomics dataset described in Chapter 
5, where variability in phosphopeptide quantification and small fold changes were 
observed.  
 
It is possible that the small fold changes observed were due to the short centrinone 
incubation times (4 hours). This was likely to be insufficient to study the PLK4-regulated 
proteome due to differential protein turnover rates (Doherty et al., 2009). Similarly, a 
longer incubation time may be required to increase the effects of inhibited PLK4 activity at 
the level of phosphorylation. Therefore, future studies could include assessment of the 
PLK4 regulated phosphoproteome following centrinone treatment for longer time periods.  
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An additional complication of phosphoproteomics studies arises from the consideration of 
the protein and phosphopeptide datasets as separate. Ideally, the phosphosite SILAC ratios 
would be normalised to the total protein ratios, to permit the determination of 
stoichiometric changes in phosphorylation. However, to date, there is no established 
method for this. One major complication is that there will be many instances where a 
phosphopeptide has been identified, with no corresponding protein identification, which 
would lead to a loss of potentially important data. This work therefore considered the two 
datasets separately; referring to the protein level data in instances where the protein and a 
phosphosite were both identified as significantly changing following treatment with 
centrinone. Future advances in instrumentation will undoubtedly lead to even greater 
numbers of peptide identifications, maximising coverage of the proteome under study and 
potentially overcoming the issue of missing data currently preventing normalisation.  
 
One exciting result described in this thesis was the identification of a potential proline 
directed PLK4 phosphorylation consensus motif. This motif was validated using in vitro 
kinase assays, which showed PLK4 phosphorylation of both SP and PSP directed motifs. 
These data were somewhat unexpected, as this consensus motif varies significantly from 
that proposed from peptide spot arrays, in which proline at +1 was not tolerated (Leung et 
al., 2007).  In addition, proline-directed motifs are known to be targets of cyclin-dependent 
kinases (Songyang et al., 1994; Swaffer et al., 2016), and a number of the downregulated 
phosphosites identified are direct substrates of CDK activity.  
 
NCKAP5L, discussed in Chapter 5, has also been identified as a substrate of CDK1.  
Phosphorylation within a proline rich domain of NCKAP5L by CDK1 at seven residues results 
in dissociation from the centrosome during mitosis (Mori et al., 2015b). The sites included 
Ser571 and Ser577 however, Ser567, identified in this study, was not observed. This 
suggests that both PLK4 and CDKs can phosphorylate NCKAP5L within the proline directed 
motifs, and additional residues nearby may dictate subtle differences in their target 
proteins. For example, Lys/Arg at the +3 position is included in the full CDK consensus motif 
(Songyang et al., 1994). 
 
Cdc6 pSer74, identified as downregulated in this phosphoproteomics study in response to 
centrinone treatment, is located near to a KEN destruction box and is a known target of 
CDKs. CDK2-cyclin E phosphorylation of Ser74 stabilises Cdc6 by preventing its degradation 
by the APC/C E3 ubiquitin ligase and allows pre-replicative complexes to assemble prior to S 
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phase (Mailand & Diffley, 2005).  Following the completion of G1/S phase, CDK 
phosphorylation of Ser74 causes Cdc6 to be exported out of the nucleus in to the cytoplasm 
to prevent the formation of pre-replication complexes (Yim et al., 2013). This suggests that 
downregulated Cdc6 pSer74 in this study is an off-target effect of centrinone treatment. 
 
A number of downregulated phosphosites have also been shown to be substrates of Aurora 
A. WDR62 phosphorylation at Ser33 is a target of TPX2- bound Aurora A to recruit WDR62 
to the mitotic spindles with roles in organisation and chromosome alignment during 
metaphase (Lim et al., 2015). Similarly, Aurora A phosphorylates NUMA1 at Ser1991, which 
has roles in spindle orientation (Gallini et al., 2016).  
 
The identification of downregulated phosphorylation of established CDK & Aurora A targets 
suggests the possibility of off-target inhibition of these proteins with centrinone. As shown 
in Chapter 3, centrinone is capable of inhibiting Aurora A, and so it is possible that 
centrinone can also inhibitor CDKs, as dual inhibition of Aurora A, and CDKs has been shown 
with the compound JNJ-7706621 (Emanuel et al., 2005). Taken together, these observations 
highlight the complexity of using a small molecule inhibitor to study the activities of a 
specific protein kinase and the requirement for methods to validate the results. 
Downregulated phosphosites within PSP motifs of target proteins will need to be validated 
as true PLK4 substrates by other methods. This could include in vitro kinase assays, in which 
PLK4 is incubated with potential substrates identified in the phosphoproteomics study. 
Subsequent LC-MS/MS analysis could then be used to identify phosphorylated peptides 
containing the PSP motif.  
 
This work attempted to validate PLK4 targets by the parallel analysis of a drug-resistant 
G95R PLK4 expressing cell line, to monitor the off-target effects of centrinone. Analysis of 
the G95R PLK4 expressing cells revealed a significant number of dysregulated proteins and 
phosphosites, with the strong possibility that the use of a drug-resistant mutant led to an 
increased amount of unbound centrinone in the cell, which could then bind to off-target 
proteins with higher affinity. Unfortunately, this meant that the dataset could not be used 
to validate true targets of WT PLK4 signalling.  Incubating the WT PLK4 expressing cells with 
higher concentrations of centrinone and analysing the effects on the phosphoproteome 
would allow for the off-target effects of centrinone to be studied. If the dysregulated 
proteins/phosphosites in the G95R PLK4 dataset are due to off-target effects, then the 
same should be observed in the WT PLK4 expressing cells treated with a higher 
Chapter 7 
194 
 
concentration of centrinone. An additional limitation of the G95R PLK4 dataset was the 
presence of endogenous PLK4. Whilst expressed at very low levels in the cell, it is still 
possible that a number of the regulated proteins/phosphosites in the data were due to 
inhibition of the endogenous protein.  
 
There is a pressing need to find solutions to validate phosphoproteomics datasets acquired 
following inhibition of a protein kinase with a small-molecule inhibitor. One solution could 
be to abolish kinase activity by protein depletion using an siRNA approach. This would 
increase the specificity of the response and allow dysregulated proteins and phosphosites 
to be linked directly to PLK4 activity with greater confidence (Santamaria et al., 2011).  
Additionally, target proteins need to be validated by western blotting where specific 
antibodies are available. Chapter 5 showed downregulation of cyclin D2 following 
centrinone treatment of WT PLK4 expressing cells to match the proteomics datasets. 
However, the decrease observed was small and therefore, a centrinone time-course could 
be employed to assess down regulation of proteins over time. This was performed to assess 
EGFR and pThr669 EGFR upregulation however; conflicting results were obtained, with no 
consistent changes in expression observed. This data reflects the complexity of cell 
signalling mechanisms within the cell and further highlights the requirement for robust 
validation of phosphoproteomics data.  
 
Chapter 6 described an interaction between PLK4 and Aurora A, whereby PLK4 
phosphorylated Aurora A, including within the activation loop, leading to hyperactivation. 
Analysis of the interaction in cells confirmed that both Aurora A and pThr288 Aurora A 
localise with PLK4 in interphase cells. However, this work was unable to show that the two 
proteins co-immunoprecipitated. Using the knowledge that PLK4 and Aurora A appear to 
co-localise in interphase cells, an alternative approach to study this interaction could 
include arresting the cells in G1/S and repeating the co-immunoprecipitation experiment. In 
this way, all of the cells should remain in interphase where PLK4 is most abundant and 
active, and increase the likelihood of observing an interaction. In addition, the role of PLK4 
phosphorylated pThr288 Aurora A in the early phases of the cell cycle needs to be 
understood to ascertain the functional relevance of this interaction in somatic cells. This is a 
complicated task, as pThr288 is also a target of autophosphorylation and can be enhanced 
upon binding to co-factors such as TPX2 (Eyers et al., 2003). Therefore, unravelling the 
separate roles of pThr288 resulting from autophosphorylation or PLK4 will be very 
challenging. As the interaction was identified in a G1/S phase cell, it is possible that PLK4 
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regulated phosphorylation of Aurora A has a functional role in centrosome duplication, 
whereas TPX2 bound, pThr288 autophosphorylated Aurora A has roles in the later stages of 
the cell cycle at the mitotic spindle.  
 
Overall, the work in this thesis described the development of biochemical tools to study 
PLK4 in cells, and the optimisation of MS acquisition parameters and data processing, which 
allowed for a comprehensive investigation in the PLK4-regulated phosphoproteome for the 
first time. This work revealed novel PLK4-regulated proteins and phosphosites implicated in 
a variety of cellular processes, including the cell cycle, rRNA processing and regulation of 
apoptosis. In particular, the identification of a potential novel PLK4 consensus sequence will 
prove a useful starting point for future work aiming to investigate PLK4 substrates. 
Similarly, the datasets provide a number of potential PLK4 substrates that could be further 
investigated. PLK4 is a key chemotherapeutic target and therefore, the work in this thesis 
can be used to further understand the global effects on the cell when PLK4 activity is 
inhibited.  
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Appendix 1 
 
 
 
Heavy lysine (13C6 15N2) incorporation in U2OS cells. The extracted ion chromatograms (top panels) 
show the ion signals for the indicated peptide. The top left panel shows a peptide at m/z 608.34 and 
represents the presence of the peptide in its light form due to growth in ‘light’ media. MS/MS 
(bottom left) reveals that the peptide is from HSP60. Following 4 cell doublings in SILAC (R10K8) 
media, the same peptide is shown as a SILAC pair, with a mass difference of 8 Da. The ‘heavy’ 
peptide is at a higher intensity but still contains sufficient ‘light’ peptide to be identified by MS/MS 
(bottom, middle panels), reflecting partial incorporation of the label. At 7 cell doublings, no ‘light’ 
peptide can be identified reflecting full incorporation of the heavy label.  
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Appendix 2 
 
List of centrosomal-associated phosphoproteins. Analysis of significantly downregulated 
(A) and upregulated (B) (adj. p value ≤0.075) phosphosites in DAVID revealed an enrichment 
of phosphoproteins localised at the centrosome. 
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Appendix 3 
 
The following excel files are available upon request: 
 
Table 9.1. Preparation of synthetic phosphopeptide library pools. Lists of the 
phosphopeptides included in each of the five pools created are shown. Phosphoisomers 
were separated to ensure the exact site of localisation could be identified by LC-MS/MS and 
downstream data processing.  
 
Table 9.2. Bayesian statistical analysis of protein expression data in the WT PLK4 dataset.  
Table 9.3. Bayesian statistical analysis of protein expression data in the G95R PLK4 
dataset 
 
Identified proteins were filtered in Perseus to remove ‘contaminants’, ‘reverse hits’ and 
those identified ‘only by site’. In addition, proteins were filtered to include those identified 
in ≥3 bioreplicates. Bayesian statistical analysis was then performed using the LIMMA 
package in R, with the Benjamini-Hochberg multiple corrections procedure to generate adj. 
p values.  
 
 
Table 9.4. Bayesian statistical analysis of phosphosite data in the WT PLK4 dataset.  
Table 9.5. Bayesian statistical analysis of phosphosite data in the G95R PLK4 dataset.  
 
Identified proteins were filtered in Perseus to remove ‘contaminants’, ‘reverse hits’ and 
those identified ‘only by site’. The site table was expanded to separate phosphosites. In 
addition, proteins were filtered to include those identified in ≥3 bioreplicates and with a 
phosphosite localisation score ≥ 0.75. Bayesian statistical analysis was then performed 
using the LIMMA package in R, with the Benjamini-Hochberg multiple corrections 
procedure to generate adj. p values.  
 
 
Table 9.6. DAVID enrichment analysis of significantly regulated proteins in the WT PLK4 
dataset.  
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Table 9.7. DAVID enrichment analysis of significantly regulated proteins in the G95R PLK4 
dataset.  
Table 9.8. DAVID enrichment analysis of significantly regulated phosphosites in the WT 
PLK4 dataset.  
Table 9.9. DAVID enrichment analysis of significantly regulated phosphosites in the G95R 
PLK4 dataset.  
 
Analysis of significantly regulated proteins and phosphosites (adj. p value ≤0.075 for WT 
and adj. p value ≤0.075 for G95R) in DAVID revealed enrichment at specific cellular 
compartments, in biological processes, molecular functions and KEGG pathways.  
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Appendix 4  
 
Publication freely available online: 
 
Ferries, S., Perkins, S., Brownridge, P. J., Campbell, A., Eyers, P. A., Jones, A. R. & Eyers, C. E. 
(2017). ‘Evaluation of Parameters for Confident Phosphorylation Site Localization Using an 
Orbitrap Fusion Tribrid Mass Spectrometer’. J Proteome Res. 16. 3448-3459.  
 
 
 
